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ABSTRACT OF THE DISSERTATION

Contribution of the Microenvironment in Bone Resident Cancer:
the Role of Thrombospondin-1 in Bone and Risk Loci Contributing to Multiple Myeloma
by
Sarah R. Amend
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Genetics and Genomics
Washington University in Saint Louis, 2014
Katherine Weilbaecher, Chair
Michael Tomasson, Co-Chair
Cancer growth in bone, a defining characteristic of multiple myeloma and common in
many solid tumors including breast and prostate cancer, is characterized by the active
participation of host microenvironment cells. Tumor cells stimulate the vicious cycle through
stimulation of bone remodeling by osteoclasts and osteoblasts, resulting in increased release of
growth factors and cytokines to further promote local tumor growth. Notably, cancer cells are
unable to remodel bone independently, and require the metabolically active bone cells for this
support.
A specific role for the bone microenvironment in mediating tumor growth was first
discussed in 1889 with the introduction of Paget’s seed-and-soil hypothesis that tumor cells will
only grow in a favorable microenvironment. This dissertation is focused on investigating the
properties of a “congenial soil.”

In Chapter 2 we discuss the role of bone-resident

Thrombospondin-1 (TSP1), a glycoprotein with well-documented roles in promoting cancer
growth. Chapter 3 is focused on the identification of genes conferring inherited susceptibility to
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multiple myeloma that participate both in malignant cells and in host supportive cells.
TSP1 is a large matricellular protein that interacts β3 integrin, CD47, and other receptors
to regulate cell migration, adhesion, and proliferation with effects on tumor angiogenesis,
inflammation, and wound healing.

We examined the role of TSP1 in the bone

microenvironment. TSP1-/- mice had increased trabecular bone volume and increased cortical
bone area and thickness compared to wild type controls. Surprisingly, TSP1-/- mouse bones did
not resist bending as much as anticipated, and we confirmed a bone materials defect, indicating
that TSP1 was important for maintaining bone quality. In addition to the mechanical defects,
TSP1-/- mice had decreased serum CTX compared to controls, indicating an osteoclast defect.
Primary osteoclast cultures require TSP1 at early stages of osteoclastogenesis, though exogenous
TSP1 is dispensable at later stages of maturation. Interestingly, we found that TSP1-deplete
osteoclast cultures had a significant and dramatic increase in inducible nitric oxide synthase
(iNOS) expression. Moreover, upon administration of a NOS inhibitor to mice, the TSP1-/- bone
resorption defect was rescued to wild type levels. To test whether osteoblast-deposited boneresident TSP1 inhibits early osteoclast NO signaling, we plated osteoclasts on either wild type or
TSP1-/- bone and found that only wild type bone was sufficient to block iNOS expression. Thus,
we conclude that TSP1 is a paracrine signaling molecule that couples OB activity to OC
formation and targeting of the TSP1 signaling pathway, currently under investigation for treating
cancer and modulating blood pressure, may have additional effects on bone.
The second part of this dissertation focuses on host susceptibility to multiple myeloma
(MM) and its requisite precursor, monoclonal gammopathy of undetermined significance
(MGUS). The C57Bl/KaLwRij (KaLwRij) mouse strain has increased susceptibility to benign
idiopathic paraproteinemia (BIP), analogous to human MGUS, and is a common mouse model
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for the disease. Following immunization, KaLwRij mice developed a sustained M-spike at a
higher frequency than 12 other genetically diverse mouse strains, most notably, the highly
related C57Bl/6J (B6) strain. To query the genetic basis for BIP susceptibility in KaLwRij mice,
we completed SNP analysis to identify variation between KaLwRij and B6. We found that
KaLwRij is a unique inbred strain, completely distinct from the closely related B6.

We

identified several thousand variants between KaLwRij and B6 and compiled a candidate gene list
of 419 genes. To ensure that we would pursue genes applicable to human disease, we completed
whole genome association analysis between MM patients and healthy controls and identified
SNPs located in 180 gene loci. Combining these two gene sets resulted in a candidate gene list
of 5 genes, one of which, Samsn1, is annotated as a negative regulator of B-cell activation. Upon
closer examination of the Samsn1 locus, we found that KaLwRij harbored a germline deletion of
all coding exons of the gene, resulting in absent RNA and protein expression. Consistent with
the published role of SAMSN1 in genetically deficient mice, KaLwRij mice had enhanced B-cell
function as evaluated by B-cell proliferation in primary culture and in vivo IgG2b response. To
investigate the role of Samsn1 in host cells, we profiled Samsn1 expression in bone
microenvironment cells and found that macrophages were high expressers. KaLwRij
macrophages had enhanced expression of polarization markers, suggesting that they are preactivated under homeostatic conditions.

Further, we found that KaLwRij macrophages

stimulated to a pro-tumorigenic M2 polarization promoted 5TG myeloma tumor growth more
than B6 control macrophages in mice.

In conclusion, we identified candidate gene lists

underlying murine and human susceptibility to MGUS and myeloma. Specifically, we found
that Samsn1 contributes to KaLwRij susceptibility to BIP, and likely to human MGUS, through
effects in pre-malignant B-cells and in macrophages.
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Chapter 1
Introduction
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The seed and soil hypothesis of metastasis
Metastasis is the dissemination of primary tumor cells to a distant site. In 1889, Stephen
Paget, a physician in the West London hospital, analyzed the autopsies of 735 fatal breast cancer
patients. He noted that secondary growth was more often seen in some organs than others, even
in those with the same potential for metastasis (e.g. liver vs. spleen). Furthermore, he noted that
“the bones [of breast cancer patients] suffer in a special way,” more than would be predicted
based on the circulation of tumor cells alone, based on evidence from other cancer types (Paget,
1889).
These observations led to his proposal of the “seed and soil” hypothesis: “when a plant
goes to seed, its seeds are carried in all directions, but they can only live and grow if they fall on
congenial soil.” Cancer biologists, then, must be “scientific botanists,” concerned not just with
the malignant seed, but also with the “properties of the soil” that make up a favorable tumor
microenvironment (Paget, 1889).
The goal of this thesis is to contribute to the understanding of the “congenial soil.” First,
we will address the role of the antiangiogenic Thrombospondin-1 in the “fertile soil” of bone, a
common site of metastasis. Second, we will identify genetic risk loci that confer whole-host
“congeniality” to multiple myeloma (MM) and its precursor syndrome monoclonal gammopathy
of undetermined significance (MGUS).
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Part I: The role of the bone microenvironment in metastasis.

Homeostatic bone remodeling requires coupled bone formation and destruction
Bone is a dynamic connective organ that, together with the cartilage, comprises the
skeleton and provides mechanical, protective, and metabolic support for the rest of the body.
Cancellous bone is made of a lattice of trabeculae localized to the metaphysis of long bones with
high surface area for mineral metabolism. Cortical bone forms the outer shell of the metaphysis
and the diaphysis (shaft) of long bones to provide mechanical support. The bone marrow found
in the marrow space formed by the cortical bone is made up of hematopoietic and stromal cells
that give rise to blood cells, platelets, endothelial cells, fibroblasts, adipocytes, osteoblasts (OBs),
and osteoclasts (OCs) (Baron, 1996).
The bone matrix is composed of two compartments: osteoid (primarily collagen type I
fibers–90%, and non-collagenous proteins–10%) and mineral (calcium-phosphate hydroxyapatite
crystals). The numerous noncollagenous proteins include growth factors, proteoglycans, and
adhesion molecules. These molecules contribute to maintenance of homeostatic bone
remodeling, promoting cell attachment, differentiation, and growth of bone remodeling cells. In
addition, some molecules aid in osteoid and mineral matrix organization, directly influencing
bone strength.
Bone-forming OB arise from mesenchymal stem cells and express specific markers
during differentiation including Runx2, alkaline phosphatase, osteonectin, and osteocalcin,
useful for tracking OB formation in an experimental setting. To form bone, OBs deposit
collagen fibers to form the extracellular matrix that is subsequently calcified with hydroxyapatite
crystals. Osteoid also contains non-collagenous proteins secreted by the OBs including
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thrombospondin-1 (TSP1), BMPs, IGFs, and TGFβ that play diverse roles in maintaining matrix
structure and as signaling molecules to promote adhesion, survival, and differentiation of cells
within the bone marrow (Puzas, 1996). OBs also directly promote OC formation through preOB secretion of MCSF and expression of RANKL, key cytokines necessary for
osteoclastogenesis.
OCs arise from the MCSF- and RANKL-dependent fusion of macrophages. Following
fusion, pre-OCs polarize and form the characteristic ruffled membrane necessary for bone
resorption. OCs form a contractile actin ring to create a highly acidic sealing zone, the site of
bone resorption (Baron, 1996; Novack and Teitelbaum, 2008). Cells committed to the OC
lineage are TRAP+, useful for in vitro staining. Furthermore, each stage of OC formation is
characterized by a unique gene expression signature: early OC precursors express N-FATc1,
fusing OC express DC-STAMP and CD47, polarized cells express αvβ3 integrin, and mature
resorbing cells express Cathepsin K. Dissolving of the mineral and underlying matrix releases
growth factors and cytokines essential for OB activity, thus recruiting bone formation to a site of
recent bone destruction.
Bone remodeling is a tightly regulated process that requires the coupled activity of bone
forming OBs and bone resorbing OCs. Bone remodeling is necessary to preserve the integrity of
the skeleton and to maintain calcium and phosphate levels (Baron, 1996; Hadjidakis and
Androulakis, 2006). Misregulation of the basal bone remodeling, as in osteoporosis or bone
metastasis, leads to decreased bone integrity, resulting in hypercalcemia, nerve-compression, and
pathologic fracture.
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Bone is a favorable microenvironment for metastatic invasion and growth
Bone metastasis is common to many cancers, including breast (70%), prostate (70%) and
lung (35%), and bone disease is characteristic of multiple myeloma (Coleman, 2001; Lipton,
2004; Mundy, 2002). The consequences of bone metastases are devastating and cause pain,
pathologic fracture, spinal cord and other nerve-compression syndromes, and life-threatening
hypercalcemia (Roodman, 2004). Both osteolytic lesions and osteoblastic bone metastases are
associated with increased OC activity and disrupted bone micro-architecture (Coleman et al.,
2005; Lipton et al., 2001). Notably, while cancer cells are unable to resorb bone independently,
they secrete soluble factors that promote bone remodeling resulting in the release of additional
bone matrix-bound growth factors which further activates OCs and OBs and promotes tumor
growth (Bendre et al., 2003; Clines and Guise, 2008; Guise et al., 2006; Hirbe et al., 2006; Hirbe
et al., 2007; Kakonen et al., 2002; Kingsley et al., 2007; Kozlow and Guise, 2005; Mundy, 2002;
Pfeilschifter et al., 1987; Roodman, 2004; Yin et al., 1999). This process of pathologic induction
of bone remodeling by the cancer cells results in a “vicious cycle” of tumor growth and bone
destruction (Figure 1.1). Anti-resorptive therapy, e.g. with bisphosphonates or denosumab,
significantly decreases skeletal complications of cancer and is a standard of care for patients with
bone metastases (Body et al., 2009; Fizazi et al., 2009; Hamdy, 2008; Hirbe et al., 2006;
Roodman, 2004).

Integrins play a critical role in bone metastasis in both tumor cells and host stromal cells
The site of metastasis is tumor cell specific depending on adhesion molecule and
chemokine receptor expression profiles of both the cancer cell and the host organ cells (Kang et
al., 2003; Marcellini et al., 2006; Wei et al., 2005; Yoneda, 2000). At the metastatic site, normal
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physiology is changed towards increased secretion of cytokines and activation of adhesion
molecules to support recruitment, survival, and growth of tumor cells. Integrins expressed by
tumor cells, in concert with bone microenvironment chemokine secretion and further adhesion
molecule activation, determines the osteotropic characteristics of metastasizing cancer cells and
represent an ideal target for skeletal metastatic cancer therapy.
Integrins are heterodimeric transmembrane glycoproteins that facilitate cell-cell and cellextracellular matrix adhesion and cell migration (Schwartz et al., 1995). Integrins recruit many
intracellular signaling molecules and can activate survival, proliferation, and motility signaling
pathways (Hynes, 1992). Tumor cells localize to specific tissues through integrin-mediated
contacts with extracellular matrix and stromal cells. Integrin expression and signaling are
perturbed in cancer cells, allowing them to “escape” from cell-cell and cell-matrix tethers,
invade, migrate, and colonize within new tissues and matrices. Integrin signaling through αvβ3
and VLA-4 on tumor cells promotes tumor metastasis to and proliferation in the bone
microenvironment. As described above, misregulated OC-mediated bone resorption is a hallmark
of bone metastasis and promotes tumor expansion in the marrow space. αvβ3 integrins are
critical for OC function and development (Faccio et al., 1998; Faccio et al., 2003; Feng et al.,
2001), and β3-/- mice have reduced tumor burden in bone and are protected from tumorassociated osteolysis due to defective OC (Bakewell et al., 2003; Morgan et al., 2009)
Integrin-mediated cell signaling plays a critical role in many of these processes during
bone metastasis, including platelet aggregation (αIIbβ3), hematopoietic/immune cell
mobilization (VLA-4, osteopontin, TSP1), neoangiogenesis (αvβ3,αvβ5, α6β4, β1 integrins,
TSP1, CD47) and stromal function (osteopontin, VLA-4) (Figure 1.2). The mechanisms by
which integrin signaling mediates the pathogenesis of bone metastasis, both from the tumor cell
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and the host microenvironment, is an area of active research. Integrin pathway signaling is
critical in the pathogenesis of bone metastasis at many stages and further study to define integrin
dysregulation by cancer cells will yield new therapeutic targets for the prevention and treatment
of bone metastasis.

Integrin signaling is critical for cell adhesion and survival
There are 8 beta and 18 alpha integrin subunits that assemble into 24 different known
combinations in different cell types, each characterized by distinct ligand binding specificities,
signaling abilities, and regulatory mechanisms(Hynes, 2002). Integrins are activated by
conformational changes in the integrin extracellular domains (“inside-out” signaling). When the
integrin α and β subunit cytoplasmic and transmembrane domains remain closely juxtaposed, the
extracellular domains are held in a closed conformation. Activation by intracellular signals to the
cytoplasmic tails results in separation of the α and β cytoplasmic and transmembrane domains
and exposure of the extracellular ligand binding domain (Shattil et al., 2010) (“inside-out”
signaling). In addition to activation by inside-out signaling, ligand binding and integrin
clustering can be significantly modulated by growth factor receptor interactions and other
integrin interacting proteins, as reviewed in (Desgrosellier and Cheresh; Hynes, 2002; Shattil et
al., 2010). The open conformation facilitates high affinity ligand binding and triggers integrinmediated cell signaling cascades (“outside-in” signaling) (Offermanns, 2006; Qin et al., 2004),
critical for growth, migration, adhesion, and survival.
Maintaining adhesion to the extracellular matrix, in part through integrin signaling, is
critical to cell survival (Frisch and Screaton, 2001). Altered cell-cell or cell-matrix interactions
can result in disruption of downstream survival signaling and anchorage-dependent non-
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transformed cells undergo anoikis (Frisch and Screaton, 2001). Under normal conditions,
because each cell type expresses a unique set of integrins that recognize underlying extracellular
matrix ligands, this form of apoptosis ensures that detached cells do not colonize inappropriate
locations (Frisch and Screaton, 2001). Cells that resist anoikis, such as metastatic cells, take
advantage of aberrant integrin expression that enables the cell to adhere to a novel extracellular
matrix (Bissell and Radisky, 2001) and colonize a distant site.

Integrin signaling in tumor cells that metastasize to bone
Tumor progression, invasion, and metastasis require the activity of many adhesion
proteins, including the integrin superfamily. At each stage of cancer progression, subsets of
integrin heterodimers are activated, providing the necessary signaling pathways for adhesion,
migration, and cell survival. Metastatic tumor cells show differential integrin heterodimerization
and activation compared to non-metastatic tumor cells that enable the cell to home to and
colonize in a metastatic site, such as the bone marrow cavity (Edlund et al., 2001; Yoneda,
2000). In order for primary epithelial cancers to metastasize, the tumor cells must become
resistant to anoikis and detach from the primary tumor site extracellular matrix, enter the
vasculature, and eventually colonize a distant site. Upon reaching a successful metastatic site,
however, tumor cells use both anoikis and anoikis-resistance to their advantage, in some cases
forming micro-metastases that are resistant to cancer treatment via integrin binding to the
underlying bone matrix as reviewed in (Clezardin, 2009). In addition to evading apoptosis, tumor
cells must also form interactions between the tumor cell and bone stroma to establish and
maintain skeletal metastasis.
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The β3 integrin signaling pathway has been implicated in tumor cell-host bone stroma
interactions during bone metastasis and tumor growth in bone (Figure 1.2). Breast cancer cells
that overexpress αvβ3 have increased levels of bone metastasis and associated tumor burden and
osteolysis (Nakamura et al., 2007; Pecheur et al., 2002; Sloan et al., 2006; Van der VeldeZimmermann et al., 1997; Zhao et al., 2007). This overexpression of αvβ3 in the tumor cells
leads to increased tumor cell adhesion, migration, and invasion to bone as well as enhanced OC
recruitment within the bone microenvironment (Pecheur et al., 2002; Sloan et al., 2006),
implicating a role of tumor-specific αvβ3 expression in breast cancer metastasis to bone as well
as tumor-associated osteolysis. Likewise, in prostate cancer cells, active αvβ3 is necessary for
the adherence and migration to bone matrix proteins at early stages of skeletal metastasis. This
tumor cell αvβ3 integrin expression allows cancer cells to adhere to the bone matrix and interact
directly with the native bone cells, OBs and OCs, as well as with the bone matrix itself
(Nakamura et al., 2007).

CD47 and TSP1 augment αvβ3 integrin signaling
β3 integrins are activated upon binding to an Arg-Gly-Asp (RGD) protein motif,
contained in many extracellular matrix proteins including vitronectin, fibronectin, osteopontin,
bone sialoprotein, and TSP1, among others. Importantly, integrin associated protein CD47
augments integrin activation and affects the ability of αvβ3 integrin to cluster upon ligand
binding (Brown and Frazier, 2001). CD47 augments β3 integrin-dependent adhesion, with
CD47-deficient β3-expressing cells showing decreased adhesion to vitronectin (Lindberg et al.,
1996). Notably, TSP1 ligation of CD47 further enhances adhesion (Gao et al., 1996), suggesting
that TSP1-binding of CD47 mediates the enhancement of β3 function. Pertussis toxin inhibits
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these effects, providing evidence that the mechanism likely involves Gαi GTPase activity
(Frazier et al., 1999; Green et al., 1999). Investigation of the role of TSP1 in the bone
microenvironment will be discussed in Chapter 2.

αvβ3 integrin and thrombospondin-1 regulate tumor angiogenesis
Tumor neovascularization is essential for tumor growth and metastasis, providing the
cancer cells with host nutrients and access to the circulation for the dissemination for metastatic
cells. The ability of tumor cells to activate the normally quiescent vasculature is proposed to be
controlled by an “angiogenic switch” mechanism, whereby tumor or stromal cells induce
changes in the relative balance of inducers (VEGF, TGFβ) and inhibitors (TSP-1) of
angiogenesis (reviewed in (Desgrosellier and Cheresh; Hanahan and Weinberg, 2000; HodivalaDilke, 2008; Hood and Cheresh, 2002; Silva et al., 2008; Stupack and Cheresh, 2004)).
Many integrins have been implicated in angiogenesis, but one of the best characterized is
αvβ3. Integrin αvβ3 is highly expressed on tumor-associated vasculature, and angiogenesis is
inhibited with β3 neutralizing antibodies. Interestingly, however, β3-/- mice have enhanced (not
reduced) tumor-associated angiogenesis in subcutaneous tumors (Reynolds et al., 2002). In β3
floxed mice crossed with endothelial-specific Cre mice, depletion of β3 integrin in endothelial
cells inhibits angiogenesis and tumor growth in a preventative setting, but not in established
tumors. Moreover, these tumor effects are transient, and long-term endothelial cell β3 deletion is
ineffective to reduce angiogenesis (Steri et al., 2014). Reports that low dose integrin antagonists
can increase tumor growth and angiogenesis while higher doses suppress tumor growth and
angiogenesis (Reynolds et al., 2009) (Carmeliet, 2002; Martin et al., 2002; Wang et al., 2001;
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Zhao et al., 2005) further underscore the complexity of targeting β3 integrins for angiogenesis
and cancer therapy.
In some scenarios, β3 integrin influences angiogenesis through interactions with ligand
TSP1. TSP1 was the first identified endogenous anti-angiogenic factor (Isenberg et al., 2007a)
and plays a role in neoangiogenesis in endothelial cells and platelets through its interactions with
CD47 and β3 integrin. In numerous studies, TSP1 has tumor suppressing effects in the tumor
microenvironment and many tumors have low expression of TSP1 (reviewed in (Kazerounian et
al., 2008)). TSP1-/- mice have increased tumor burden and tumor-associated vasculature in a
primary tumor model, while mice that over-express TSP1 have delayed tumor growth and
reduced tumor-associated vasculature (Rodriguez-Manzaneque et al., 2001). In contrast, other
studies demonstrate a role for TSP1 in promoting tumor progression (Dias et al., 2012; John et
al., 2010; Tuszynski et al., 1987) in part through TSP1 stimulation of endothelial cell migration
through interactions with the α6 integrin pathway (Dias et al., 2012; John et al., 2010). Thus,
TSP-1 can play both pro- and anti-angiogenic roles, depending on its specific integrin
interaction.
The role of αvβ3 integrin in tumor-associated angiogenesis is complex, not only
involving integrin-ligand interactions and associated signaling pathways, but also specific
temporal regulation and indirect effects through proteins such as TSP1, and are important for the
progression of angiogenesis and eventual metastasis.

Integrin αvβ3 is necessary for osteoclast function and plays a key role in bone metastasis
Bone invading metastatic tumor cells co-opt integrin signaling pathways that enhance OC
function and recruitment. As part of bone remodeling, OC bind to the bone matrix, form an actin
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ring mediated sealing zone, secrete enzymes and acid to degrade bone, and then migrate to a new
site. Each of these functions is regulated in part by integrins located on the membrane surface of
the OC, interacting with neighboring cells and with the extracellular matrix (Teitelbaum and
Ross, 2003).
αvβ3 is the predominant integrin found on OCs and plays roles in multiple components of
osteoclastogenesis and resorption (Novack and Teitelbaum 2008; Ross and Teitelbaum 2005.
αvβ3 is responsible for mediating OC

bone matrix recognition (Crippes et al., 1996; Liapis et

al., 1996; Ross et al., 1993; Zambonin Zallone et al., 1989), adhesion (Chellaiah, 2006; Ross et
al., 1993), formation of the ruffled border, and overall organization of the cytoskeleton (Faccio et
al., 2003; McHugh, 2000; Rucci et al., 2005; Zhang et al., 2000). Antibody inhibition of αvβ3
inhibits OC attachment to the bone matrix and OC-mediated bone resorption(Ross et al., 1993).
In addition, β3-/- have defective OC function (McHugh, 2000) and are protected from tumor
associated osteolysis (Bakewell et al., 2003).
Integrin αvβ3 ligand CD47 also plays important roles in OC formation and tumorassociated osteolysis, both through augmenting β3 activity, and in an integrin-independent
manner. CD47-/- mice have increased bone volume due in part to reduced OC number and
function (Koskinen et al., 2013; Uluckan et al., 2009), and CD47-/- mice are partially protected
from tumor-associated osteolysis (Uluckan et al., 2009). CD47 in OC include binding to SIRPα
in hematopoietic cells is an important “self-signal” to prevent phagocytosis. CD47:SIRPα
binding is also important for macrophage fusion, an early event in OC formation (Han et al.,
2000; Lundberg et al., 2007; Vignery, 2005). Interestingly, CD47-/- OCs have increased levels
of inducible nitric oxide synthase and the CD47-/- OC formation defect is rescued in vitro
through blockade of nitric oxide signaling (Uluckan et al., 2009). Notably, in other cell types
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TSP1-CD47 binding inhibits nitric oxide signaling; we will investigate the role of TSP1 in nitric
oxide mediated regulation of OC in Chapter 2.
OC targeted therapy is a standard of care for the treatment of bone metastasis and
myeloma bone disease. Tumor cells recruit OCs resulting in bone destruction and pain (Clohisy
and Ramnaraine, 1998; Honore et al., 2000; Mundy, 2002). Because of its known role in OC
function and its high expression in skeletal metastatic tumors as discussed above, much research
has focused on αvβ3 integrin and its ligands in bone. Elucidating the role of β3 integrin pathway
member TSP1 is the subject of Chapter 2.

β3-/-, CD47-/-, and TSP1-/- mice have phenotypic overlap suggesting a common pathway
Mice with genetic deficiency in individual components of the αvβ3 pathway, including
β3, CD47, and TSP1, show phenotypic overlap in characteristics essential for bone metastasis
(Table 1.1). Importantly, both β3-/- and TSP1-/- mice have increased primary tumor growth and
neoangiogenesis (Reynolds et al., 2002; Rodriguez-Manzaneque et al., 2001), while CD47-/mice have decreased tumor burden with no apparent effect on angiogenesis, suggesting that the
β3-CD47 signaling pathway may not participate in primary tumorigenesis. In the bone
microenvironment, however, β3-/- and CD47-/- mice both have increased bone volume and
decreased tumor-associated osteolysis (Bakewell et al., 2003; Uluckan et al., 2009), largely due
to decreased OC activity. While the TSP1-/- mouse bone phenotype has not been fully
evaluated, there is some evidence implicating TSP1 in OC activity (Carron et al., 2000; Carron et
al., 1995).
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Together, these data led us to hypothesize that the β3 – CD47 – TSP1 signaling axis is
important in the bone microenvironment, both under homeostatic and pathologic states.
Investigation of the role of TSP1 in the bone is the topic of Chapter 2.

Thrombospondin-1 is expressed in the bone matrix, but its role remains unknown
TSP1 is a large matricellular glycoprotein (350 kDa) that is ligand for at least 11 unique
receptors, including αvβ3 integrin, CD47, and CD36, as well as many extracellular matrix
proteins, including collagen, calcium, and osteopontin, among others. It is expressed and
secreted by all vascular, endothelial, and hematopoietic cells, but is most highly secreted by
activated platelets as part of wound healing. As a matricellular protein, TSP1 has dual function,
both as a member of the ECM and as a signaling molecule.
TSP1 deficient mice are reported to have mild spine deformation(Crawford et al., 1998)
and mild growth plate cartilage disorganization (Posey et al., 2008) but detailed analysis of bone
has not been reported. TSP1 is expressed by OBs and is present in osteoid and mineralized bone
matrix (Grzesik and Robey, 1994; Kannus et al., 1998; Robey et al., 1989) where it is directly
deposited by bone-forming OBs (Clezardin et al., 1989; Robey et al., 1989). TSP1 participates in
OB differentiation in part through activation of latent TGF-β (Bailey Dubose et al., 2012; Ueno
et al., 2006), and TSP1 receptors CD47 and CD36 also regulate OB (Kevorkova et al., 2013;
Koskinen et al., 2013). TSP1 has been implicated in OC activity, but its mechanism of action
remains unknown(Carron et al., 1995). TSP1-CD47 interactions play a role in the formation of
multiple myeloma-dendritic cell fusions with bone-resorbing capacity (Kukreja et al., 2009), and
TSP1-CD36 ligation can promote osteoclastic resorption on dentine slices (Carron et al., 2000).
Together these data led us to hypothesize that OB-secreted TSP1 sequestered in bone matrix will
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modulate OC function thereby coupling OB activity to OC formation which we will investigate
in Chapter 2.

Nitric oxide signaling modulates endothelial cell and osteoclast activity
Nitric oxide (NO) is synthesized by NO synthases (NOSs): eNOS and nNOS synthesize
low levels of NO(Tsutsui, 2004) while higher levels are produced by iNOS, induced upon
inflammatory cell activation (Figure 1.2) (Ridnour et al., 2005; Ridnour et al., 2006). NO binds
sGC to catalyze the reaction of cGMP (Roy and Garthwaite, 2006), responsible for regulating
signaling that controls proliferation, migration, cell cycle and apoptosis (Thomas et al., 2008).
NO exerts a biphasic effect with low (<10 nM) levels of NO necessary for maintaining normal
cell function (Isenberg et al., 2007b), while high (>100 nM) levels of NO are toxic (Lau, 2003)
(Figure 1.3). Thus, tight regulation of NO is critical for normal cell function and unregulated
increases in NO is typical of many pathologic conditions, including cancer, and can lead to cell
toxicity or disrupted cell function.
NO signaling is a critical signaling pathway during homeostatic bone resorption. Upon
stimulation with RANKL, OC precursors upregulate iNOS expression through an NFκBdependent mechanism and the subsequent high NO concentration inhibits further OC formation
(Zheng et al., 2006). iNOS deficient bone marrow macrophages show increased OC formation
and resorption (Zheng et al., 2006). Misregulation of NO signaling, therefore, may lead to
aberrant bone remodeling, compromising skeletal integrity.
TSP1 is a regulator of NO in endothelial cells, platelets, and vascular smooth muscle
cells(Bergseth et al., 2000; Chen et al., 2000). Notably, only TSP1 receptors CD36 and CD47
have been implicated in NO regulation. TSP1-/- mice show elevated levels of endothelial cell
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cGMP compared to wild type, and primary cultures show increased proliferation, migration, and
adhesion (Isenberg et al., 2005). NO-stimulated endothelial cells and vascular smooth muscle
cells have increased proliferation and migration and elevated cGMP (Isenberg et al., 2005).
These responses are blocked upon addition of TSP1, CD47-binding peptide, or CD36-binding
peptide (Isenberg et al., 2005). Vascular outgrowth is increased in TSP1-/- mice, an effect that is
augmented with NO stimulation (Isenberg et al., 2006). Interestingly, while addition of TSP1
inhibits the NO-stimulated vascular outgrowth in CD36-/- mice, it has no effect in CD47-/- mice
(Isenberg et al., 2006), indicating that CD47 is necessary for NO-mediated endothelial cell
function. Despite identification of CD36 as a regulator of eNOS (Isenberg et al., 2007b), the
direct mechanism of action for CD47 inhibition of NO has not been identified. Our lab reported
that CD47 suppression of NO signaling in OCs plays an important role in pathologic osteolysis
(Uluckan et al., 2009), but the CD47-activating ligand in OCs has not been defined. We will
explore the role of TSP1-regulation of NO signaling in OC in Chapter 2. We hypothesize that
TSP1 is a negative regulator of NO signaling in OC, promoting early stages of OC formation.

Goals of the present study
The seed-and-soil hypothesis of cancer metastasis has been accepted for decades, and the
field of cancer biology acknowledges the necessity of host support for tumor growth. While
many molecules have been implicated in host-cell support of tumor growth, the components of
“congenial soil” remain incomplete. Therapeutic targeting of the host cells, specifically the
uncoupling of the “vicious cycle” within the bone microenvironment, represents a promising site
of intervention for the treatment of bone metastasis.
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In Chapter 2, we elucidate the role of potent anti-angiogenic TSP1 in bone in order to
better understand the impacts of TSP1-pathway directed therapeutics. While many receptors of
TSP1 are known to be important for bone integrity, both in the bone matrix and in metabolically
active bone cells, the role of the matricellular ligand is unclear. We demonstrated that TSP1
played both structural and signaling roles to maintain bone homeostasis. Using TSP1-null mice,
we showed that TSP1 contributed to bone quality and that it was essential for OC formation. We
found that pharmacologic inhibition of NO signaling in TSP1-/- mice restored OC activity,
placing TSP1 upstream of NO regulation of OC formation. Importantly, we present strong
evidence for TSP1 as a paracrine signaling molecule, coupling OB activity to OC formation, thus
building upon the literature of critical bone remodeling factors.
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Part II: Genetic susceptibility to monoclonal gammopathy of undetermined significance,
the requisite precursor to multiple myeloma

Monoclonal gammopathy of undetermined significance is a common disorder of aging
Monoclonal gammopathy of undetermined significance (MGUS) is a common syndrome
of aging, with a prevalence of 3.2 – 5.2 percent in 50 – 70 year olds, respectively (Kyle et al.,
2006; Landgren et al., 2009). MGUS is characterized by the presence of a constant serum level
of monoclonal paraprotein (less than 3 g/dl) termed “M-spike” as detected by a persistent band in
the gamma region of a serum protein electrophoresis (SPEP, Figure 1.4a) in the absence of endorgan damage. While largely benign, MGUS is associated with increased fracture risk and
osteoporosis (Melton et al., 2005), and MGUS patients have elevated serum levels of OCactivating (MIP1α) and OB-inhibiting (DKK1) factors (Ng et al., 2011). Importantly, MGUS is
the requisite precursor to multiple myeloma (MM), and progresses to overt malignancy at a rate
of 1% per year. Due to the largely asymptomatic state and low rate of transformation to myeloma
(lifetime risk of 10-30% (Kyle et al., 2010; Sirohi and Powles, 2006; Zingone and Kuehl, 2011)),
MGUS is not clinically treated, though patients are monitored with annual blood chemistry tests.

Step-wise transformation from MGUS multiple myeloma
MM is the second most common hematological malignancy and is invariably fatal with a
~6 year median survival (Kumar et al., 2013). MM is a malignancy of plasma B-cells that is
clinically diagnosed by an M-spike of >3 g/dL and the presence of CRAB syndromes:
hypercalcemia, renal insufficiency, anemia, and lytic bone lesions, highlighting its dependence
on the bone microenvironment (Figure 1.4b).

!

18!

Normal plasma B-cell development results in a long-lived non-proliferative antibodyproducing cell. One of the hallmarks of B-cell differentiation is a DNA rearrangement for
increased variation: VDJ recombination in immunoglobulin (Ig) heavy and light chains, somatic
hypermutation, and Ig heavy change switch recombination. In the bone marrow, pro- and preB-cells undergo Ig heavy and light chain recombination, respectively. Immature B-cells that
undergo receptor editing and express IgM receptor leave the bone marrow and travel to the
spleen or lymph nodes as antigen-presenting cells. Upon encountering an antigen, the B-cell will
endocytose the antigen and presents the antigenic peptides as part of the MHC II complex.
These activated B-cells enter a germinal center and undergo somatic hypermutation of both the
heavy and light chains. Cells that express high-binding antigen-receptors undergo Ig class
switch recombination then home to the bone marrow as mature, antibody producing plasma Bcells.
The affected cell in MGUS and MM is the typically non-proliferative terminallydifferentiated post-germinal center B-cell. In MGUS, there is a clonal expansion of one or more
of these plasma cells, resulting in an elevated level of immunoglobulin in the serum. MM is
characterized by a further expansion of one or more of these clones to fill the marrow space,
again resulting in an elevated immunoglobulin level, but now accompanied with more significant
end-organ damage.

The bone microenvironment contributes to MGUS and MM pathology
Differentiation and function of normal plasma cells is dependent on the bone marrow
microenvironment. Bone marrow stromal cells and OBs support B-cell lymphopoiesis,
proliferation, and plasma cell homing to the marrow. Likewise, MM::microenvironment
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interactions parallel normal B-cell::microenvironment cross-talk, with similar mechanisms
identified for homing (CXCR4/SDF1 gradient) and proliferation (IL-6, IGF1, TGFB) (reviewed
in (Kuehl and Bergsagel, 2002)). In addition, myelomas further modulate the bone
microenvironment and produce OC-stimulatory (Basak et al., 2009; Esteve and Roodman, 2007;
Oyajobi et al., 2003) and OB-inhibitory factors (Giuliani et al., 2005; Yaccoby, 2010) that
deregulate the coupled process of healthy bone remodeling (Mundy, 2002; Weilbaecher et al.,
2011). This results in osteolytic lesions in 70-80% of MM patients (Terpos et al., 2007) (Figure
1.4b). Such pathologic bone resorption releases tumor growth factors stored within the bone
matrix. Bone marrow stromal cells, a heterogeneous population including mesenchymal stem
cells, support myeloma growth through adhesion-dependent mechanisms (VLA-4/VCAM) and
the production of soluble growth factors including IL-6(Terpos et al., 2007). MM causes
significant bone destruction, hypercalceimia, bone pain, and facture.

Tumor associated macrophages promote myeloma progression
In addition to the crucial role of bone remodeling cells, there is a growing literature
implicating tumor-associated macrophages (TAMs) in the pathogenesis of MM (reviewed in
(Asimakopoulos et al., 2013; Berardi et al., 2013; Ribatti et al., 2013)). TAMs are typically
categorized as classically-activated pro-inflammatory macrophages (M1) or alternativelyactivated anti-inflammatory macrophages (M2), though the distinction between the two classes
likely represents a spectrum rather than specific identity. M1 macrophages, activated by bacterial
lipopolysaccharide (LPS) and interferon-gamma (IFNg), promote a strong host immune
response. In contrast, M2 macrophages, activated by IL-4, IL-13, and TGFβ, suppresses Th1mediated inflammation and promotes wound healing, including angiogenesis and destruction of
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the extracellular matrix. Thus, even within their normal physiologic roles, M1 macrophages are
inherently anti-tumor while M2 macrophages promote tumor progression.
MM patients with active disease have higher percentage of macrophages in the bone
marrow than either MGUS patients or patients with non-active disease (Scavelli et al., 2008). In
addition, these macrophages are functionally distinct from non-affected patients and contribute to
angiogenesis through vasculogenic mimicry (Scavelli et al., 2008). MM TAMs have increased
pro-MM factor secretion such as IL-6 (Kim et al., 2012; Zheng et al., 2009) and higher levels of
pro-angiogenic VEGF expression compared to non-MM macrophages (Ribatti et al., 2006;
Scavelli et al., 2008; Vacca and Ribatti, 2011). The role of Samsn1 in macrophages will be
explored in Chapter 3.

Genetic risk factors contributing to MGUS and MM susceptibility
Human population studies suggest that genetic risk factors underlie susceptibility to
MGUS and MM. Interestingly, however, the majority of plasma-cell intrinsic genetic events in
MM cells are present in MGUS-affected B-cells (Davies et al., 2003), though not in normal
plasma B-cells. Epidemiological studies have identified a higher incidence for MM in African
Americans and that this is the result of elevated risk to MGUS, rather than an increased rate of
conversion from MGUS to MM (Kyle et al., 2010; Kyle et al., 2006; Landgren et al., 2006). In
addition, studies in affected families showed a higher risk of MM in patients with an MGUSaffected relative (Jain et al., 2009; Kyle et al., 2004; Vachon et al., 2009).
Genome wide significance studies of MM have identified seven SNPs that confer a
significant increase in MM risk (Broderick et al., 2012; Chubb et al., 2013). Interestingly, a
recent study in an MGUS patient population showed that these SNPs also conferred increased
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risk to MGUS (Weinhold et al., 2014), providing further evidence that increased MM risk is due
to increased MGUS risk. These studies highlight the need for a better understanding of the
genetic predisposition to MGUS that will be the subject of Chapter 3.

C57Bl/KaLwRij is a spontaneous mouse model of MGUS and MM
One of the most common experimental models for MGUS and MM is the
C57BL/KaLwRij mouse (KaLwRij). KaLwRij was first identified to have a high frequency of
benign idiopathic paraproteinaemia (BIP), the murine counterpoint to human MGUS, in 1974
(Radl and Hollander, 1974). KaLwRij mice have increased serum levels of homogeneous
immunoglobulin by SPEP, similar to the M-spike observed in MGUS and MM patients, by 12
months of age with a penetrance of ~45% (Radl et al., 1978). Affected mice progress to overt
malignancy at a rate of approximately 1% with similar clinical features as human MM, including
severe bone pathology (Radl et al., 1978).
5T myeloma cell lines were generated from spontaneous myelomas in KaLwRij mice,
and can be transplanted into KaLwRij mice to propagate the myeloma (Alici et al., 2004;
Asosingh et al., 2000; Vanderkerken et al., 2003). Intravenous injection into KaLwRij mice
yields robust bone marrow-disseminated myeloma with significant osteolytic bone lesions and
increased monoclonal paraprotein (M-spike) within 28 days (Dallas et al., 1999; Edwards et al.,
2009; Garrett et al., 1997). Importantly, the 5TMM cell lines will not engraft in the closely
related C57Bl/6 (B6) strain (Asosingh et al., 2000), highlighting the requirement of a supportive
host microenvironment for establishment of early disease. Notably, while KaLwRij represents
an ideal model for MGUS and for a MM-supportive host microenvironment, the genetic basis of
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BIP susceptibility in these mice remains largely unknown. We characterized the genetic
variation between KaLwRij and B6 using SNP mapping which is presented in Chapter 3.

Mouse genetic mapping to identify genetic susceptibility loci for BIP
The KaLwRij mouse strain is an ideal model to dissect genetic risk loci contributing to
the complex trait of BIP susceptibility, analogous to human MGUS. Importantly, identifying
germline risk alleles will encompass genes at play in all cell types participating in the step-wise
progression from a normal plasma cell to overt MM, including host stromal cells predicted to
contribute to MGUS and MM. In our studies presented in Chapter 3 we use a variety of genetic
techniques to identify MGUS risk alleles using KaLwRij mice and human MM samples.
The BIP-prone KaLwRij strain has been interbred since approximately 1978, and we
demonstrated that it is distinct from, but closely related to, the commonly used wild type (and
BIP-resistant) strain, B6 (Chapter 3, Figure 3.1). We used SNP analysis, also known as linkage
disequilibrium mapping, to identify candidate loci underlying risk to MGUS. Haplotype
analysis, while uncommon in the genomic era, is used to narrow quantitative trait loci regions
and to characterize regions of interest contributing to phenotype in recombinant inbred strain
analysis (Burgess-Herbert et al., 2008).
Linkage disequilibrium is the non-random assortment of alleles based on physical
proximity. Loci that are physically proximal to each other are more likely to be inherited
together than expected by random assortment, due to low rates of recombination in short
physical space. Contiguous loci that are inherited together represent a haplotype. Therefore, by
identifying regions which are shared in “high” phenotype mouse strains and not in “low”
phenotype mouse strains allows for the identification of candidate gene loci. Traditional
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haplotype block analysis assumes that any variation between strains is a result of ancestral
variation rather than recent variation, resulting in large DNA regions that are identical by
descent. We modified the approach to identify smaller units of variation between the closely
related KaLwRij and B6, and therefore used a lower threshold than is typical for this analysis.
In our analyses presented in Chapter 3, we identified candidate lists of genes underlying
susceptibility to (1) murine BIP, (2) human MM/MGUS, and (3) both murine BIP and human
MM/MGUS.

Goals of the present study
Epidemiological evidence points to genetic risk to MGUS and subsequent progression to
MM, representing a “congenial soil” for malignant cell transformation, both inherent to the premalignant B-cell and to the non-cancerous host cells contributing to disease progression.
In Chapter 3, we focus on whole-host “congeniality” to MGUS and MM. We identify
genetic risk loci contributing to susceptibility to microenvironment-dependent MGUS. Using a
combinatorial approach, we compiled candidate gene lists derived from mouse SNP analysis and
human MM patient association studies to ultimately identify a shared candidate list of five genes
and focused our studies on Samsn1. We show that the most common murine model for human
MGUS and myeloma, KaLwRij mouse strain, has a germline deletion for the B-cell inhibitor
Samsn1. We present compelling evidence that Samsn1 confers genetic risk to B-cell malignancy
through effects both in pre-malignant cells inn cooperating cells of the host microenvironment,
namely TAMs. Therefore, Samsn1 represents a single tumor-suppressor gene contributing to
myeloma progression through two mutually exclusive mechanisms.
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Figure 1.1. The “vicious cycle” of bone metastasis.
In the bone marrow space, metastatic cells secrete factors (including PTHrP, IL-6, VEGF, TNF,
and MMPs) to stimulate bone resorption, through both direct and indirect effects on osteoclasts.
In turn, osteoclasts releases bone-sequestered growth actors (including TGFβ and IGFs) that
further stimulate tumor growth.
Reproduced from (Weilbaecher et al., 2011).
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Figure 1.2.
Expression of integrins in tumor cells and host microenvironment cells during metastasis.
Reproduced from (Schneider et al., 2011).
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Figure 1.3. Nitric oxide (NO) exerts a biphasic (or “Goldilocks”) effect on cell activation.
In the absence of nitric oxide, cells remain inactive or fail to differentiate. Under tonic levels
of NO, synthesized by the constitutive nitric oxide synthases (NOSs) endothelial NOS and
neuronal NOS, cells are activated or differentiate. High levels of NO, produced by inducible
NOS, results in cell toxicity.
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Figure 1.4. Clinical diagnosis of MGUS and multiple myeloma.
(a) Serum protein electrophoresis (SPEP). Arrowhead indicates band in the gamma
region, indicative of an accumulation of monoclonal paraprotein (M-spike). Negative
(left) and positive (right) M-spike.
(b) X-ray of a multiple myeloma patient with characteristic “hole-punch” bone lesions
(arrows). Reproduced from the American Academy of Orthopedic Surgeons.!
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Table 1.1. Integrin β3-/-, CD47-/-, and TSP1-/- mouse model phenotypic overlap
!Mouse
model

!Primary tumor
!
Tumor Angiogenesis

!Bone metastasis
!
Tumor Osteolysis

!
!Homeostatic bone !
Bone volume
Osteoclasts

β3-/-!

!
"
!

!
!#!#!#!!

"
"

"
"

!
!

"
"

!

?

?

?

?

CD47-/TSP1-/-
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Chapter 2
Thrombospondin-1 regulates bone homeostasis through effects on bone matrix integrity
and nitric oxide signaling in osteoclasts
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Abstract

Thrombospondin-1 (TSP1), an endogenous antiangiogenic, is a widely expressed
secreted ligand with roles in migration, adhesion and proliferation and is a target for new
therapeutics. While TSP1 is present in the bone matrix and several TSP1 receptors play roles in
bone biology, the role of TSP1 in bone remodeling has not been fully elucidated. Bone turnover
is characterized by coordinated activity of bone-forming osteoblasts (OB) and bone-resorbing
osteoclasts (OC). TSP1-/- mice had increased bone mass and increased cortical bone size and
thickness compared to wild type (WT). However, despite increased size, TSP1-/- femurs showed
less resistance to bending than expected, indicative of diminished bone quality and a bone
material defect. Additionally, we found that TSP1 deficiency resulted in decreased OC activity in
vivo and reduced OC differentiation. TSP1 was critical during early osteoclastogenesis, and
TSP1 deficiency resulted in a substantial overexpression of inducible nitric oxide synthase
(iNOS). Importantly, administration of a NOS inhibitor rescued the OC functional defects of
TSP1-/- mice in vivo. To investigate the role of bone-derived TSP1 in osteoclastogenesis, we
found that wild type (WT) pre-OCs had defective iNOS expression when cultured on TSP1-/bone compared to WT bone, suggesting that TSP1 in bone plays a critical role in iNOS signaling
during OC development. These data implicate a new role for TSP1 in bone homeostasis with
roles in maintaining bone matrix integrity and regulating OC formation. It will be critical to
monitor bone health of patients administered TSP1-pathway directed therapeutics in clinical use
and under development.
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Introduction

Bone is a dynamic tissue, characterized by balanced bone resorption and formation. This
bone remodeling is necessary to preserve the structural integrity of the skeleton and to maintain
calcium and phosphate homeostasis (Baron, 1996; Hadjidakis and Androulakis, 2006). Bone is a
matrix composed of two compartments: osteoid (primarily collagen type I fibers) and mineral
(calcium-phosphate hydroxyapatite crystals). The bone matrix also contains numerous
noncollagenous proteins including growth factors, proteoglycans, and adhesion molecules. These
molecules contribute to maintenance of homeostatic bone remodeling, promoting cell
attachment, differentiation, and growth of bone remodeling cells. In addition, some molecules
aid in osteoid and mineral matrix organization, directly influencing bone strength.
Mesenchymal osteoblasts (OBs) form bone by depositing collagen and other molecules to
form osteoid and subsequently calcify this matrix to form rigid bone. Osteoclasts (OCs),
polarized multi-nucleated hematopoietic cells formed from the fusion of macrophages, resorb
bone through protease- and acid-dependent processes. The formation and activity of OCs and
OBs is a tightly coupled process. OCs are activated by OB-derived cytokines such as M-CSF and
RANK-L. In turn, OCs promote osteoblastic bone formation by releasing stored growth factors
including bone morphogenic proteins, TGFβ, and insulin growth factor from the bone matrix.
Misregulation of healthy bone remodeling, as in cancer metastasis, arthritis, or osteoporosis,
leads to decreased bone integrity, pathologic fracture, nerve-compression syndromes, and
hypercalcemia (Weilbaecher et al., 2011). While many factors that individually regulate OC and
OB formation and activity have been identified, our understanding of the role of OB-deposited
bone matrix-sequestered proteins in homeostatic OC activity remains incomplete.
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Thrombospondin-1 (TSP1) is a large secreted protein that binds at least 11 distinct
receptors, including β3 integrin, CD47, and CD36, thereby influencing downstream pathways.
By regulating migration, adhesion and proliferation, TSP1 participates in diverse processes
including angiogenesis, inflammation, and wound healing. TSP1 was the first identified
endogenous antiangiogenic molecule, and TSP1 mimetics have entered clinical trials as cancer
therapeutics (Taraboletti et al., 2010). Antibodies against the TSP1 receptor CD47, used to
induce macrophage phagocytosis of cancer cells, have completed pre-clinical studies(Tseng et
al., 2013; Weiskopf et al., 2013), and a humanized antibody is under clinical development. In
addition, nitric oxide (NO) signaling, a pathway regulated by TSP1, is being therapeutically
targeted for vasodilation (NO donors) or hypotension (NO synthase inhibitors)(Deshpande et al.,
2012). As these TSP1 pathway-targeted therapies enter broad clinical use, it is important to
consider the action of TSP1 in other systems, including the skeleton, where TSP1 receptors
CD47, β3 integrin, and CD36 (Faccio et al., 2003b; Kevorkova et al., 2013; Koskinen et al.,
2013; McHugh et al., 2000; Schneider et al., 2011; Uluckan et al., 2009) are involved in OC and
OB signaling. Bone-related off-target effects will be especially crucial to consider in advanced
cancer patients at risk for skeletal metastasis and post-menopausal women who are at risk for
osteoporosis.
TSP1 deficient mice are reported to have mild spine deformation (Crawford et al., 1998)
and mild growth plate cartilage disorganization (Posey et al., 2008) in addition to enhanced
angiogenesis (Smadja et al., 2011) but detailed analysis of bone has not been reported. TSP1 is
expressed by OBs and is present in osteoid and mineralized bone matrix (Grzesik and Robey,
1994; Kannus et al., 1998; Robey et al., 1989) where it is directly deposited by bone-forming
OBs (Clezardin et al., 1989; Robey et al., 1989). TSP1 is involved in OB differentiation in part
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through activation of latent TGF-β (Bailey Dubose et al., 2012; Ueno et al., 2006), and TSP1
receptors CD47 and CD36 also regulate OB (Kevorkova et al., 2013; Koskinen et al., 2013).
TSP1 is a regulator of nitric oxide (NO) in endothelial cells, platelets, and vascular smooth
muscle cells (Chen et al., 2000; Isenberg et al., 2009), but only receptors CD36 and CD47 have
been implicated in NO regulation (Isenberg et al., 2009; Isenberg et al., 2006; Isenberg et al.,
2005). TSP1 has been implicated in OC activity, but its mechanism of action remains unknown
(Carron et al., 1995). TSP1-CD47 interactions play a role in the formation of multiple myelomadendritic cell fusions with bone-resorbing capacity (Kukreja et al., 2009), and TSP1-CD36
ligation can promote osteoclastic resorption on dentine slices (Carron et al., 2000). CD47-/- mice
have a bone resorption defect (Koskinen et al., 2013; Lundberg et al., 2007; Uluckan et al.,
2009), which we have shown is due to increased iNOS in OCs (Uluckan et al., 2009). Together
these data led us to hypothesize that OB-secreted TSP1 sequestered in bone matrix will modulate
OC function thereby coupling OB activity to OC formation.
In this study, we describe the role of bone-sequestered TSP1 in the maintenance of bone
homeostasis, both as a structural protein contributing to bone strength and as a signaling ligand
promoting OC formation. Here we have used mice genetically deficient in TSP1 and neutralizing
anti-TSP1 antibody to investigate the role of TSP1 in bone homeostasis. Together, these data
implicate a novel role for TSP1 in bone homeostasis, both in mediating bone matrix integrity and
by regulating OC formation as a matrix-derived paracrine signaling molecule. Our findings
provide an important rationale to monitor the effects on bone health of TSP1 pathway-directed
therapeutics, currently in clinical use and under development, especially in patients affected by
bone pathology such as osteoporosis and skeletal metastasis.
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Materials and Methods

Animals
TSP1-/- mice were originally obtained from Jack Lawler (Lawler et al., 1998) and backcrossed
over 20 times to C57BL/6J. TSP1-/- and TSP1+/+ mice were housed in shared pathogen-free
conditions according to the guidelines of the Division of Comparative Medicine, Washington
University School of Medicine. The animal ethics committee approved all experiments.
Reagents
Anti-TSP1 function blocking antibody, clone A4.1 (IgM, mouse anti-human)(Annis et al., 2006)
was purchased from Thermo Scientific (Waltham, MA). TSP1 is highly conserved among
species and clone A4.1 has cross-species reactivity with mouse and bovine TSP1. IgM istoype
control was purchased from eBioscience (San Diego, CA).
Micro-computed tomography
Tibiae and femurs from TSP1-/- and WT sex-matched mice were suspended in agarose and tibial
metaphyses and femoral mid-diaphysis were scanned by micro-computed tomography (uCT-40;
Scanco Medical) as described previously (Heller et al., 2012; Uluckan et al., 2009). For image
acquisition, the long bones were placed in a 13-mm holder and scanned. The cancellous region
was selected using contours inside the cortical shell on each 2d image. The growth plate was
used as a marker to determine a consistent location to start analysis and 40 slices were analyzed.
A 3-dimentional cubical voxel model of bone was built and calculations made: relative
trabecular bone volume over total volume, trabecular number, and trabecular spacing. The
cortical region was selected using contours outside the cortical shell at the mid-diaphysis and 50
slices were analyzed. The average cross-sectional geometry measurements were calculated for
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cortical thickness and total cross-sectional area. The bending moment of inertia was determined
using standard engineering parallel-axis theory as previously described (Brodt et al., 1999; Silva
et al., 2006).
Bone biomechanics
Immediately following dissection, femurs were frozen at -20OC for a minimum of 12 hours.
Femurs were thawed in phosphate-buffered saline for 1 h prior to use, and testing was carried out
at room temperature using a servohydraulic testing machine (8841 Dynamite, Instron, Norwood,
MA). Femurs were positioned on two supports 7 mm apart, and the central loading point was the
mid-diaphysis. Displacement was applied transverse to the long axis of the bone at a rate of 0.03
mm/s until failure. Force-displacement data were recorded at 60 Hz and analyzed to determine
stiffness (a measure of elastic resistance to bending), yield force (a measure of the force required
to permanently deform the bone), ultimate force (the highest force attained prior to failure), postyield displacement (a measure of ductility) and energy-to-fracture (a measure of overall
resistance to fracture) (Brodt et al., 1999; Silva et al., 2006). Estimated material properties
(elastic modulus, yield stress, ultimate stress) were calculated using standard engineering beam
theory that normalizes for bone size.
Reference point indentation
Femurs were subjected to reference point indentation as previously described (Randall et al.,
2009). A 25 µm testing probe was placed on the cortical bone surface and a preload force of
0.1N and a waveform of 10 cycles of 2N force was applied as a frequency of 2 Hz (Biodent,
Active Life Sciences, Santa Barbara, CA). Each bone was subjected to 3 indents 1 mm apart.
Measurements were made for each indent: initial indentation distance and indentation distance
increase (cycle 1 – cycle 10).
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Serum CTX assay
Carboxy-terminal telopeptide collagen crosslinks (CTX) was measured in the serum of overnight
fasted mice by ELISA (RatLaps; Immunodiagnostic Systems, Scottsdale, AZ) according to the
manufacturer’s instructions.
Serum P1NP assay
N-terminal propeptide of type I procollagen (P1NP) was measured in serum of overnight fasted
mice using ELISA (Immunadiagnostic Systems, Scottsdale, AZ) according to the manufacturer’s
instructions.
L-NAME administration
L-NAME (Sigma Aldrich, St. Louis, MO) was administered in the drinking water of 8 week old
mice for 6 weeks, changed every 2 days (40 mg/kg/day).
In vitro osteoclast differentiation
To generate macrophages, whole bone marrow cells were cultured in αMEM, 10% FBS, 1%
penicillin-streptomycin, 100 ng/ml MCSF for 3 days as previously described (Morgan et al.,
2010). To generate OCs, 9x104/ml were plated on plastic or bone powder as indicated and
cultured in αMEM, 10% FBS (on plastic), 1% penicillin-streptomycin, 50 ng/ml MCSF, 50
ng/ml RANKL, refed every 48 hours. Where indicated, macrophages were cultured with 5 µg/ml
antibody. TRAP staining was performed according to the manufacturer’s instructions (SigmaAldrich, St. Louis, MO).
In vitro osteoblast differentiation
To generate bone marrow stromal cells (BMSCs), whole bone marrow cells were cultured in
ascorbic-acid free αMEM, 10% FBS, 1% penicillin-streptomycin for 7 days. For OB
differentiation, 2x105 BMSC/ml were cultured in αMEM, 10% FBS, 1% penicillin-streptomycin,

49

!

10 mM β-glycerophosphate, 50 ug/ml ascorbic acid for 14 days, refed every 7 days. Cultures
were fixed in 10% neutral buffered formalin and stained with Alkaline Phosphatase (Fast Blue
RR salt, Sigma Aldrich) and 0.4% Alizarin Red. Chromogenic alkaline phosphatase was
quantitated according to manufacturer’s instructions (Sigma-Aldrich, St. Louis, MO). Alizarin
red stain was measured using the Osteogenesis Quantitation Kit according to manufacturer’s
instructions (Millipore, Billerica, MA).
Bone powder coated plates
Plates were coated with bone powder as previously described(Cremasco et al., 2012) with
modifications. Bone marrow was flushed from the long bones of WT and TSP1-/- mice, and the
bones were frozen at -20OC. Frozen bones were crushed to powder using a Bullet Blender Bead
Lysis Kit (Midsci, St. Louis, MO), and the powder was washed 3 times in 70% ethanol. Plates
were coated with 1:20 bone powder:PBS + 4 ug/ml poly-l-lysine for 4 hours at 68OC. Plates were
sterilized under UV light and experiments completed as described.
Quantitative reverse-transcription PCR
RNA was extracted using RNeasy Mini kit (Qiagen, Venlo, Netherlands) and cDNA generated
using iScript (Bio-Rad, Hercules, CA). Quantitative PCR was completed using SsoFast EVA
Green Supermix (Bio-Rad, Hercules, CA).
qRT-PCR primer sequences (forward/reverse)
NFATc1:
GGTAACTCTGTCTTTCTAACCTTAAGC / GTGATGACCCCAGCATGCACCAGTCA
DC-STAMP: ACAAACAGTTCCAAAGCTTGC / TCCTTGGGTTCCTTGCTTC
TRAP: CAGCTGTCCTGGCTCAAAA / ACATAGCCCACACCGTTCTC
β3 integrin: TGGTGCTCAGATGAGACTTTGTC / GACTCTGGAGCACAATTGTCCTT
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Cathepsin K: GAGGGCCAACTCAAGAAGAA / GCCGTGGCGTTATACATACA
iNOS: GGCAGCCTGTGAGACCTTTG / GCATTGGAAGTGAAGCGTTTC
cyclophilin: AGCATACAGGTCCTGGCATC / TTCACCTTCCCAAAGACCAC
In vivo calcein labeling
Calcein labeling was completed as previously described (Su et al., 2012). Briefly, mice were
injected 8 and 2 days prior to sacrifice with 20 mg/kg calcein (Sigma-Aldrich, St. Louis, MO) in
a 2% sodium bicarbonate solution i.p. Calveria were fixed in 70% ethanol and embedded in
methylmethacrylate and sectioned.
Bone histomorphometry
Bones were prepared and analyzed as previously described. Mouse tibiae were fixed in 10%
formalin for 24 hours and decalcified in 14% EDTA solution for 2 weeks. Paraffin embedded
sections were stained with TRAP. Sections were analyzed by a blinded operator according to
standard protocol using Bioquant Osteo V7 10.10 (Bioquant Image Analysis Corp.).
Statistical analysis
All experiments were analyzed using Student’s t-test. In calculating two-tailed significance
levels for equality of means, equal variances were assumed for both populations. Results were
considered to reach significance at p<0.05. *p<0.05; **p<0.01; ***p<0.001.
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Results

TSP1-/- mice had increased cancellous and cortical bone mass
We have previously shown that mice deficient in the TSP1-receptor CD47 have modestly
increased bone mass (Koskinen et al., 2013; Lundberg et al., 2007; Uluckan et al., 2009). To
determine if TSP1-/- mice would similarly display increased bone volume, we performed
microCT analysis on WT and TSP1-/- mice to evaluate cancellous and cortical bone. We
observed a significant increase in trabecular bone volume in 8 week-old (+32.6%), 16 week-old
(+112.1%), and 32 week old (+158.8%) TSP1-/- mice (Figure 2.1 A-B). Coordinately,
trabecular number was increased and trabecular spacing was decreased in TSP1-/- mice (Figure
2.2). This dramatic increase in trabecular bone volume is in contrast to the modest bone volume
phenotypes of TSP1-receptor deficient mice (CD47, CD36, β3 integrin-/- (Faccio et al., 2003a;
Kevorkova et al., 2013; Koskinen et al., 2013; McHugh et al., 2000; Uluckan et al., 2009)), and
is consistent with TSP1 binding to multiple receptors. TSP1-/- mice also had significantly
increased cortical bone thickness and total cortical area at 12 weeks (Figure 2.1 C-E), indicating
a geometrically larger bone in TSP1-/- compared to WT mice. Therefore, TSP1-/- mice had both
increased size and increased relative bone mass compared to WT mice.

TSP1 improved bone strength through effects on the bone material properties
Because TSP1 null mice showed enhanced cortical thickness and cross-sectional area
(Figure 2.1 C-E), and because TSP1 is a known component of the bone matrix (Clezardin et al.,
1989; Robey et al., 1989), we hypothesized that TSP1 deletion may influence bone mechanical
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properties. Bone mechanical properties are influenced by many factors including overall
structural morphology and the material properties (“quality”) of the bone matrix.
MicroCT analysis of the femoral mid-diaphysis showed a striking increase in moment of
inertia in TSP1-/- mice (+67.1%), predicting increased strength based on morphology (Figure
2.3 A). Interestingly, however, direct measurement of mechanical strength by 3-point bending
did not recapitulate these results. Bone is permanently deformed upon reaching its yield force
and eventually fractures after reaching its highest (ultimate) force. TSP1-/- femurs showed only a
modest increase ultimate force (+16.7%) and no difference compared to WT in yield force
(Figure 2.3 B-C). Notably, a normalized measure of yield force that accounts for differences in
morphology (yield stress) is significantly decreased in TSP1-/- femurs (Figure 2.3 D). This
suggests a bone material defect in TSP1-/- mice that offsets the morphological size advantage.
To directly evaluate the local material properties of the bone matrix, we performed
reference point indentation by applying a repetitive force on the cortical bone surface through a
small probe. TSP1-/- femurs had increased initial indentation distance and a larger increase in
indentation at the end of 10 cycles (Figure 2.3 E-F). These data indicate that TSP1-/- bone
material had less resistance to microfracture compared to WT control. Dynamic
histomorphometric analysis to quantitate bone formation rate and mineral apposition rates were
difficult to perform because of fuzzy and poor bone mineral labeling in the TSP1-/- mice (Figure
2.4 B), consistent with a bone mineral defect. Taken together, these mechanical and material
properties demonstrate that TSP1 plays a role in maintaining the matrix quality necessary for
normal bone strength.
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TSP1-/- mice had decreased bone resorption and OC formation
While we identified differences in long bone size and bone material properties that
contribute to reduced bone quality, the underlying mechanism leading to the increased bone mass
in TSP1-/- mice remained unclear. The progressive increase in trabecular bone volume with age
in TSP1 null animals (Figure 2.1 A-B) is consistent with a failure in bone resorption. To test
this, we measured serum markers of bone turnover, which include CTX (carboxy-terminal
telopeptide collagen crosslinks), a measure of osteoclastic bone resorption and P1NP (procollagen type I N-terminal telopeptide), a measure of OB function. There were no statistically
significant differences in serum P1NP at 8, 16, or 32 weeks of age (Figure 2.4 A) and no
differences in ex vivo OB formation assays (Figure 2.4 C-E). We did observe significant
decreases in serum CTX levels in TSP1-/- mice compared to WT controls at 8 weeks and 16
weeks of age (Figure 2.5 A) consistent with a defect in OC resorption. Histomorphometric
analysis of mouse tibiae showed that TSP1-/- mice did not have significantly different OC
number/bone surface at 8 or 32 weeks of age (Figure 2.6). To investigate the role of TSP1 in
osteoclastogenesis and function, we differentiated WT primary OCs from bone marrow
macrophages in vitro. TSP1 is secreted by activated platelets, leading to high levels of the
protein in blood serum. Fetal bovine serum (FBS), necessary in OC culture media, contains
approximately 100 ng/ml TSP1 (data not shown). To neutralize FBS-derived TSP1, we treated
cultures with TSP1 neutralizing antibody (clone A4.1). Notably, in control cultures, TSP1-/- OCs
were indistinguishable from WT OCs, indicating that exogenous, FBS-derived TSP1 was
sufficient to maintain normal OC formation (Figure 2.7). In contrast, OC differentiation in the
presence of anti-TSP1 antibody was dramatically reduced, while cells treated with the IgM
control antibody developed large multinucleated TRAP+ OCs (Figure 2.5 B, left panels; Figure
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2.7). Interestingly, while there was no change in NFATc1, a marker of OC lineage commitment,
RT-qPCR analysis showed decreased expression of OC differentiation markers (DC-STAMP,
TRAP, β3 integrin, Cathepsin K) in anti-TSP1 antibody treated cultures, consistent with reduced
osteoclastogenesis (Figure 2.5 C).
To define the temporal requirement of TSP1 in OC formation, we treated early (d0-2),
mid (d3-4), or late (d4-5) stage OC cultures with A4.1 to neutralize TSP1 at different times
during OC formation. We found that neutralizing TSP1 in early OC precursors (d0-2) was
sufficient to decrease OC differentiation, while mid- or late-stage TSP1 neutralization had no
effect (Figure 2.5 B). These data indicate that TSP1 promotes early-stage OC formation while it
is dispensable for later maturation.

Inhibition of NOS rescued TSP1-/- bone resorption phenotype
TSP1 is an established mediator of NO signaling in endothelium and inflammatory
macrophages (Chen et al., 2000; Isenberg et al., 2009), and we have previously shown that
TSP1-receptor CD47 null mice show reduced OC formation due to increased levels of iNOS
transcription (Uluckan et al., 2009). In primary OC cultures treated with TSP1 neutralizing
antibody, we saw a dramatic elevation of iNOS expression compared to isotype control (Figure
2.8 A). Neither nNOS nor eNOS were elevated in anti-TSP1 antibody treated cultures (data not
shown). To test whether the bone resorption defect in TSP1-/- mice was attributable to elevated
NO signaling, we inhibited NO production in vivo by administration of the pan-NOS inhibitor LNAME in the drinking water of TSP1-/- and WT mice (40 mg/kg/day) for six weeks. L-NAMEtreatment increased the serum CTX level of TSP1-/- mice to that of their WT counterparts,
demonstrating that osteoclastic bone resorption was restored (Figure 2.8 B). Together, these data
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indicate that aberrant NO signaling in TSP1-/- mice was in part responsible for decreased OC
function in vitro and in vivo.

TSP1 in bone was sufficient to inhibit OC iNOS
It is well established that TSP1 is secreted by OBs and is present in the bone matrix
(Clezardin et al., 1989; Robey et al., 1989). We found that TSP1 contributes to maintaining bone
strength (Figure 2.3), but its role as matricellular signaling molecule in the bone remained
unknown.
We hypothesized that bone-sequestered TSP1 signals to immature OCs to inhibit RANKL-induced iNOS. We therefore differentiated WT bone marrow macrophages into OC on plates
coated with bone powder derived from WT or TSP1-/- mice. The osteoclastogenic culture
medium was serum free to ensure that the bone was the only source of TSP1. OCs plated on
TSP1-/- bone powder had increased iNOS expression compared to the same cells plated on WT
bone after 24 hours of differentiation (Figure 2.9 A). Notably, the lineage marker NFATc1 was
unchanged between cells plated on WT and TSP1-/- bone, indicating that osteoclastogenic
signaling was initiated equally (Figure 2.9 A). Together, these data indicate that bonesequestered TSP1 plays a critical role in iNOS signaling during early osteoclastogenesis.
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Discussion

We demonstrate here that TSP1 is critical for the maintenance of bone homeostasis,
contributing both to matrix material integrity and regulation of OC formation (Figure 2.9 B).
TSP1-/- mice were protected from age-associated bone loss and had increased cross-sectional
area, but failed to show proportional resistance to bending. Instead, we found that TSP1 null
mice had a bone material properties defect, resulting in decreased bone material quality and
reduced strength. The increased trabecular bone mass in TSP1-/- mice was due to decreased
osteoclastic resorption that was rescued upon in vivo pharmacologic inhibition of NO signaling.
We demonstrated that TSP1 inhibition of iNOS was necessary for early OC formation, but was
dispensable for later OC maturation. Finally, we showed that bone-sequestered TSP1 modulated
OC iNOS levels, indicating TSP1 as a novel paracrine signaling molecule, coupling OB function
to OC formation.
The bone matrix is composed of two compartments: mineral of calcium-phosphate
hydroxyapatite crystals and osteoid of collagen (90%) and other non-collagenous proteins (10%,
NCP). Many diseases including osteogenesis imperfecta and rickets impact bone quality through
modification of the osteoid tissue or mineralized matrix leading to increased risk of fragility
fracture. Notably, TSP1 binds many components of the bone matrix, including collagen and
hydroxyapatite, as well as numerous NCPs including osteonectin, fibronectin, osteopontin, and
proteoglycans, among others (reviewed in (Tan and Lawler, 2009)). These NCPs are critical for
bone matrix organization, both for collagen organization and hydroxyapatite deposition (Termine
and Robey, 1996). In osteogenesis imperfecta patient OBs, secretion of TSP1 and its NCP
binding partners are misregulated, suggesting that TSP1 participates with collagen and other
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NCPs for osteoid organization (Fedarko et al., 1995). Our data indicate that TSP1 is critical for
maintaining the material properties of bone necessary for high bone quality. We postulate that
TSP1 mediates the proper physical organization and protein stoichiometry of the bone matrix
through its interactions with other bone matrix components. Further work is necessary to
understand the role of the matrix proteins that interact with TSP1 to mediate bone quality.
The TSP1-/- bones had both cancellous and cortical bone phenotypes. The increased area
and cortical thickness of the TSP1-/- bones suggest an effect of TSP1 loss on OB bone
formation. Assessment of bone formation rate and mineral apposition rates by dynamic
histomorphometry in the TSP1-/- mice were hampered by the lack of double labels and diffuse
single labels (Figure 2.4 B). These labeling abnormalities are consistent with a bone matrix
defect. Ex vivo OB formation assays were not abnormal in the TSP1-/- cells or in WT cells in the
presence of TSP1 neutralizing antibody (data not shown). It is possible that there was a
compensatory increase in bone mineral formation due to defects in bone quality or that there are
effects of TSP1 on osteocyte and OB formation and function that may be present early in
development. Experiments are underway to explore the role of TSP1 in OBs.
In addition to its role in maintaining bone matrix material integrity, we also found that
TSP1 binding to early OC precursors promotes differentiation. While our data supports the
hypothesis that bone-resident TSP1 regulates iNOS in early OC, it is also possible that TSP1
modulation of the matrix, including stoichiometry of NCPs and protein presentation, may
indirectly influence NO signaling. As ongoing research better characterizes the protein
interactions in the bone matrix, the impact of matricellular TSP1 on cell signaling will be
elucidated. Our data shows that exogenous TSP1 promotes osteoclastogenesis through
modulation of NO signaling in OC precursors, similar to its function in endothelial cells,
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platelets, and vascular smooth muscle cells through CD36 and CD47 (Chen et al., 2000; Isenberg
et al., 2009; Isenberg et al., 2006; Isenberg et al., 2005). The dramatic OC phenotype of TSP1
deficiency, in contrast with the modest effects reported for receptors CD47 and CD36 (Carron et
al., 2000; Kevorkova et al., 2013; Koskinen et al., 2013; Lundberg et al., 2007; Uluckan et al.,
2009), suggests that TSP1 binds multiple receptors to influence OC formation. We have
previously reported that CD47 promotes OC formation through inhibition of iNOS (Uluckan et
al., 2009). In the setting of bone homeostasis, OCs sense increased NO produced by iNOS early
in differentiation as negative feedback to regulate the extent of osteoclastic bone resorption
(Zheng et al., 2006). We demonstrated in vitro that TSP1 inhibits iNOS expression in OC
precursors, thereby permitting OC formation. Notably, inhibition of NO synthesis in vivo
rescued the TSP1-/- bone resorption defect, consistent with TSP1’s influence on OC through
modulation of NO signaling.
We present data to support novel roles of TSP1 that place it as a critical member of the
bone microenvironment. We propose the following model: TSP1 is directionally secreted by OB
into the matrix during bone formation (Clezardin et al., 1989; Robey et al., 1989). In the bone,
TSP1 promotes matrix material integrity through interactions with other essential bone matrix
proteins. Moreover, the matrix-derived TSP1 acts as a paracrine signaling molecule to promote
OC formation via inhibition of iNOS, thus linking OB function to OC formation via the bone
matrix (Figure 2.9 B).
Due to its pleiotropic nature, with roles in inflammation, angiogenesis, and bone health,
the TSP1-signaling axis represents a promising therapeutic target for many disease states. NOS
inhibitors, including the compound L-NAME used in our study, are under clinical investigation
to modulate blood pressure. Their converse, nitric oxide donors, have been in clinical use for
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decades to relieve angina and hypertension. Given our data of elevated OC activity upon
administration of L-NAME to TSP1-/- mice, it will be important to monitor the bone health of
patients administered these NO-targeted drugs long-term, especially in an elderly patient
population with common bone pathological comorbidities such as osteoporosis and
osteoarthritis.
Bone pathologies such as osteoporosis and bone metastasis are characterized by a
disruption of healthy bone turnover leading to pathologic fracture, hypercalcemia, and nerve
compression. Modulation of OCs and OBs represent an attractive point for therapeutic
intervention with agents such as bisphosphonates and anti-RANKL antibody (denosumab) in
clinical use (Weilbaecher et al., 2011). Our findings provide further rationale to target the TSP1pathway, especially in comorbidities such as osteoporosis and bone metastasis. Importantly, we
showed that TSP1-/- mice are protected from age-associated bone loss, but the increased bone
mass was accompanied by a loss in bone quality. This provides important rationale to monitor
bone health, both bone density and bone quality, as part of studies investigating TSP1-pathway
directed therapeutics for bone-related and other indications. As targeted drugs, including antiCD47 antibodies, TSP1 mimetics, and NOS inhibitors, enter development and clinical use, it will
be important to further investigate the role of TSP1, its receptors, and its downstream signaling
molecules in bone health, to identify and monitor both harmful and positive bone effects.
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Figure 2.1.
TSP1-/- mice had increased bone mass.
MicroCT analysis for calculation of bone morphological parameters: (A) Trabecular
bone volume of 8-, 16-, and 32-week-old WT and TSP1-/- mice tibiae (8- and 32-week
n=6/group; 16-week n=5/group). (B) Representative images of three- dimensional
microCT reconstruction. (C) Cortical bone thickness and (D) total area of 12-week-old
WT and TSP-/- mice femurs (WT n=5; TSP1-/- n=4). (E) Representative images of
three-dimensional microCT reconstruction. (scale bars = 500 um)
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Figure 2.2.
TSP1-/- mice had altered trabecular morphology.
MicroCT analysis for calculation of bone morphological parameters: (A) Trabeculae
number and (B) trabecular spacing of 8-, 16-, and 32-week-old WT and TSP1-/- mice
tibiae (8- and 32-week n=6/group; 16-week n=5/group).
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Figure 2.3.
TSP1 improved bone strength through effects on bone material properties.
12-week old WT and TSP1-/- femurs were evaluated for structural and material
strength. (A) MicroCT analysis of WT and TSP1-/- mice femurs for minimum moment
of inertia. Femurs were subjected to three-point bending to evaluate structural
mechanical parameters (B) ultimate force and (C) yield force (ns, p=0.0727). (D) Yield
stress was calculated to normalize for differences in cortical bone morphology (WT
n=5; TSP1-/- n=4). Reference point indentation was completed to evaluate local
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(n=3 tests/femur; WT n=5 femurs; TSP1-/- n = 3 femurs)
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Figure 2.4.
TSP1-/- mice had normal bone formation parameters.
(A) Pro-collagen type I (P1NP) was measured in the serum of fasted WT and TSP1-/mice (8-week WT n=6, TSP1-/- n=5; 16- and 32-week n=5/group). (B) Double calcein
labeling of 16-week old WT and TSP1-/- mice. (C) WT and TSP1-/- bone marrow
stromal cells were differenitated into OB in osteogenic media and stained for alkaline
phosphatase (ALP) and alizarin red on day 14. (D) ALP and (E) alizarin red were
quantitated on day 3 and day 7.
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Figure 2.5.
TSP1 deficiency resulted in decreased osteoclast function in vivo and reduced
osteoclast formation in vitro.
(A) Collagen breakdown products (CTX) was measured in the serum of fasted WT and
TSP1-/- mice (8-week n=5/group; 16-week n=4/group; 32-week n=7/group). (B) WT
bone marrow macrophages differentiated into OC in the presence of anti-TSP1 A4.1
antibody or IgM isotype control antibody at indicated days. TRAP staining for
multinucleated OC at day 5 shown (representative images of n>3 biological replicates,
scale bar = 0.25 mm). (C) qRT-PCR analysis for day 3 OC cultured with anti-TSP1
A4.1 or IgM control (n=3 biological replicates).
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Figure 2.6.
TSP1-/- mice did not have significantly reduced osteoclast numbers in vivo.
(A) 8-week old (left panels) and 32-week old (right panels) WT and TSP1-/- tibiae
were sectioned and stained for TRAP (scale bar = 2 mm; representative images of n >
3). (B) OC per bone surface and (C) OC surface per bone surface of 8- and 32-week
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Figure 2.7.
Neutralization of exogenous TSP1 prevents OC formation in wild type and TSP1-/- cells.
TRAP stain of WT or TSP1-/- bone marrow macrophages differentiated into OC in IgM
isotype control of TSP1 neutralizing antibody (clone A4.1). TRAP staining for multinucleated
OC at day 5 shown. (scale bar = 0.25 mm; representative images of n>3 biological replicates)
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Figure 2.8.
TSP1 regulates osteoclasts through inhibition of iNOS.
(A) qRT-PCR of iNOS from WT OC cultures in the presence of TSP1 neutralizing
antibody (A4.1) or istoype control (IgM). (n=3 biological replicates). (B) WT and
TSP1-/- mice were administered pan-NOS inhibitor L-NAME, 40 mg/kg/day for 6
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Bone-derived TSP1 is sufficient to inhibit iNOS in osteoclasts.
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TSP1 in bone biology.
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Table 2.1. Mechanical properties of WT and TSP1-/- femurs
Property
WT (n=5)
TSP1-/- (n=4)
Stiffness (N/mm)
58.71 ± 14.34
70.41 ± 7.961
Yield displacement (mm)
0.1180 ± 0.02089
0.1190 ± 0.01096
Post-yield displacement (mm)
0.2248 ± 0.01568
0.3100 ± 0.02640
Energy to fracture (N*mm)
2.806 ± 0.2241
3.940 ± 0.4317
Data are expressed as mean ± SEM
!
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p-value
0.5294
0.9699
0.0225
0.0419
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Chapter 3

Samsn1 deletion contributes to monoclonal gammopathy of undetermined significance and
multiple myeloma susceptibility through effects on multiple cell types

75

Abstract
Multiple myeloma (MM) is a malignancy of plasma B-cells that is invariably preceded by
monoclonal gammopathy of undetermined significance (MGUS), a pre-neoplastic plasma cell
proliferative disorder. Epidemiologic and population association studies demonstrated that
inherited susceptibility to MM is due to an increased risk of MGUS, rather than an increased rate
of transformation to overt malignancy. Therefore, prevalence of MM is likely mediated by
germline MGUS risk alleles. C57Bl/KaLwRij (KaLwRij) is a spontaneous mutant mouse strain
predisposed to benign idiopathic paraproteinemia (BIP), analogous to human MGUS. Using a
integrative approach, we combined KaLwRij x B6 SNP analysis (418 genes) and a MM patient
association study (180 genes) to identify five candidate genes likely to contribute to both murine
BIP-susceptibility and human MM risk. Surprisingly, we found KaLwRij mice had complete
germline deletion of one of the five candidate genes, Samsn1, a negative regulator of B-cell
activation. Samsn1 is expressed in hematopoietic cells, including B-cells and macrophages.
Consistent with the reported inhibitory function of SAMSN1 in B-cells, KaLwRij mice had
enhanced B-cell responses in vitro and in vivo. We also found that SAMSN1 re-expression
decreases proliferation in myeloma cells, demonstrating its inhibitory function in malignant Bcells. Moreover, we found KaLwRij macrophages to have increased proliferation and markedly
elevated expression of pro-tumorigenic M2 macrophage markers in vitro, and increased tumorpromoting activity in vivo, suggesting that Samsn1 regulates macrophage activation. Thus, we
identified Samsn1 as a gene contributing to BIP-susceptibility in KaLwRij mice through
mutually exclusive function in multiple cell types. It is likely that SAMSN1 and its pathway
members contribute to human MM progression, and may represent a point for preventative
therapeutic intervention.
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Introduction
Monoclonal gammopathy of undetermined significance (MGUS) is a hematological
disorder characterized by an expansion of one or more antibody-producing plasma cells in the
bone marrow, diagnosed by the presence of constant serum level of monoclonal paraprotein (<3
g/dL, “M-spike”). MGUS is a common syndrome of aging, with a prevalence of >3-5% in 50-70
year olds (Kyle et al., 2006; Landgren et al., 2009). While MGUS does not present with severe
clinical features, the disorder is not wholly benign, and is associated with increased fracture risk
and osteoporosis (Melton et al., 2005). Most significant, MGUS is the requisite precursor to
multiple myeloma (MM), and MGUS patients progress to overt malignancy at an annual rate of
1%. MM is the second most common hematological malignancy and is invariably fatal with a
~6 year median survival (Kumar et al., 2013). MM is characterized by an M-spike of >3 g/dL
and is clinically diagnosed by the presence of CRAB symptoms: hypercalcemia, renal
insufficiency, anemia, and lytic bone lesions. Because of the low rate of transformation to
myeloma (lifetime risk of 10-30% (Kyle et al., 2010; Sirohi and Powles, 2006; Zingone and
Kuehl, 2011)), however, MGUS is not clinically treated, and, due to lack of symptoms, most
cases remain undiagnosed until the patient presents with MM.
Epidemiologic and association studies indicate germline risk alleles contribute to MM
and MGUS susceptibility. Interestingly, the majority of plasma-cell intrinsic genetic events in
MM cells are present in MGUS-affected B-cells (Davies 2003). There is a higher incidence for
MM in African Americans that is the result of elevated risk to MGUS, rather than an increased
rate of conversion from MGUS to MM (Kyle et al., 2010; Kyle et al., 2006; Landgren et al.,
2006). In addition, there is a higher risk of MM in individuals with an MGUS-affected first
degree relative (Jain et al., 2009; Kyle et al., 2004; Vachon et al., 2009). Seven common variants
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were identified to confer a significant increase in MM risk in patients (Broderick et al., 2012;
Chubb et al., 2013). Interestingly, these SNPs also confer increased risk to MGUS, (Weinhold et
al., 2014), providing further evidence that MM risk is a consequence of increased risk to MGUS.
These studies highlight the necessity for a better understanding of the genetic predisposition to
MGUS.
A common spontaneous model for MGUS and MM is the C57Bl/KaLwRij mouse
(KaLwRij). KaLwRij has been inbred separate from the other C57Bl strains, including the
common wild-type C57Bl/6 (B6) strain, since approximately 1978. KaLwRij mice develop
benign idiopathic paraproteineima (BIP), analogous to human MGUS, with a penetrance of
~45% by 12 months of age (Radl and Hollander, 1974; Radl et al., 1978). Affected mice may
also progress to overt malignancy (~1%) with similar clinical features as MM, including severe
bone pathology (Alici et al., 2004; Asosingh et al., 2000; Vanderkerken et al., 2003). The 5T
myeloma cell lines were subcloned from these spontaneous myelomas, and may be transplanted
into KaLwRij mice to propagate the myeloma (Radl et al., 1979). Importantly, the 5TMM cell
lines will not engraft in closely related C57Bl/6 (B6) mice (Asosingh et al., 2000). Notably,
while KaLwRij is a model that recapitulates many features of human disease, the genetic basis of
BIP susceptibility in these mice remains unknown.
In this study, we identify Samsn1 as a candidate gene contributing to inherited risk of
KaLwRij mice to BIP, analogous to human MGUS. We used KaLwRij x B6 mouse SNP
analysis and a human MM population association study to identify a candidate gene list. We
found that KaLwRij mice were null for Samsn1, a negative regulator of B-cell activation, and
show that Samsn1 plays a role in B-cells, myeloma cells, and macrophages. We sequenced
Samsn1 in unaffected tissue from MM patients and found genetic variability that suggests that
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the SAMSN1 pathway may be relevant to human disease. Together, these data suggest that
Samsn1 underlies predisposition to BIP in KaLwRij mice and that the SAMSN1 pathway may be
involved in human MGUS and MM.
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Materials and Methods

Mice
129S1/SvImJ, A/J, AKR/J, BALB/cByJ, CBA/J, C3H/HeJ, C57BL/6J, DBA/2J, FVB/NJ,
NOD/ShiLtJ, SJL/J, and NOD-scid –IL2Rγ mice were purchased from Jackson Laboratory (Bar
Harbor, ME). C57Bl/KaLwRij mice were originally obtained from Dr. Gregory Mundy at
Vanderbilt University. Mice were housed in shared pathogen-free conditions according the
guidelines of the Division of Comparative Medicine, Washington University School of
Medicine. The animal ethics committee approved all experiments.
Immunization
Mice were immunized with 50 µg chicken gamma globulin (Biosearch Technologies, Novato,
CA) in complete or incomplete Freund’s adjuvant (Sigma-Aldrich, St. Louis, MO) by
intraperitoneal injection at 6 (primary immunization) and 7.5 (boosting immunization) months of
age. Blood samples were collected serially as indicated and stored frozen.
Immunoglobulin ELISA
Serum levels of immunoglobulins were monitored by ELISA for IgG and IgG2b according to
manufacture’s instructions (Bethyl Laboratories, Montgomery, TX).
Serum protein electrophoresis (SPEP)
SPEP test was performed with the SPIFE 3000 analyzer according to the manufacturer’s
instructions, using SPIFE SPE gel (Helena Laboratories, Beaumont, TX). The protein fractions
were quantified by densitometer (QuickScan 2000, Helena Laboratories, Beaumont, TX).
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Mouse phylogenetic analysis
KaLwRij genomic DNA was isolated from kidney using DNeasy blood & tissue kit as described
by the manufacturer (QIAGEN, Valencia, CA). SNP array analysis was performed using the
Affymetrix mouse diversity genotyping array. Sample preparation, hybridization and scanning
were performed by Jackson Laboratory according to the standard Affymetrix genotyping
protocol. The PHYLIP package (University of Washington, Seattle, WA) was used for the
phylogenetic analysis. A distance matrix was created by the Neighbor program based on the
KaLwRij and the published SNP data of other 11 strains (Didion et al., 2012; Yang et al., 2009).
The neighbor-joining algorithm was used to calculate a phylogenetic tree followed by the
Drawtree program for drawing the tree.
B6xKaLwRij mouse strain SNP analysis
SNP analysis was completed as previously described (Burgess-Herbert et al., 2008). KaLwRij
SNPs identified from the Affymetrix mouse diversity genotyping array were compared the
published SNP data of B6 mice (Yang et al., 2009). All genes annotated in Ensembl mouse
genome build 37 with ≥ 5 variants were included as candidate genes for further analysis.
Human subjects
DNA for WGAA and sequencing analysis was extracted from skin cells. The study cohort
consisting of 183 MM patients and 105 unaffected controls was approved by the Human
Research Protection Office at Washington University School of Medicine and at the Mayo
Clinic. Informed consent from the patients was obtained in accordance with the Declaration of
Helsinki.
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Whole-genome association analysis (WGAA)
305 MM patients and 353 unaffected volunteers were genotyped using Affymetrix 6.0 platform.
Data was analyzed by logistic regression analysis, adjusted for sex and group using PLINK
software (http://pngu.mgh.harvard.edu/purcell/plink/) (Purcell et al., 2007). SNPs in the 99th
significance percentile were included in further analysis. Genes containing these SNPs were
included as human candidate genes.
Sequencing of SAMSN1 in MM patients
Coding exons and adjacent intronic regions of SAMSN1 were sequenced in non-affected tissue
from 183 MM patients and 105 unaffected volunteers by the Genome Technology Access Center
at Washington University School of Medicine. PCR amplicons were constructed using the
Fluidigm Access Array (Fluidigm, San Francisco, CA). Samples were harvested and indexed
using the BioMark HD system (Fluidigm, San Francisco, CA). Samples were pooled into
sample libraries and sequenced on a MiSeq sequencer (Illumina, San Diego, CA). Following
annotation, variants in the case and control population were analyzed using logistic regression of
reference allele dosage in cases and controls.
Immunoblotting
Western blot was performed as previously described(Chu et al., 2012). Antibodies: SAMSN1
(Sigma-Aldrich, St. Louis, MO), actin (Sigma), and GFP (Santa Cruz Biotechnology, Dallas,
TX). Blots were incubated with horseradish conjugated secondary antibodies (GE Healthcare,
Fairfield, CT) and visualized by chemiluminescence (Pierce Biotechnology, Rockford, IL).
Primary cell culture
Splenic B-cells were negatively selected via MACS with anti-CD43 beads (Miltenyi Biotec,
Cologne, Germany). Cells were cultured in RPMI1650 media, 10% FBS, BME, 1% penicillin-
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streptomycin and stimulated with 10 ng/ml LPS and 20 ng/ml IL-4 for 72 hours. To generate
macrophages, whole bone marrow or peritoneal fluid was cultured in αMEM, 10% FBS, 1%
penicillin-streptomycin, 50 ng/ml MCSF for 3 days (bone marrow macrophages) or 12 hours
(peritoneal macrophages). Proliferation was measured by standard MTT assay (Sigma-Aldrich,
St Louis, MO). M2 polarized macrophages were generated by stimulating day 3 bone marrow
macrophages with 5 ng/ml IL-4 for 24 hours. Osteoclasts were generated by culturing bone
marrow macrophages in 50 ng/ml MCSF and 50 ng/ml RANKL for 3 days. Bone marrow
macrophages were generated by plating whole bone marrow cells in ascorbic acid-free αMEM,
10% FBS, 1% penicillin-streptomycin for 7 days in 5% oxygen followed by negative selection
via MACS with anti-CD45 beads (Miltenyi Biotec, Cologne, Germany).
5TGM1 cell culture
The 5TGM1 murine myeloma line was originally obtained from Dr. Gregory Mundy at
Vanderbilt University. 5TGM1 stably overexpressing Samsn1 were generated using lentivirus
transduction. Briefly, full-length mouse Samsn1 cDNA was subconed into an MSCV-PGK-Puro
plasmid (MPP). To generate lentivirus, SAMSN1-MPP or MPP control and lentiviral vectors
pCMVΔ8.9 and pM2G were transfected into HEK293T cells. Cell supernatant containing
lentivirus was then plated on 5TGM1 cells and selected with puromycin for 72 hours. Samsn1
expression was assayed by Western Blot. Cells were maintained in DMEM, 10% FBS, 1%
penicillin-streptomycin. Proliferation was measured by BrdU ELISA according to the
manufacture’s instructions (Roche Diagnostics, Indianapolis, IN).
M2-macrophage injection into 5TGM1 subcutaneous tumors
1x106 5TGM1 cells were injected subcutaneously in the right flank of NOD-scid –IL2Rγ female
mice. 14 days following tumor inoculation, 3x106 in vitro M2 polarized macrophages from B6
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or KaLwRij mice were injected directly into the tumor. Tumor burden was monitored by serum
murine IgG2b ELISA (Bethyl Laboratories, Montgomery, TX).
Macrophage comparison by microarray
Bone marrow macrophages were isolated from B6 and KaLwRij mice (n = 3 biologic replicates)
and RNA extracted using RNeasy Mini kit (Qiagen, Venlo, Netherlands). RNA samples were
submitted to the Genome Technology Access Center at Washington University School of
Medicine for hybridization using the GeneChip Mouse Gene 1.0 ST array (Affymetrix, Santa
Clara, CA). Data was analyzed using Partek Genomics Suite (Partek Inc., St. Louis, MO).
Differentially expressed genes were based on changes of 1.5 fold or more between B6 and
KaLwRij.
Quantitative reverse-transcription PCR
RNA was extracted using RNeasy Mini kit (Qiagen, Venlo, Netherlands) and cDNA generated
using iScript (Bio-Rad, Hercules, CA). Quantitative PCR was completed using SsoFast EVA
Green Supermix (Bio-Rad, Hercules, CA). All samples run with biological replicates of ≥ 2.
Primer sequences (forward/reverse):
Cyclophilin: AGCATACAGGTCCTGGCATC / TTCACCTTCCCAAAGACCAC
Samsn1: TTCACGCCAAGTCCCTATGAC / TTCCCATTGGTGTTTTGCACATA
FIZZ1: GCTGATGGTCCCAGTGAATA / CGTTACAGTGGAGGGATAGTTAG
YM1: GGGCATACCTTTATCCTGAG / CCACTGAAGTCATCCATGTC
VEGF: GGAGAGCAGAAGTCCCATGA / AGATCTCCACCAGGGTCTCA
DNA amplification
Genomic DNA was extracted from tail tissue or 5TGM1 culture using DNeasy blood & tissue kit
as described by the manufacturer (QIAGEN, Valencia, CA). DNA was amplified using standard
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PCR and amplified products were visualized on an agarose gel stained with ethidium bromide
under UV light.
Primer sequences (forward/reverse):
Gapdh: ACTTTGTCAAGCTCATTTCC / TGCAGCGAACTTTATTGATG
Samsn1 exons:
exon 1: TCACCAAGTGCTTTCCTTCC / AAGGCAGCAACGTGACATAA
exon 2: AGTCTTCATCATGCCCTTGG / GTTGCTTGGCAGATGGAGTT
exon 3: AACACACACACCGCCAAAGT / CCAAACCTCTTTCCAAACACA
exon 4: TCCCTTTTCAGGTTTCATGG / CTGGGACTAAACCCCCAATC
exon 5: CATCCGAGGACCACTGTTTT / TTTGCCTTTTCCTTCACCTG
exon 6: GGGTTCATCCCATTTTGTTG / TCTCACCTGCTTCCTGGACT
exon 7: TTCCTGGCTTATCCTGTGCT / GGAGCATCTCTGATCTTTGGA
exon 8: TAATGGGGGAAGGGATTAGG / AATGTCCTTACCTAACTCAGAAAAAT
exon 9: AGGCAGCCTGTTGAACAAT / TGTCCCAACTTAAACAATGCAC
exon 10: AATTGCAGTTGAATTCCACAAT / CATTGCACCAGATCCCTGTA
exon 11: ATGCCCTTTAAGGCAGATCA / TGCTAACAGCCACAGTCGAT
exon 12: CCCAGCACATATGAGTGAGTACTAT / GAACTGTTCTAGGAAATCAGGTTTA
Statistics
Data are shown as mean +/- SEM. Unless otherwise indicated, experiments were analyzed using
Student’s t-test or 1-way ANOVA as appropriate. Sequencing results were considered to reach
significance at p<0.05. *p<0.05; **p<0.01; ***p<0.001.
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Results

KaLwRij mice are an inbred strain susceptible to BIP
The KaLwRij mouse strain is reported to have a high frequency of BIP (Radl et al.,
1978). KaLwRij has been inbred separately from the other C57Bl strains, including B6, for over
30 years. To evaluate the relatedness of KaLwRij to B6 and other common lab strains, we
performed high-density mouse SNP array analysis using KaLwRij genomic DNA. The genetic
distance values were estimated based on the comparison between the KaLwRij SNP data and the
published single nucleotide polymorphism (SNP) data of 11 mouse strains (Yang et al., 2009),
selected for relative genetic diversity. These data demonstrated that, while closely related to B6,
KaLwRij is a unique inbred strain (Figure 3.1a).
We hypothesized that the predisposition of KaLwRij mice to BIP and myeloma would be
reflected in a unique antibody response to immune challenge. We evaluated immune response in
KaLwRij and the other 11 strains of mice. We treated mice with a primary and boosting
immunization, collected serial serum samples, and performed immunoglobulin ELISA and serum
protein electrophoresis (SPEP) (Figure 3.1b). We quantitated immunoglobulin isotypes IgG
(Figure 3.1c), IgM, and IgA. Differences in antibody isotype response among strains were
highly significant, indicating that immunoglobulin response was influenced by genetic
background.
In patients, SPEP is used to screen for the presence of clonal serum immunoglobulin
(Figure 1.4a). In mice, an abnormal peak in the gamma fraction suggests an accumulation of
monoclonal protein (M-spike) and indicates BIP, analogous to human MGUS. Most strains
presented with an M-spike post-primary or post-boosting immunization, indicating a normal
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immune response. By 18 months, however, the highest frequency of sustained M-spike was
found in KaLwRij (Table 1.1). Notably, the M-spike incidence in its closest related mouse
strain, B6, had resolved.
Our initial intention to map quantitative trait loci underlying murine BIP was confounded
by the fact that the ELISA profiles we obtained appeared to reflect heterogeneity of normal
immune responses rather than BIP development, and the SPEP signal took 18 months to
manifest, making repeated crosses impractical.

SNP analysis identified 418 genes divergent between B6 and KaLwRij haplotypes
To identify candidate loci underlying susceptibility to BIP, we compared B6 and
KaLwRij genotypes using high-density genome-wide SNP data. Of the 562,061 SNPs queried
across the 19 mouse autosomes, 21,133 SNPs varied between KaLwRij and B6. 11,323 were
single nucleotide variation (53.6% of variation observed), while the remaining 9,810 SNPs
grouped into 3,468 blocks of two or more consecutive non-identical SNPs. Included in the
observed SNP variation between B6 and KaLwRij, SNP no-calls in KaLwRij were also
identified. While most of these were solitary, there were 48 groups of two or greater consecutive
SNP no-calls, suggesting possible deletions affecting the locus. The largest blocks of no-calls
(two instances of 6 SNPs) fall in the Samsn1 locus that contains a total of 22 no-calls, the highest
number of observed in a single gene locus.
SNP blocks of two or greater fell within a total of 1,519 gene loci, with the highest
number of variants in Ptprt, containing 128 polymorphic SNPs between B6 and KaLwRij. For
subsequent analysis, we used an arbitrary cut-off off blocks of five or greater consecutive SNPs,
representing 56.1% of all SNPs that group in blocks of two or greater (Figure 3.2a). This
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defined a ranked candidate gene list of 418 genes that many contribute to BIP susceptibility in
KaLwRij mice (Table 3.2). !

Association analysis of MM patients identified common variants in 180 genes
Inherited genetic susceptibility to MM is likely due to increased risk of MGUS, rather
than increased risk of MGUS-to-MM transformation. We next sought to identify genetic loci
contributing to increased risk of human MGUS and MM. We performed whole-genome
association analysis (WGAA) in a Caucasian population of MM patients (n=305) and healthy
controls (n=353) to identify common genetic variation associated with MM and its requisite
precursor MGUS (Figure 3.2b). Relatively low sample size resulted in overall decreased
significance of SNPs, and only one SNP (rs1029654 in an intergenic region) reached genomewide significance (p<5×10-8). Therefore, to encompass all possible genetic variation
contributing to MGUS and MM risk, we queried SNPs in the 99th significance percentile as
differentially represented in MM patients versus controls (343 SNPs). This identified a
candidate gene list of 180 genes that may contribute to MM risk in humans (Table 3.3).

Integrating murine BIP and human MM genetic analyses identified 5 shared genes
To further narrow our gene list and ensure that we pursued loci of clinical relevancy, we
employed an integrative cross-species approach. Combining the murine KaLwRij x B6 SNP
analysis (418 genes) and human MM patient WGAA analysis (180 genes) yielded five shared
genes (Figure 3.3a). These genes are likely to contribute to inherited susceptibility to both
human MGUS/MM and murine BIP/myeloma: Fstl14, Samsn1, Ccm2, Tenm2, and Csmd1
(Figure 3.3b).
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KaLwRij mice have a germline homozygous deletion of Samsn1
MGUS is a syndrome characterized by a clonal expansion of plasma B-cells and
increased monoclonal immunoglobulin production; therefore, Samsn1, a negative regulator of Bcell function, drew particular interest. In activated B-cells, SAMSN1 is an adaptor protein in a
B-cell signaling inhibitory complex, binding SHP-1/2 and the ITIM domain of PIR-B (Wang et
al., 2010; Zhu et al., 2004). We hypothesized that inactivating SNPs in the Samsn1 locus of
KaLwRij would lead dysregulation of B-cells, increased B-cell activation, and subsequent BIP
development.
Close inspection of the KaLwRij SNP array data at the gene locus (Chromosome 16:
75,858,793-76,022,270; SNPs encompassing Chromosome 16: 75,815,371-75,999,906) revealed
that 29 no-calls in KaLwRij, suggesting a gene deletion (Figure 3.4a). We amplified the coding
regions of Samsn1 from DNA of KaLwRij and B6 by PCR. Surprisingly, all protein-coding
exons 1-12 of Samsn1 failed to amplify from KaLwRij germline DNA, further implying deletion
of the locus (Figure 3.4b). To confirm loss of protein expression anticipated by gene deletion,
we probed for SAMSN1 in splenic B-cells treated with IL-4 and LPS. Following treatment,
SAMSN1 was strongly expressed in B6 B-cells, but not in KaLwRij B-cells (Figure 3.4c).
Together, these data indicate a homozygous germline deletion of the Samsn1 gene in KaLwRij
mice.

KaLwRij mice have enhanced B-cell function
SAMSN1 has been shown to regulate B-cell activity, likely through its interactions with
the B-cell inhibitory protein PIR-B (Zhu et al., 2004). Samsn1-/- mice have enhanced B-cell
function compared to wild type, with increased proliferation in purified splenic B-cell culture
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and increased immunoglobulin response following immunization in vivo (Wang et al., 2010). To
evaluate whether KaLwRij mice showed similar increased B-cell activity, we cultured purified
CD43- splenic B-cells from KaLwRij and B6 mice. Importantly, we demonstrated loss of
SAMSN1 in KaLwRij cells, while purified splenic B-cells from B6 mice showed increased
levels of SAMSN1 protein following stimulation with IL-4 and LPS (Figure 3.4c). Next, we
measured proliferation of cultured primary B-cells in response to IL-4 and LPS stimulation by
MTT assay. KaLwRij B-cells displaced enhanced proliferative response to B-cell activation
compared to B6 (Figure 3.5a).
To test whether KaLwRij mice also had increased B-cell activity in vivo, we immunized
6 month old KaLwRij and B6 mice (Figure 3.1b) and monitored immunoglobulin response until
the mice reached 24 months of age. KaLwRij mice had a significant and progressive elevation in
IgG2b levels, first evident after primary immunization and continuing throughout the entirety of
the experiment, more than a year following immunization (Figure 3.5b). Therefore, we
demonstrated that KaLwRij mice showed considerable B-cell phenotypic overlap with Samsn1-/mice, both in vitro and in vivo.

Samsn1 decreases KaLwRij MM cell line 5TGM1 proliferation
The murine 5T myeloma cell lines were originally isolated from a myeloma-bearing
KaLwRij mouse (Asosingh et al., 2000; Radl et al., 1979), and subsequent subclones were
isolated, including 5TGM1. We confirmed Samsn1 deletion in 5TGM1 by PCR and RT-qPCR
(Figure 4.6a-b). Because SAMSN1 is down regulated in many human MM cell lines (Claudio et
al., 2001), and because of Samsn1’s role in regulating murine B-cell activation, we hypothesized
that Samsn1 was a myeloma-cell intrinsic tumor suppressor. 5TGM1 cells with stable
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overexpression of Samsn1 had decreased proliferation compared to control under both basal and
IL-6 stimulated conditions (Figure 3.6b-c). These data suggest that Samsn1 contributes in part
to myeloma tumor growth through a cell-intrinsic mechanism, consistent with its published antiproliferative role (Wang et al., 2010; Zhu et al., 2004).

KaLwRij mice have an altered MGUS- and MM-supportive bone microenvironment
Germline risk alleles to MGUS and MM may also influence cell types beyond premalignant plasma B-cells. MGUS and MM are both characterized by bone microenvironment
contributions from host cells including macrophages, bone marrow stromal cells, and osteoclasts
(reviewed in (Kuehl and Bergsagel, 2002)). Differential gene expression in whole bone marrow
of KaLwRij and B6 mice has been previously demonstrated (Fowler et al., 2011), but individual
cell-type gene expression variation has not been evaluated.
To query specific components of the BIP- and myeloma-supportive bone
microenvironment we cultured primary macrophages and CD45- bone marrow stromal cells
from whole bone marrow of B6 and KaLwRij mice. Microarray analysis identified 31
differentially expressed genes, including Samsn1, in bone marrow macrophages (Figure 3.7a,
Table 3.4) and eight differentially expressed genes in bone marrow stromal cells (Figure 3.7b,
Table 3.5). Notably, six genes from the macrophage analysis (Tnfrsf26, Samsn1, Lyrm7, Sparc,
Lrrc27, and Qpct) and three genes from the stromal cell analysis (Tnfrsf26, Tnfrsf23, and Lyrm7)
are included in the list of candidate genes underlying genetic susceptibility to BIP in KaLwRij
mice (Table 3.2).
We verified the Samsn1 expression observed in the bone marrow macrophage and bone
marrow stromal cell microarrays, and confirmed that bone marrow macrophages express Samsn1
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while bone marrow stromal cells are non-expressors (Figure 3.7c). To further evaluate the role
of Samsn1 in other BIP- and myeloma-supportive host microenvironment cells, we cultured
primary peritoneal macrophages and differentiated osteoclasts from bone marrow macrophages.
Osteoclasts expressed low but detectable levels of Samsn1. Peritoneal macrophages were high
Samsn1 expressors, with 70-fold higher levels than bone marrow macrophages (Figure 3.7c).
As a population, peritoneal macrophages are more mature and have increased activation
compared to bone marrow macrophages, likely due to recruitment to the peritoneal cavity in
response to infection (Wang et al., 2013). These data suggest that Samsn1 may play a role in
macrophage activation.

Enhanced macrophage function in KaLwRij mice
Gene expression data from bone marrow macrophages and peritoneal macrophages
suggest that Samsn1 may contribute to macrophage function, similar to its role in B-cells.
Notably, SAMSN1 binding partners (PIR-B and SHP-1/2) and pathway members (Syk, PI3K,
among others) in B-cells, also participate in macrophage biology (Brenner et al., 2004; Munitz et
al., 2010; Xie et al., 2014). To assess macrophage activity in Samsn1-null KaLwRij mice, we
cultured bone marrow macrophages from whole bone marrow and measured proliferation by
MTT assay. We found that KaLwRij macrophages had increased proliferation compared to B6
(Figure 3.8a).
Tumor associated macrophages (TAMs) are established host microenvironment
contributors to myeloma pathogenesis (reviewed in (Asimakopoulos et al., 2013; Berardi et al.,
2013; Ribatti et al., 2013)). TAMs are broadly classified as anti-tumor M1 macrophages and
pro-tumor M2 macrophages. In vitro, macrophage polarization to M1 requires stimulation with
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interferon-gamma, while polarization to M2 is induced upon addition of IL-4. Under basal
conditions, that is, without the addition of any stimulatory cytokines, we found that KaLwRij had
significant and dramatic elevation of M2-macropahge markers FIZZ1 and YM1 in both bone
marrow macrophages (Figure 3.8b) and peritoneal macrophages (Figure 3.8c). TAMs from
MM patients promote tumor growth through vasculomimicry, including increased expression of
pro-angiogenic VEGF. We found that KaLwRij had increased levels of VEGF transcription
compared to B6 in both bone marrow (Figure 3.8b) and peritoneal (Figure 3.8c) macrophage
cultures. These data suggest that under homeostatic conditions, KaLwRij macrophages are
skewed towards a pro-tumor M2 polarization phenotype.
To evaluate the ability of KaLwRij M2 macrophages to promote tumor growth in vivo,
we inoculated 5TGM1 myeloma cells subcutaneously in NOD-scid –IL2Rγ mice. Once tumors
were established (day 14), we injected B6 or KaLwRij ex vivo M2-polarized macrophages
directly into the tumor and monitored tumor growth by IgG2b, the 5TGM1 Ig clonotype (Figure
3.8d). Tumors injected with KaLwRij M2 macrophages had significantly increased tumor
growth as measured by serum IgG2b compared to tumors injected with B6 M2 macrophages
(Figure 3.8e; representative tumors Figure 3.8f). Together, these findings indicate that
KaLwRij macrophages have enhanced activation and contribute to myeloma pathogenesis.

SAMSN1 genetic variation in unaffected tissue of MM
To directly investigate the impact of SAMSN1 to confer risk in patients, SAMSN1 exome
sequencing was performed on non-affected tissue from MM patients (n=183) and healthy
controls (n=105). In total, we identified 38 SNPs contained in the protein coding regions, 5’ and
3’ untranslated regions (UTR), and exon/intron boundaries (Table 3.6). Of these, 15 SNPs only
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occurred in one individual. While the majority of variants were previously known and annotated
in the dbSNP database, we identified six novel SNPs, all private variants. Of the annotated
SNPs, six fell in the 3’UTR, three in the 5’UTR, and two SNPs were located in exon/intron
splice regions. In addition, we observed seven annotated missense variants. The remainder 20
SNPs were silent mutations or fell in intronic regions or were unannotated. Two variants
reached statistical significance, rs2822790 (OR = 0.5098, p = 0.0472) and rs2822792 (OR =
0.5098, p = 0.0472). Both variants were present at lower frequency in MM cases (4.12%) than
controls (8.09%), suggesting that the alternate allele may be protective. While few SNPs
reached statistical significance, the variability observed in MM patients suggests that the
SAMSN1 pathway may play a role in human MGUS and MM pathogenesis.
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Discussion

Using a combinatorial genetics approach, we identified genes underlying inherited
susceptibility to MGUS and MM in humans and in mice. Specifically, this study identifies
Samsn1 as a novel MGUS/MM susceptibility gene, likely conferring risk via effects in both preneoplastic B-cells as well as host supportive macrophages. We found that KaLwRij mice are null
for Samsn1, reported to have decreased expression in human MM cell lines (Claudio et al.,
2001), thus providing compelling evidence that Samsn1 is a permissive allele in both mouse and
human pathogenesis. KaLwRij mice phenocopied the published enhanced B-cell response in
Samsn1-/- mice (Zhu et al., 2004). We further found a cell-intrinsic role for Samsn1 as a tumor
suppressor in malignant myeloma cells. We identified a novel putative role for Samsn1 in
macrophages, with KaLwRij macrophages exhibiting enhanced macrophage activation under
basal conditions and increased ability to enhance myeloma growth in mice. Finally, we found
two SNPs at reduced frequency in a MM patient population, providing further evidence that
germline variants SAMSN1 may confer increased risk to MGUS and MM in humans. Together,
these data indicate that Samsn1 confers risk to murine BIP and human MGUS with roles both in
the pre-neoplastic B-cell and in the host macrophages.
While KaLwRij mice are a widely used spontaneous model of MGUS and MM, the
genetic basis for its susceptibility to BIP remains largely unknown. SNP analysis of KaLwRij x
B6 revealed more than 1000 genes containing multiple variants, including several deletions, in
the KaLwRij strain. We generated a candidate gene list underlying inherited susceptibility to
BIP in KaLwRij of 418 genes. Importantly, it is likely that multiple genes contribute to the
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complex trait of BIP, and investigation of additional candidate genes in KaLwRij mice is
underway.
To query genetic loci conferring risk to human MGUS and MM and ensure that we were
pursuing genes with clinical relevancy in the KaLwRij mouse model, we completed a WGAA of
human MM patients and healthy controls. Typically, sample sizes of greater than 2000 cases and
controls are necessary to identify causal variants in WGAA; published MM WGAA analyzed
1675-4692 cases and 5903-10990 controls to identify risk loci with genome-wide significance
(Jain et al., 2009; Kyle et al., 2004; Vachon et al., 2009). In the study described here, low
sample size (205 cases, 353 controls) resulted in overall decreased significance of SNPs. To
ensure inclusion of all biologically significant genetic variation, therefore, we queried SNPs in
the 99th significance percentile that fell in 180 gene loci. Importantly, we identified SNPs in
three of the seven previously published genetic loci associated with MGUS and MM risk
(2p23.3, 3p22.1, and 7p15.3), validating our approach.
Finally, in order to identify candidate genes for biologic validation in the KaLwRij mouse
model, we combined the mouse and human gene sets. This approach ensures clinical relevancy
of further work in gene variant validation and investigation of biologic function. Moreover,
combining the mouse and human datasets also guarantees that the human variants of interest
have a murine counterpart, providing a practical, relevant, and immediate mouse model. Using
this integrative approach, we identified five genes that may underlie susceptibly murine BIP and
also contribute to MGUS and MM risk in patients.
Because it has been implicated in human MM cell lines and has an established role in
regulating B-cell activation, we investigated the Samsn1 locus in the KaLwRij mouse strain.
Surprisingly, we found that KaLwRij had homozygous germline deletion for the coding regions
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of Samsn1. Moreover, KaLwRij mice have a similar phenotype as the the published enhanced
B-cell response of Samsn1-/- mice with increased B-cell proliferation in vitro and enhanced and
sustained antibody response in vivo (Wang et al., 2010). These data strongly indicate that loss of
Samsn1 in pre-malignant plasma B-cells confers increased risk of developing BIP in mice.
Next, we evaluated the role of Samsn1 in myeloma cells. In human MM cell lines,
Samsn1 expression is dramatically reduced (Claudio et al., 2001), suggesting a role as a tumor
suppressor in myeloma. Like the KaLwRij mouse, the KaLwRij-derived myeloma cell line
5TGM1 is null for Samsn1. Overexpression of Samsn1 in 5TGM1 reduces in vitro proliferation
under both basal and pro-tumorigenic conditions. These data provide compelling evidence that
Samsn1 is a myeloma-autonomous intrinsic negative regulator of tumor growth.
While it is well established that genetic risk factors contribute to susceptibility to MM,
the majority of genetic alterations in MM cells are already present in MGUS plasma cells
(Davies et al., 2003). These data suggest that plasma-cell extrinsic factors contribute to the
conversion of MGUS to MM. Rather than being confined to the affected plasma cell, it is likely
that genetic susceptibility alleles are expressed in both the pre-malignant B-cell and in supportive
host microenvironment cells.
To investigate specific cell types of the bone microenvironment in BIP-susceptible
KaLwRij mice, we completed gene expression analysis of B6 and KaLwRij bone marrow
macrophages and bone marrow stromal cells. 31 genes were differentially expressed in B6 and
KaLwRij bone marrow macrophages, and eight genes were differentially expressed in bone
marrow stromal cells. Interestingly, six of the 31 differentially expressed macrophage genes
(including Samsn1) and three of the eight differentially expressed stromal cell genes contain
germline variants in KaLwRij mice as identified in the B6xKaLwRij SNP analysis. This
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suggests that genetic variation likely influences these genes’ macrophage expression and
provides further evidence of B-cell extrinsic activity of BIP susceptibility alleles.
Samsn1 is expressed in many cells of the hematopoietic lineage, and we found that
Samsn1 is expressed by bone marrow macrophages and, to a greater extent, peritoneal
macrophages from B6 mice. Increased expression in the more mature peritoneal macrophages
compared to bone marrow macrophages led us to hypothesize that Samsn1 may participate in
macrophage activation via similar mechanisms as its role in B-cells.
Host tumor-associated macrophages (TAMs) have been implicated in promoting MM
progression. Macrophages from MM patient bone marrow are functionally distinct from bone
marrow macrophages from MGUS patients (Scavelli et al., 2008). MM tumor-associated
macrophages (TAMs) support MM progression directly through elevated secretion of protumorigenic factors such as IL-6 (Kim et al., 2012; Zheng et al., 2009) and by promoting
angiogenesis through elevated expression of VEGF (Ribatti et al., 2006; Scavelli et al., 2008;
Vacca and Ribatti, 2011).
We investigated KaLwRij macrophages to determine whether they had increased capacity
to support BIP- and myeloma cells. Non-stimulated KaLwRij bone marrow macrophages and
peritoneal macrophages had significantly increased macrophage activation, with elevated protumorigenic M2 macrophage markers. These data suggest that, similar to its role in B-cells,
Samsn1 negatively regulates macrophage activation. Importantly, we further demonstrated that
KaLwRij M2-polarized macrophages potently increased myeloma tumor growth in vivo.
Together, these data indicate that KaLwRij Samsn1-null macrophages have enhanced
macrophage response and a greater capacity to support tumor growth in vivo.
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Finally, we sought to identify whether SAMSN1 germline variants confer risk to MM in a
patients. We sequenced SAMSN1 in 183 MM patients and 105 controls. We observed 38 SNPs
and identified six rare variants that are not annotated in the dbSNP database. Two SNPs had
greater frequency in the control population, suggesting that they may confer MM or MGUS
resistance. Further GWAS studies and sequencing of normal tissue from MM patients in
necessary to validate and expand upon these findings. SAMSN1 does not represent the only
possible locus for genetic lesions; variation in other members of the SAMSN1 signaling pathway
likely also contribute to MM susceptibility. Further work is necessary to elucidate binding
partners and downstream effects of SAMSN1 in human cells, and in different cell types
including macrophages.
Described here is a novel integrative approach to identify candidate genes contributing to
risk of murine BIP and human MGUS and MM. Combining mouse and human datasets was
successful in identifying genes relevant to human disease, including Samsn1. BIP-prone
KaLwRij mice harbor a homozygous deletion of Samsn1, the first germline mutation identified
in the KaLwRij strain. We demonstrate that Samsn1 plays functionally important and cellautonomous roles in multiple cell types involved in MM pathogenesis, including B-cells (as
previously published), in myeloma cells, and in host supportive macrophages. Importantly,
while our work focused on the role of Samsn1, other identified genes listed are also promising
candidates to influence MM risk in multiple cell types, and work is ongoing to investigate these
candidates. In particular, candidate gene Fstl4 is especially intriguing with possible downstream
effects on B-cell immunoglobulin production and M2 macrophage activation (Ogawa et al.,
2008; Sierra-Filardi et al., 2011). In conclusion, this work informs and prioritizes ongoing and
future human genetics studies and mechanistic studies in mice. It is highly likely that SAMSN1
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and other members of its pathway play important roles in MGUS and MM pathogenesis in
humans, and future work will further define the effects of Samsn1 in myeloma progression as
well as explore other risk loci contributing to MGUS and MM susceptibility.
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Figure 3.1.
Immunoglobulin responses are significantly different between mouse strains.
(a) Phylogenetic tree demonstrating genetic distances of 12 strains of mice by whole
genome SNP array. (b) Schema for immunization and serial serum sample protocol.
Serum was collected at baseline (T0), post-primary immunization (T1), post-boosting
immunization (T2), 12 months (T3), and 18 months (T4). (c) Serum IgG analysis of
serial serum samples by ELISA.
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Combinatorial genetic approach identified a candidate gene list underlying human MGUS and murine BIP.
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Differential gene expression in B6 and KaLwRij bone marrow macrophages and
bone marrow stromal cells.
Microarray analysis of gene expression in B6 and KaLwRij (a) bone marrow
macrophages and (b) bone marrow stromal cells.. (c) Samsn1 expression in B6
peritoneal macrophages (PM) bone marrow macrophages (BMM), osteoclasts (OC),
and bone marrow stromal cells (BMSC).
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KaLwRij mice have enhanced pro-tumorigenic macrophage activation
Proliferation of B6 and KaLwRij macrophages was measured by MTT assay. (b) M2
macrophage polarization markers (FIZZ1, YM1) and VEGF in (b) bone marrow
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Table 3.1. Mice with positive M-spike on SPEP
Strain
KaLwRij
C57BL/6J
129S1/SvlmJ
A/J
AKR/J
BALB/cByJ
C3H/HeJ
CBA/J
DBA/2J
FVB/NJ
NOD/ShiLtJ
SJL/J

Baseline
0/12 (0)
0/10 (0)
0/10 (0)
0/10 (0)
0/10 (0)
0/10 (0)
0/10 (0)
0/10 (0)
0/10 (0)
0/10 (0)
2/10 (20)
0/10 (0)

Post-PI
1/12 (8)
0/10 (0)
2/9 (22)
7/7 (100)
4/7 (57)
3/10 (30)
3/8 (38)
3/30 (30)
1/9 (11)
1/10 (10)
7/3 (43)
0/9 (0)

Post-BI
2/11 (18)
4/10 (40)
6/9 (67)
4/7 (57)
5/6 (83)
3/9 (33)
5/8 (63)
1/10 (10)
1/9 (11)
6/10 (60)
4/5 (80)
4/5 (80)

M-spike positive mice / total mice (percentage)
No strain AKR/J mice survived to 18 months.
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12 mo
8/11 (73)
3/9 (33)
2/8 (25)
0/4 (0)
1/2 (50)
4/9 (44)
4/8 (50)
6/7 (86)
0/5 (0)
4/9 (44)
0/5 (0)
1/5 (20)

18 mo
5/9 (56)
0/7 (0)
0/8 (0)
0/2 (0)
-0/7 (0)
0/2 (0)
0/1 (0)
0/2 (0)
0/6 (0)
0/4 (0)
1/3 (33)

Table 3.2. Candidate genes underlying genetic susceptibility to BIP in KaLwRij mice
Gene
SNP score
Ptprt
128
Thsd4
109
Arfip1
102
Dab1
95
5033411D12Rik
95
Shank2
92
Rora
85
Cdh4
75
Elmo1
74
Ush2a
68
Esrrg
63
Fgfr2
62
Dock1
62
Sgcd
61
Fstl5
58
Fstl4
54
Gm12132
52
Pou6f2
44
Kcnq1
43
Kcnq5
42
Gm12239
41
Adamtsl1
38
Map2k5
37
A230004M16Rik
34
Samsn1
33
Stpg2
33
Slc24a2
32
C1qtnf7
32
Ptprd
31
Wdr17
30
Col23a1
29
Arid5b
27
Vps41
27
Ano1
26
Tln2
26
Aoah
25
Mark1
25
Nxph1
25
Unc5c
25
Iqsec1
24
Vps13c
24
Znrf3
24
Dhx35
23
D7Ertd443e
23
Neo1
23
Focad
23
Tcerg1l
22
Adcy1
21

Ensembl gene ID
ENSMUSG00000053141
ENSMUSG00000032289
ENSMUSG00000074513
ENSMUSG00000028519
ENSMUSG00000055137
ENSMUSG00000037541
ENSMUSG00000032238
ENSMUSG00000000305
ENSMUSG00000041112
ENSMUSG00000026609
ENSMUSG00000026610
ENSMUSG00000030849
ENSMUSG00000058325
ENSMUSG00000020354
ENSMUSG00000034098
ENSMUSG00000036264
ENSMUSG00000085301
ENSMUSG00000009734
ENSMUSG00000009545
ENSMUSG00000028033
ENSMUSG00000086020
ENSMUSG00000066113
ENSMUSG00000058444
ENSMUSG00000087306
ENSMUSG00000022876
ENSMUSG00000047940
ENSMUSG00000037996
ENSMUSG00000061535
ENSMUSG00000028399
ENSMUSG00000039375
ENSMUSG00000063564
ENSMUSG00000019947
ENSMUSG00000041236
ENSMUSG00000031075
ENSMUSG00000052698
ENSMUSG00000021322
ENSMUSG00000026620
ENSMUSG00000046178
ENSMUSG00000059921
ENSMUSG00000034312
ENSMUSG00000035284
ENSMUSG00000041961
ENSMUSG00000027655
ENSMUSG00000030994
ENSMUSG00000032340
ENSMUSG00000038368
ENSMUSG00000091002
ENSMUSG00000020431

Chr Strand Start (bp) End (bp)
2
161521990 162661147
9
59966931 60522046
3
84496093 85887516
4
+
103619359 104744844
13
16857855 17694732
7
+
144001928 144424494
9
+
68653786 69388246
2
+
179442431 179899373
13
+
20090507 20608353
1
+
188262023 188965041
1
+
187608791 188214885
7
130162451 133123350
7
+
134670687 135173639
11
46896253 47988969
3
+
76074270 76710019
11
+
52764634 53188538
11
+
40008194 40337831
13
18121101 18382041
7
+
143107254 143427042
1
21398403 21961942
11
+
55772088 56070848
4
+
86053915 86428385
9
63163769 63377902
11
+
41710342 41973117
16
75858793 76022270
3
+
139205694 139710299
4
86983124 87230477
5
+
43515569 43618817
4
75941238 78211961
8
54629055 54887184
11
+
51289920 51583918
10
68095593 68278726
13
+
18717292 18866809
7
144588549 144751974
9
67217087 67559703
13
+
20794119 21024252
1
184896443 184999549
6
+
8948431
9249032
3
+
141465564 141834924
6
90659598 90810123
9
+
67840396 67995634
11
5276324
5444847
2
+
158794807 158858214
7
134266262 134385661
9
58874679 59036441
4
+
88094629 88411011
7
138208974 138397730
11
+
7063489
7178506
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Band
H2
B
F1
C6
A2
F5
C
H4
A2
H6
H5
F3
F3
B1.1
E3
B1.3
A5
A2
F5
A4
B1.3
C4
C
A5
C3.1
H1
C4
B3
C3
B1.3
B1.3
B5.2
A2
F5
C
A2
H5
A1
H1
D1
C
A1
H1
F3
B
C4
F4
A1

Table 3.2. con't
Gene
Tspan5
Ldb2
Ebf1
Stk32c
Tns3
Spata17
Prom1
Itga11
Atg2b
Bmpr1b
4933427D06Rik
Kcnn3
Rab28
Coro2b
Tnip1
Trim2
Foxp2
Fam196a
Nf2
Osbp2
Phf14
Etl4
Rtel1
Akap9
Dscam
Gm20388
Lrba
Rap1gds1
Car12
Adamts2
Ppp1r16b
Arhgef11
Mgmt
Map2k1
Ankrd36
Pdgfc
Gpm6a
Lyplal1
Ak7
2410076I21Rik
Glra1
Prdm15
Slc22a4
Vit
Strn
Fam83d
Sepsecs
Vegfc

SNP score
21
21
21
20
20
20
20
20
20
20
20
19
19
19
18
18
18
18
17
17
17
17
17
17
17
17
16
16
16
16
16
16
16
15
15
15
15
15
15
15
14
14
14
14
14
14
14
14

Ensembl gene ID
ENSMUSG00000028152
ENSMUSG00000039706
ENSMUSG00000057098
ENSMUSG00000015981
ENSMUSG00000020422
ENSMUSG00000026611
ENSMUSG00000029086
ENSMUSG00000032243
ENSMUSG00000041341
ENSMUSG00000052430
ENSMUSG00000055403
ENSMUSG00000000794
ENSMUSG00000029128
ENSMUSG00000041729
ENSMUSG00000020400
ENSMUSG00000027993
ENSMUSG00000029563
ENSMUSG00000073805
ENSMUSG00000009073
ENSMUSG00000020435
ENSMUSG00000029629
ENSMUSG00000036617
ENSMUSG00000038685
ENSMUSG00000040407
ENSMUSG00000050272
ENSMUSG00000092329
ENSMUSG00000028080
ENSMUSG00000028149
ENSMUSG00000032373
ENSMUSG00000036545
ENSMUSG00000037754
ENSMUSG00000041977
ENSMUSG00000054612
ENSMUSG00000004936
ENSMUSG00000020481
ENSMUSG00000028019
ENSMUSG00000031517
ENSMUSG00000039246
ENSMUSG00000041323
ENSMUSG00000074269
ENSMUSG00000000263
ENSMUSG00000014039
ENSMUSG00000020334
ENSMUSG00000024076
ENSMUSG00000024077
ENSMUSG00000027654
ENSMUSG00000029173
ENSMUSG00000031520

Chr Strand Start (bp) End (bp)
3
+
138742195 138904433
5
44472133 44799707
11
+
44617317 45008091
7
139103638 139213307
11
8431652
8664535
1
187044648 187215465
5
43993625 44102032
9
+
62677826 62783982
12
105613539 105685241
3
141837136 142169425
6
+
88950683 89110030
3
+
89520164 89667761
5
41624976 41708155
9
62419492 62537044
11
54910785 54962917
3
84160439 84305446
6
+
14901349 15441977
7
134881926 134938430
11
4765845
4849536
11
3703731
3863903
6
+
11907809 12081197
2
+
19909780 20810713
2
+
181319739 181356616
5
+
3928054
4080209
16
96592079 97170752
8
+
119910841 124345722
3
+
86224690 86782693
3
138925906 139075199
9
+
66713686 66766845
11
+
50602084 50807573
2
+
158665398 158766334
3
+
87617559 87738034
7
+
136894611 137128187
9
64185770 64253631
11
+
5569684
5689337
3
+
81036416 81214040
8
+
54954728 55060877
1
186087731 186117310
12
+
105705982 105782447
9
58652856 58741559
11
55514238 55608198
16
97791467 97851850
11
53983123 54028090
17
+
78508063 78627409
17
78649913 78737196
2
+
158768093 158786637
5
52640087 52669729
8
+
54077532 54186454
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Band
H1
B3
B1.1
F4
A1
H5
B3
B
E
H1
D1
F1
B3
B
B1.3
F1
A1
F3
A1
A1
A1
A3
H4
A1
C4
E1
F1
H1
C
B1.3
H1
F1
F3
C
A1
E3
B1.3
H5
E
B
B1.3
C4
B1.3
E3
E3
H1
C1
B1.3

Table 3.2. con't
Gene
Zfyve9
Iqch
Gpatch2
Myo9a
Adam12
Atp10b
Ppapdc1a
Lrig3
Ascc2
Nup210l
Ddah1
Pias1
Eri3
Mtmr3
Rtkn2
Heatr5b
Pnldc1
Gm12160
Gm11376
Igsf5
Stard3nl
Sh3gl2
Fam154a
Mllt3
Podn
Stra6
Nptn
Map9
Acot11
Nudcd3
Fat2
Tox2
Ccm2
Tmprss2
Csf2
Gabrg2
Prkd3
Eif2ak2
Pja2
4930555F03Rik
Scaper
Rxfp1
Megf11
Ppfia1
Rapgef6
Osbpl2
Olfr56
Gal3st1

SNP score
14
14
14
14
14
14
14
13
13
13
13
13
13
13
13
13
13
13
13
12
12
12
12
12
12
12
12
12
12
12
12
12
11
11
11
11
11
11
11
11
11
11
11
11
11
11
11
11

Ensembl gene ID
ENSMUSG00000034557
ENSMUSG00000037801
ENSMUSG00000039210
ENSMUSG00000039585
ENSMUSG00000054555
ENSMUSG00000055415
ENSMUSG00000070366
ENSMUSG00000020105
ENSMUSG00000020412
ENSMUSG00000027939
ENSMUSG00000028194
ENSMUSG00000032405
ENSMUSG00000033423
ENSMUSG00000034354
ENSMUSG00000037846
ENSMUSG00000039414
ENSMUSG00000073460
ENSMUSG00000087089
ENSMUSG00000087140
ENSMUSG00000000159
ENSMUSG00000003062
ENSMUSG00000028488
ENSMUSG00000028492
ENSMUSG00000028496
ENSMUSG00000028600
ENSMUSG00000032327
ENSMUSG00000032336
ENSMUSG00000033900
ENSMUSG00000034853
ENSMUSG00000053838
ENSMUSG00000055333
ENSMUSG00000074607
ENSMUSG00000000378
ENSMUSG00000000385
ENSMUSG00000018916
ENSMUSG00000020436
ENSMUSG00000024070
ENSMUSG00000024079
ENSMUSG00000024083
ENSMUSG00000031559
ENSMUSG00000034007
ENSMUSG00000034009
ENSMUSG00000036466
ENSMUSG00000037519
ENSMUSG00000037533
ENSMUSG00000039050
ENSMUSG00000040328
ENSMUSG00000049721

Chr Strand Start (bp) End (bp)
4
108637466 108780798
9
63421455 63602493
1
+
187215508 187351704
9
+
59750896 59928866
7
133883199 134232146
11
+
43149877 43262285
7
+
129257094 129391307
10
+
125966219 126015359
11
+
4637747
4685699
3
+
90104132 90212017
3
+
145758675 145894277
9
62880077 62980879
4
+
117550365 117674297
11
4480868
4594863
10
+
67979570 68059740
17
78752906 78835381
17
12888902 12910000
11
+
45160943 45213656
13
+
31299628 31396579
16
+
96361668 96525580
13
19357677 19395752
4
+
85205126 85639195
4
86444641 86558328
4
87769925 88033364
4
108014791 108096445
9
+
58063788 58153996
9
+
58582240 58657955
3
+
82358072 82395268
4
106744555 106804998
11
6105691
6200415
11
55250609 55336564
2
+
163203125 163324170
11
+
6546887
6596744
16
97564684 97611195
11
54247271 54249667
11
41910195 42000857
17
78949405 79020816
17
78852564 78882573
17
64281005 64331916
8
+
49370886 49521095
9
55549883 55919605
3
79641611 79737880
9
+
64385626 64709205
7
144476758 144553729
11
+
54522847 54699285
2
+
180119306 180162680
11
+
48978889 49135387
11
+
3983636
3999326
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Band
C7
C
H5
B
F3
A5
F3
D3
A1
F1
H2
B
D1
A1
B5.1
E3
A1
B1.1
A3.2
C4
A2
C4
C4
C4
C7
B
B
E3
C7
A1
B1.3
H2
A1
C4
B1.3
A5
E3
E3
E1.1
B1.2
B
E3
C
F5
B1.3
H4
B1.2
A1

Table 3.2. con't
Gene
SNP score
Dlgap4
11
Gm16223
11
D430019H16Rik
11
Galntl6
11
Pkn2
10
Ebf3
10
Mcoln2
10
Kcnq2
10
Sparc
10
Lyrm7
10
Hormad2
10
Papola
10
Sfrp4
10
Arih1
10
Anxa2
10
Ptpn9
10
Thsd7a
10
Szt2
10
Mnd1
10
Osbpl5
10
D630003M21Rik
10
Lgi2
10
Ccbl2
10
Fez2
10
Ica1
10
B3galt5
10
Gm16759
10
Gm12153
10
Gm17231
10
Zfp804b
10
Th
9
Rmnd5b
9
Arid3b
9
Lbp
9
Kremen1
9
Qpct
9
Inpp5a
9
Fbxw7
9
Slc6a9
9
Scp2
9
Glcci1
9
Plxna1
9
Gm498
9
Aga
9
Uaca
9
Zfp365
9
Pogz
9
Gm12169
9

Ensembl gene ID
ENSMUSG00000061689
ENSMUSG00000067285
ENSMUSG00000094910
ENSMUSG00000096914
ENSMUSG00000004591
ENSMUSG00000010476
ENSMUSG00000011008
ENSMUSG00000016346
ENSMUSG00000018593
ENSMUSG00000020268
ENSMUSG00000020419
ENSMUSG00000021111
ENSMUSG00000021319
ENSMUSG00000025234
ENSMUSG00000032231
ENSMUSG00000032290
ENSMUSG00000032625
ENSMUSG00000033253
ENSMUSG00000033752
ENSMUSG00000037606
ENSMUSG00000037813
ENSMUSG00000039252
ENSMUSG00000040213
ENSMUSG00000056121
ENSMUSG00000062995
ENSMUSG00000074892
ENSMUSG00000086539
ENSMUSG00000087172
ENSMUSG00000091908
ENSMUSG00000092094
ENSMUSG00000000214
ENSMUSG00000001054
ENSMUSG00000004661
ENSMUSG00000016024
ENSMUSG00000020393
ENSMUSG00000024084
ENSMUSG00000025477
ENSMUSG00000028086
ENSMUSG00000028542
ENSMUSG00000028603
ENSMUSG00000029638
ENSMUSG00000030084
ENSMUSG00000031085
ENSMUSG00000031521
ENSMUSG00000034485
ENSMUSG00000037855
ENSMUSG00000038902
ENSMUSG00000078924

Chr Strand Start (bp) End (bp)
2
+
156613705 156764363
5
+
42067960 42216798
12
+
105453856 105493095
8
57776225 57962564
3
142790902 142882004
7
137193673 137314445
3
+
146149833 146195513
2
181075579 181135291
11
55394500 55420080
11
54826866 54860916
11
4345814
4441105
12
+
105784694 105838944
13
+
19623175 19632821
9
59388258 59486618
9
+
69453620 69491795
9
+
56994968 57062805
6
12311610 12749410
4
118362743 118409273
3
84087934 84155786
7
143688762 143756985
2
158182533 158229222
5
52537864 52566303
3
+
142701051 142744910
17
78377885 78418131
6
8630527
8778488
16
+
96235801 96319859
9
+
63399381 63568691
11
+
43959089 44134987
9
+
57777865 57834295
5
6769030
6876523
7
142892752 142931128
11
51623671 51635896
9
57790353 57836793
2
+
158306493 158332852
11
5191552
5261558
17
+
79051906 79090243
7
+
139389109 139579652
3
+
84815268 84979198
4
+
117834506 117875198
4
108043839 108144998
6
+
8509600
8597548
6
89316316 89362613
7
+
143866871 143897506
8
+
53511702 53523421
9
+
60794548 60880370
10
67886103 67912662
3
+
94837567 94882326
11
+
46524212 46538156
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Band
H1
B3
E
B2
H1
F3
H2
H4
B1.3
B1.3
A1
E
A2
B
C
B
A1
D2.1
F1
F5
H1
C1
H1
E2
A1
C4
C
B1.1
B
A1
F5
B1.3
B
H1
A1
E3
F4
F1
D2.1
C7
A1
D1
F5
B1.3
B
B5.1
F2.1
B1.1

Table 3.2. con't
Gene
Gm15866
Gm12130
Gm12680
Pcp4
Gm17114
Xpo6
Sod2
Lrrc27
Anxa6
Slc36a2
Cyfip2
Zfp354a
Ralgapb
Ash1l
Sh3d19
Dnajc6
Rnf220
Sesn2
Ctbp2
Pstpip1
Tesk2
Golim4
Chst11
Cdc42ep3
Ccdc33
Sox5
Rims1
Tenm2
Cdc42se2
5830411N06Rik
Alk
Lepr
Acat3
Arhgap40
Gm12147
4930401O12Rik
Gm16039
Olfr1328
1110019D14Rik
Celf2
Tpra1
Pabpc4
P4ha2
Vdac1
Eif4enif1
Lrrc71
Tubgcp2
Serpini1

SNP score
9
9
9
9
9
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
8
7
7
7
7
7
7
7
7
7

Ensembl gene ID
ENSMUSG00000087290
ENSMUSG00000087296
ENSMUSG00000087349
ENSMUSG00000090223
ENSMUSG00000091237
ENSMUSG00000000131
ENSMUSG00000006818
ENSMUSG00000015980
ENSMUSG00000018340
ENSMUSG00000020264
ENSMUSG00000020340
ENSMUSG00000020364
ENSMUSG00000027652
ENSMUSG00000028053
ENSMUSG00000028082
ENSMUSG00000028528
ENSMUSG00000028677
ENSMUSG00000028893
ENSMUSG00000030970
ENSMUSG00000032322
ENSMUSG00000033985
ENSMUSG00000034109
ENSMUSG00000034612
ENSMUSG00000036533
ENSMUSG00000037716
ENSMUSG00000041540
ENSMUSG00000041670
ENSMUSG00000049336
ENSMUSG00000052298
ENSMUSG00000054672
ENSMUSG00000055471
ENSMUSG00000057722
ENSMUSG00000062480
ENSMUSG00000074625
ENSMUSG00000086791
ENSMUSG00000087460
ENSMUSG00000089862
ENSMUSG00000096368
ENSMUSG00000097616
ENSMUSG00000002107
ENSMUSG00000002871
ENSMUSG00000011257
ENSMUSG00000018906
ENSMUSG00000020402
ENSMUSG00000020454
ENSMUSG00000023084
ENSMUSG00000025474
ENSMUSG00000027834

Chr Strand Start (bp)
5
43557285
11
38493330
4
+
85514327
16
+
96467606
4
117835299
7
126101715
17
+
13007839
7
+
139212988
11
54979108
11
55158470
11
46193850
11
+
51059257
2
+
158409848
3
+
88965812
3
+
85971109
4
+
101496648
4
117271463
4
132492032
7
132987563
9
+
56089962
4
+
116720948
3
75876183
10
+
82985498
17
79334025
9
58028677
6
143828425
1
22286251
11
36006656
11
54717456
7
+
140247301
17
71869442
4
+
101717404
17
12923833
2
+
158512796
11
43259791
13
31213410
6
+
8259288
4
118933897
6
+
13871526
2
6539694
6
+
88902251
4
+
123262351
11
+
54100095
11
+
52360860
11
+
3202392
3
87736923
7
139995955
3
+
75557547
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End (bp)
43601730
38520013
85783127
96525793
117868558
126200501
13018119
139242979
55033445
55185077
46312859
51072799
158499253
89079373
86130526
101642799
117497052
132510501
133124354
56128888
116805956
75956949
83195900
79355091
58118823
144781977
22805994
37235964
54787675
140299791
72603709
101815352
12940402
158550762
43311088
31222096
8597480
118934840
14044373
7509563
88912238
123298925
54131665
52389397
3244588
87748625
140036350
75643495

Band
B3
A5
C4
C4
D2.1
F3
A1
F4
B1.3
B1.3
B1.1
B1.3
H1
F1
F1
C6
D1
D2.3
F3
B
D1
E3
C1
E3
B
G3
A5
A5
B1.3
F4
E1.3
C6
A1
H1
A5
A3.2
A1
D2.1
A1
A1
D1
D2.2
B1.3
B1.3
A1
F1
F4
E3

Table 3.2. con't
Gene
Glrb
Dclk2
Snx27
Gtf2b
Ndc1
Ermap
Ppt1
Pik3r3
Pi4k2b
Zranb1
Hcn4
Mgll
Tie1
Fgb
Zbbx
Glis1
Ttc22
Smad6
Btnl9
Gsg1l
Lrp1b
Aff4
8030423F21Rik
Fut9
Dhcr7
Slc22a21
Cntnap5a
Gm12649
Gm12223
4930564K09Rik
3110021N24Rik
Gm26551
Wwox
Ripk4
Gabrb2
Vps72
Camta1
Fcrls
G3bp1
Canx
Drg1
Bdkrb2
Plce1
Paox
Stmn3
Lce1m
Asic5
Arhgef2

SNP score
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
7
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6

Ensembl gene ID
ENSMUSG00000028020
ENSMUSG00000028078
ENSMUSG00000028136
ENSMUSG00000028271
ENSMUSG00000028614
ENSMUSG00000028644
ENSMUSG00000028657
ENSMUSG00000028698
ENSMUSG00000029186
ENSMUSG00000030967
ENSMUSG00000032338
ENSMUSG00000033174
ENSMUSG00000033191
ENSMUSG00000033831
ENSMUSG00000034151
ENSMUSG00000034762
ENSMUSG00000034919
ENSMUSG00000036867
ENSMUSG00000040283
ENSMUSG00000046182
ENSMUSG00000049252
ENSMUSG00000049470
ENSMUSG00000052295
ENSMUSG00000055373
ENSMUSG00000058454
ENSMUSG00000063652
ENSMUSG00000070695
ENSMUSG00000084833
ENSMUSG00000085585
ENSMUSG00000086273
ENSMUSG00000094958
ENSMUSG00000097219
ENSMUSG00000004637
ENSMUSG00000005251
ENSMUSG00000007653
ENSMUSG00000008958
ENSMUSG00000014592
ENSMUSG00000015852
ENSMUSG00000018583
ENSMUSG00000020368
ENSMUSG00000020457
ENSMUSG00000021070
ENSMUSG00000024998
ENSMUSG00000025464
ENSMUSG00000027581
ENSMUSG00000027912
ENSMUSG00000028008
ENSMUSG00000028059

Chr Strand Start (bp)
3
80843599
3
86786150
3
94497544
3
+
142765226
4
+
107367784
4
119175457
4
+
122836242
4
+
116221618
5
+
52741587
7
+
132931142
9
+
58823512
6
+
88724412
4
118471191
3
83042247
3
75037907
4
+
107434591
4
+
106622432
9
63953076
11
49165585
7
125878419
2
40595248
11
+
53350833
5
52607550
4
25609332
7
+
143823145
11
53949965
1
+
115684756
4
93453258
11
+
54247600
3
+
82876705
4
+
108719649
11
51949882
8
+
114439655
16
97741933
11
+
42419757
3
+
95111022
4
150917322
3
87250758
11
+
55469685
11
50293961
11
3187360
12
+
105563172
19
+
38481109
7
+
140125657
2
181306459
3
93017807
3
+
81982290
3
+
88607454
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End (bp)
80913660
86920884
94582716
142783603
107416346
119190011
122859175
116303056
52769344
132986391
58860955
88828360
118490061
83049803
75165034
107635061
106640189
64022059
49187159
126082411
42653598
53421830
52619011
25800244
143848410
53980332
116582026
93671070
54254495
82943638
108781904
52269514
115352708
97763737
42629028
95123051
151861876
87263738
55504838
50325673
3266415
105593071
38785030
140134334
181314500
93019060
82021233
88648052

Band
E3
F1
F2.1
H1
C7
D2.1
D2.2
D1
C1
F3
B
D1
D2.1
E3
E3
C7
C7
C
B1.2
F3
B
B1.3
C1
A3
F5
B1.3
E2.3
C5
B1.3
E3
C7
B1.3
E1
C4
A5
F2.1
E2
F1
B1.3
B1.3
A1
E
C3
F4
H4
F1
E3
F1

Table 3.2. con't
Gene
Caap1
Cap1
Dmbx1
Chchd6
Tenm3
Hpgd
Thoc5
Uroc1
Zcchc11
Rims4
Pml
Aff3
Acer2
Sult6b1
Neil3
Cc2d2a
Bace2
Nme8
Kirrel
Mat2b
Inpp5f
Zfp536
Tnfrsf26
Spesp1
Urgcp
Lrrc4c
Gpatch11
Camk2b
R74862
Olfr530
Rapgef2
Nlgn1
Kndc1
Gramd2
C230081A13Rik
Gm12856
Gm14372
Gm14342
Gm26547
2510016G02Rik
Tcf7
Rrp15
Mcm2
Gpx5
Mpl
Zmat5
Trpm5
Cars

SNP score
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
6
5
5
5
5
5
5
5
5

Ensembl gene ID
ENSMUSG00000028578
ENSMUSG00000028656
ENSMUSG00000028707
ENSMUSG00000030086
ENSMUSG00000031561
ENSMUSG00000031613
ENSMUSG00000034274
ENSMUSG00000034456
ENSMUSG00000034610
ENSMUSG00000035226
ENSMUSG00000036986
ENSMUSG00000037138
ENSMUSG00000038007
ENSMUSG00000038045
ENSMUSG00000039396
ENSMUSG00000039765
ENSMUSG00000040605
ENSMUSG00000041138
ENSMUSG00000041734
ENSMUSG00000042032
ENSMUSG00000042105
ENSMUSG00000043456
ENSMUSG00000045362
ENSMUSG00000046846
ENSMUSG00000049680
ENSMUSG00000050587
ENSMUSG00000050668
ENSMUSG00000057897
ENSMUSG00000059277
ENSMUSG00000060974
ENSMUSG00000062232
ENSMUSG00000063887
ENSMUSG00000066129
ENSMUSG00000074259
ENSMUSG00000074305
ENSMUSG00000084133
ENSMUSG00000085745
ENSMUSG00000086166
ENSMUSG00000097095
ENSMUSG00000097595
ENSMUSG00000000782
ENSMUSG00000001305
ENSMUSG00000002870
ENSMUSG00000004344
ENSMUSG00000006389
ENSMUSG00000009076
ENSMUSG00000009246
ENSMUSG00000010755

Chr Strand Start (bp)
4
94500081
4
122859047
4
115914544
6
89383146
8
48227682
8
+
56294552
11
+
4895320
6
+
90333289
4
+
108459426
2
163859751
9
58218076
1
38177326
4
+
86874396
17
78883938
8
53586867
5
+
43662379
16
+
97356728
13
19645078
3
87078593
11
40679314
7
+
128611328
7
37472135
7
143607685
9
62270729
11
5713417
2
+
96318169
17
+
78835516
11
5969644
7
143021784
7
140372587
3
79062516
3
25431811
7
+
139894696
9
+
59680144
9
56201131
4
118942060
7
144368048
2
180829490
17
+
55557166
7
132889489
11
52252371
1
186720978
6
88883475
13
21286429
4
118442415
11
+
4704678
7
143069153
7
143557230
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End (bp)
94556796
122886056
115939926
89595652
48674690
56321046
4928867
90364551
108559421
163918683
58249786
38664955
86934822
78906992
53639065
43740972
97439012
19697794
87174747
40695203
128696425
37773641
143627845
62282179
5762376
97631666
78848299
6066362
143053686
140373666
79181340
26133734
139941537
59718874
56418050
118943352
144406933
180889660
55563507
132931375
52283014
186749358
88898780
21292731
118457513
4737669
143094642
143600090

Band
C5
D2.2
D1
D1
B1.2
B2
A1
D1
C7
H3
B
B
C4
E3
B1.3
B3
C4
A2
F1
A5
F3
B3
F5
B
A1
E1
E3
A1
F5
F4
E3
A3
F4
B
B
D2.1
F5
H4
C
F3
B1.3
H5
D1
A3.1
D2.1
A1
F5
F5

Table 3.2. con't
Gene
Kif3a
Hcfc2
Mgat1
3010026O09Rik
Itk
Myo1g
Polm
Amph
Zkscan3
Exoc2
Dapk1
Marc1
Fam198b
Tmem144
Npy2r
Gucy1b3
Sh2d2a
Pdlim5
Ptplad2
B4galt2
Col9a2
Wdr65
Rcc1
Auts2
Asb5
Kirrel3
Anp32a
1700017B05Rik
Dis3l
Smad3
Cspg4
Kbtbd12
Gpbp1l1
Tmem132d
Morc2a
Arhgap10
Nmur2
Dennd4c
Slco4a1
Cdk13
Slc39a11
Zfp62
C1qtnf2
Dlgap2
Mroh7
Olfr1396
Dmbt1
Lrrc49

SNP score
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5

Ensembl gene ID
ENSMUSG00000018395
ENSMUSG00000020246
ENSMUSG00000020346
ENSMUSG00000020381
ENSMUSG00000020395
ENSMUSG00000020437
ENSMUSG00000020474
ENSMUSG00000021314
ENSMUSG00000021327
ENSMUSG00000021357
ENSMUSG00000021559
ENSMUSG00000026621
ENSMUSG00000027955
ENSMUSG00000027956
ENSMUSG00000028004
ENSMUSG00000028005
ENSMUSG00000028071
ENSMUSG00000028273
ENSMUSG00000028497
ENSMUSG00000028541
ENSMUSG00000028626
ENSMUSG00000028730
ENSMUSG00000028896
ENSMUSG00000029673
ENSMUSG00000031519
ENSMUSG00000032036
ENSMUSG00000032249
ENSMUSG00000032300
ENSMUSG00000032396
ENSMUSG00000032402
ENSMUSG00000032911
ENSMUSG00000033182
ENSMUSG00000034042
ENSMUSG00000034310
ENSMUSG00000034543
ENSMUSG00000037148
ENSMUSG00000037393
ENSMUSG00000038024
ENSMUSG00000038963
ENSMUSG00000041297
ENSMUSG00000041654
ENSMUSG00000046311
ENSMUSG00000046491
ENSMUSG00000047495
ENSMUSG00000047502
ENSMUSG00000047511
ENSMUSG00000047517
ENSMUSG00000047766

Chr Strand Start (bp)
11
+
53567379
10
+
82696160
11
+
49244191
11
+
50174444
11
46325150
11
6506548
11
5827860
13
+
18948371
13
21387013
13
30813919
13
+
60601947
1
184786776
3
+
79884533
3
79813148
3
82538383
3
82032004
3
+
87846755
3
142239586
4
88396144
4
117869260
4
+
121039385
4
118554551
4
132331919
5
131437333
8
+
54550331
9
+
34486126
9
+
62341293
9
57252322
9
64306756
9
63646767
9
+
56865104
6
88547340
4
+
116557658
5
127783491
11
+
3649494
8
77250366
11
56024987
4
+
86748555
2
+
180456245
13
17715962
11
113244853
11
+
49203292
11
+
43474276
8
+
14095865
4
106680417
11
49112777
7
+
131032076
9
60568859

117

End (bp)
53601967
82742428
49263030
50200115
46389515
6520965
5838016
19150913
21402755
30974047
60763185
184811313
79946280
79842662
82548084
82074711
87855722
142395696
88438928
117883487
121055322
118620777
132353605
132543344
54587836
35036716
62378812
57262599
64341288
63757994
56899870
88637950
116593882
128433077
3690477
77517907
56041010
86850603
180474867
17805097
113650079
49218816
43491525
14847680
106730925
49114874
131121626
60688158

Band
B1.3
C1
B1.2
B1.3
B1.1
A1
A1
A2
A3.1
A3.2
B2
H5
E3
E3
E3
E3
F1
H1
C4
D2.1
D2.2
D2.1
D2.3
G2
B1.3
A4
B
B
C
C
B
D1
D1
G1.3
A1
C1
B1.3
C4
H4
A2
E2
B1.2
B1.1
A1.1
C7
B1.2
F3
B

Table 3.2. con't
Gene
Fcrl5
Tenm4
Olfr1394
Trpm3
Bpi
Dnajc8
Sec14l3
Ubl7
Slit3
Ptprn2
Wtap
Dcc
Csmd1
Agbl4
Dpp6
Tmem117
Phactr4
Mas1
Trcg1
Ccdc24
AY761185
Gm14278
Gm11980
Gm12131
4933416E03Rik
Gm11958
Gm12648
Gm16144
Gm14204
5133400J02Rik
0610043K17Rik
Gm17359
Gm26561
9530052C20Rik

SNP score
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5

Ensembl gene ID
ENSMUSG00000048031
ENSMUSG00000048078
ENSMUSG00000048378
ENSMUSG00000052387
ENSMUSG00000052922
ENSMUSG00000054405
ENSMUSG00000054986
ENSMUSG00000055720
ENSMUSG00000056427
ENSMUSG00000056553
ENSMUSG00000060475
ENSMUSG00000060534
ENSMUSG00000060924
ENSMUSG00000061298
ENSMUSG00000061576
ENSMUSG00000063296
ENSMUSG00000066043
ENSMUSG00000068037
ENSMUSG00000070298
ENSMUSG00000078588
ENSMUSG00000079120
ENSMUSG00000080880
ENSMUSG00000083075
ENSMUSG00000083806
ENSMUSG00000085198
ENSMUSG00000085512
ENSMUSG00000085931
ENSMUSG00000086399
ENSMUSG00000086496
ENSMUSG00000086646
ENSMUSG00000087361
ENSMUSG00000091685
ENSMUSG00000097625
ENSMUSG00000097858

Chr Strand Start (bp)
3
+
87435885
7
+
96171244
11
+
49160016
19
+
22139119
2
+
158258094
4
+
132535550
11
+
4064841
9
+
57910986
11
+
35121224
12
+
116485720
17
12966796
18
71258738
8
15892537
4
+
110397661
5
+
26817203
15
+
94629185
4
132355923
17
12841079
9
+
57236556
4
117866524
8
20943693
2
156888854
11
+
6685824
11
39727070
2
+
159947341
11
+
4285460
4
94089576
9
69477029
2
158595472
11
51189833
4
+
101353783
3
+
79345376
17
+
70878078
3
+
142882495

118

End (bp)
87457836
96911093
49160954
22989884
158284531
132553742
4077736
57929968
35708507
117278167
12992546
72351069
17535586
111664324
27727505
95096097
132422489
12868143
57249863
117872557
20944748
156915383
6686809
39727712
159981288
4286939
94425588
69479598
158610723
51220418
101399181
79464129
71393284
142894644

Band
F1
E1
B1.2
B
H1
D2.3
A1
B
A4
F2
A1
E2
A1.3
C7
B1
E3
D2.3
A1
B
D2.1
A2
H1
A1
A5
H2
A1
C5
C
H1
B1.3
C6
E3
E1.3
H1

Table 3.3. Candidate loci underlying genetic sucsptibility to monoclonal gammopathy of undetermined signifiance
Chr
Gene
1 SSBP3
HSP90B3P
RP11-433J22.3
HMCN1

Ensembl gene ID
ENSG00000157216
ENSG00000203914
ENSG00000234190
ENSG00000143341

Strand
+
+
+

Start (bp)
54691105
92100568
147249700
185703683

End (bp)
54879152
92109639
147261065
186160085

CSRP1
GPR37L1

ENSG00000159176
ENSG00000170075

+

201452658
202091986

201478584
202102720

RP11-400N13.1
DNAH14
EDARADD
SMYD3

ENSG00000236230
ENSG00000185842
ENSG00000186197
ENSG00000185420

+
+
-

222262511
225083964
236511562
245912642

222560776
225586996
236648214
246670614

SH3YL1
AC012445.1
LPIN1

ENSG00000035115
ENSG00000229550
ENSG00000134324

+

217730
4184234
11817721

266398
4188321
11967535

ADCY3
CENPO
RP11-443B20.1
CTNNA2
KIAA1211L

ENSG00000138031
ENSG00000138092
ENSG00000271936
ENSG00000066032
ENSG00000196872

+
+
+
-

25042038
25016005
25048479
79412357
99410309

25142708
25045245
25049586
80875905
99552722

CACNB4

ENSG00000182389

-

152689290

152955593

UPP2
AC104820.2
PTH2R
SPAG16

ENSG00000007001
ENSG00000234663
ENSG00000144407
ENSG00000144451

+
+
+
+

158733214
181966659
209224438
214149113

158992666
182264286
209719227
215275225

2

119

Band
p32.3
p22.1
q21.2
q25.3

SNP
rs3753405
rs1887055
rs1908628
rs10911784
rs7550425
q32.1 rs645390
q32.1 rs11588918
rs12737525
q41 rs4511115
q42.12 rs13376645
q42.3 rs16833652
q44 rs10924674
rs12037567
rs10802383
p25.3 rs6742278
p25.3 rs10178086
p25.1 rs7569901
rs6726960
rs6744695
p23.3 rs17799872
p23.3 rs17799872
p23.3 rs17799872
p12 rs17017514
q11.2 rs13005148
rs6757098
rs11123756
rs12464134
q23.3 rs13416880
rs13421383
rs7591461
rs6722774
rs12693235
rs1806702
q24.1 rs6731028
q31.3 rs877226
q34 rs1598140
q34 rs1876837

P-value
0.0004368
0.0002949
0.0001312
0.00005891
0.0003429
0.0004114
0.0001055
0.00006792
0.0002854
0.0004052
0.0004461
0.00006615
0.00002431
0.00008869
0.00002812
0.00001205
0.0004234
0.0003213
0.000358
0.0002614
0.0002614
0.0002614
0.0004403
0.0003975
0.0001547
0.0001437
0.00004374
0.0001254
0.00009218
0.0003871
0.00005946
0.0000739
0.0004061
0.0004357
0.0003604
0.0003792
0.0003171

Position (bp)
54745708
92113813
147260568
185915391
186045280
201454923
202095560
202095852
222513180
225551281
236577350
246452817
246458746
246459480
226999
4187138
11897225
11898931
11899088
25044957
25044957
25044957
79903804
99467538
99471399
99508012
99540101
152868683
152879348
152882123
152916802
152924481
152930124
158890762
182117625
209471702
215077766

Table 3.3. con't
Chr
Gene
2 AC064853.2
C2orf83
AC009410.1
3 CCDC174
AC133680.1

Ensembl gene ID
ENSG00000236116
ENSG00000042304
ENSG00000232023
ENSG00000154781
ENSG00000237838

Strand
+
+

Start (bp)
228481714
228474806
229347977
14693271
24729410

End (bp)
228482506
228498036
229476111
14714166
25215796

RARB

ENSG00000077092

+

25215823

25639423

SLC4A7
CMTM8
CCDC13
HHATL
HHATL-AS1

LINC00971
CLDND1
CPOX
RP11-227H4.5
RPL38P4
TMCC1
RP11-23D24.2
KCNAB1
RP11-85M11.2

ENSG00000033867
ENSG00000170293
ENSG00000244607
ENSG00000010282
ENSG00000230970
ENSG00000244607
ENSG00000230970
ENSG00000244607
ENSG00000181061
ENSG00000244607
ENSG00000181061
ENSG00000242641
ENSG00000080822
ENSG00000080819
ENSG00000248839
ENSG00000250562
ENSG00000172765
ENSG00000238755
ENSG00000169282
ENSG00000244128

+
+
+
+
+
+

27414214
32280171
42734155
42734155
42744145
42734155
42744145
42734155
42798669
42734155
42798669
84687557
98216756
98239976
98241414
98243905
129366635
153102723
155755490
164924748

27525911
32411817
42814745
42744319
42748154
42814745
42748154
42814745
42846023
42814745
42846023
84930830
98241910
98312567
98244178
98244118
129612419
153697975
156256545
165373211

B3GNT5
MCF2L2
RP11-430L16.1
RP11-513G11.4
STK32B
MUC7

ENSG00000176597
ENSG00000053524
ENSG00000234238
ENSG00000225742
ENSG00000152953
ENSG00000171195

+
+
+
+

182971032
182895831
187824884
193920805
5053169
71296209

183016292
183146566
187864808
193967942
5502725
71348714

HIGD1A

4

120

Band
q36.3
q36.3
q36.3
p25.1
p24.2

SNP
rs16823719
rs16823719
rs16825085
rs2276754
rs17576864
rs17517875
rs17577191
rs12152294
p24.2 rs12152294
rs17518622
p24.1 rs3755652
p22.3 rs3853711
p22.1 rs9836162
p22.1 rs9836162
p22.1 rs9836162
p22.1 rs2240861
p22.1 rs2240861
p22.1 rs17238798
p22.1 rs17238798
p22.1 rs11915803
p22.1 rs11915803
p12.1 rs2326227
q11.2 rs9819403
q12.1 rs9819403
q11.2 rs9819403
q11.2 rs9819403
q22.1 rs4306849
q25.2 rs17745929
q25.31 rs1474024
q26.1 rs9839370
rs3106448
q27.1 rs6803209
q27.1 rs6803209
q27.3 rs9852144
q29 rs6800138
p16.2 rs1838973
q13.3 rs11249502

P-value
0.00004776
0.00004776
0.0001298
0.00001082
0.0002854
0.0002831
0.0002344
0.0002837
0.0002837
0.0002824
0.0003041
0.0003912
0.0002569
0.0002569
0.0002569
0.0003139
0.0003139
0.0003606
0.0003606
0.0003606
0.0003606
0.0003381
0.0003452
0.0003452
0.0003452
0.0003452
0.0004246
0.000283
0.0000279
0.00007675
0.0003237
0.0000113
0.0000113
0.0004035
0.0003418
0.0004397
0.0001027

Position (bp)
228481316
228481316
229390795
14702982
25192389
25208270
25208341
25215670
25215670
25227079
27472936
32395577
42747548
42747548
42747548
42750324
42750324
42799765
42799765
42800291
42800291
84755963
98245718
98245718
98245718
98245718
129384180
153506050
155775874
165200881
165343107
182968709
182968709
187842721
193937606
5157262
71341161

Table 3.3. con't
Chr
Gene
4 AC107072.2
SHROOM3

Ensembl gene ID
ENSG00000231335
ENSG00000138771

CCNG2
RP11-625I7.1

ENSG00000138764
ENSG00000249036
ENSG00000138764
ENSG00000249036
ENSG00000138764
ENSG00000249036

+
+
+
-

78078304
78315645
78078304
78315645
78078304
78315645

78354542
78415440
78354542
78415440
78354542
78415440

RASGEF1B
PLAC8
CCSER1
RP11-255I10.2
ZNF827
AC108142.1
MIR1305
RP11-402C9.1
TENM3
FSTL4
ARHGAP26
CTD-2270F17.1
KCNIP1
RNA5SP200

ENSG00000138670
ENSG00000145287
ENSG00000184305
ENSG00000248656
ENSG00000151612
ENSG00000177822
ENSG00000221227
ENSG00000248266
ENSG00000218336
ENSG00000053108
ENSG00000145819
ENSG00000253647
ENSG00000182132
ENSG00000252169

+
+
+
+
+
+
+
+
-

82347547
84011201
91048686
112561651
146678779
182795591
183090446
183066005
183065140
132532147
142149949
169816497
169780491
172719520

82965397
84058228
92523064
112569964
146859787
183066402
183090531
183111535
183724177
132948255
142608576
169849848
170163636
172719622

GMDS
B3GALT4
RPS18
VPS52
WDR46

ENSG00000112699
ENSG00000226936
ENSG00000235650
ENSG00000225590
ENSG00000204221
ENSG00000206285
ENSG00000096150
ENSG00000206286
ENSG00000206284

+
+
+
+
-

1624041
33166523
33161393
33139671
33168491
33173759
33168626
33146871
33175727

2245926
33168208
33165893
33161430
33178914
33175444
33173129
33168663
33186150

5

6

Strand Start (bp)
End (bp)
+
77558776
77565521
+
77356253
77704406

121

Band SNP
q21.1 rs1986966
q21.1 rs1986966
rs17002148
rs6817407
q21.1 rs12649862
q21.1 rs12649862
q21.1 rs41476645
q21.1 rs41476645
q21.1 rs12644936
q21.1 rs12644936
rs12501028
rs7689830
q21.22 rs17005163
q21.22 rs17006484
q22.1 rs1849809
q25 rs17043540
q31.22 rs6814298
q34.3 rs10009617
q34.3 rs12504374
q34.3 rs12504374
q34.3 rs12504374
q31.1 rs11242158
q31.3 rs10875602
q35.1 rs314120
q35.1 rs314120
q35.1 rs7714152
rs10061599
rs17675787
p25.3 rs3800125
p21.32 rs458679
p21.32 rs458679
p21.32 rs458679
p21.32 rs458679
p21.32
p21.32
p21.32 rs458679
p21.32

P-value
0.0003857
0.0003857
0.0001498
0.0003579
0.000331
0.000331
0.0001599
0.0001599
0.0001599
0.0001599
0.0001656
0.00003848
0.00006777
0.00006746
0.0002955
0.000003519
0.0000153
0.0004117
0.000003003
0.000003003
0.000003003
0.0004328
0.0001677
0.00006844
0.00006844
0.00005878
0.00004471
0.00002048
0.00001667
0.0001654
0.0001654
0.0001654
0.0001654
0.0001654

Position (bp)
77558777
77558777
77580240
77616338
78343820
78343820
78344385
78344385
78345120
78345120
78391533
78416791
82483468
84035969
91596240
112558571
146780732
182874271
183086701
183086701
183086701
132835992
142599713
169823196
169823196
172715409
172723332
172724246
1906861
33164098
33164098
33164098
33164098
33171335
33171335
33171335
33171335

Table 3.3. con't
Chr
6

7

Gene

KLHL31

Ensembl gene ID
ENSG00000235155
ENSG00000223367
ENSG00000228425
ENSG00000226916
ENSG00000235863
ENSG00000231500
ENSG00000223501
ENSG00000227057
ENSG00000227794
ENSG00000236014
ENSG00000236802
ENSG00000226225
ENSG00000224455
ENSG00000236222
ENSG00000124743

Strand
+
+
+
+
+
+
+
-

Start (bp)
33222842
33217712
33195972
33224810
33244917
33239787
33218049
33246885
33379131
33357416
33415294
33410160
33388442
33417262
53512699

End (bp)
33224527
33222212
33217749
33235233
33252609
33244287
33239824
33257304
33382651
33379168
33416979
33414664
33410197
33427651
53530506

RP11-304C16.3
ADGB

ENSG00000217331
ENSG00000118492

+

97120005
146920101

97120845
147136598

RP1-125N5.2

ENSG00000235815

+

169116745

169123604

ITGB8

ENSG00000105855

+

20370325

20455377

RAPGEF5

ENSG00000136237

-

22157856

22396763

STEAP1B

ENSG00000105889

-

22459063

22672544

GLI3

ENSG00000106571

-

42000548

42277469

CCM2
CCDC146

ENSG00000136280
ENSG00000135205

+
+

45039074
76751751

45116068
76958850

122

Band
p21.32
p21.32
p21.32
p21.32
p21.32
p21.32
p21.32
p21.32
p21.32
p21.32
p21.32
p21.32
p21.32
p21.32
p12.1

SNP

P-value

rs458679

0.0001654

rs458679

0.0001654

rs458679

0.0001654

rs458679

0.0001654

rs6942249
rs2478352
q16.1 rs17797978
q24.3 rs1572902
rs1340996
q27 rs196469
rs196479
p21.1 rs6461490
rs7793190
p15.3 rs17507
rs3901281
rs3807531
p15.3 rs740295
rs10250954
rs4318962
p14.1 rs846394
rs846393
rs846385
p13 rs10951785
q11.23 rs3108440
rs3108442
rs7780929
rs7786334

0.0003955
0.0003203
0.0003369
0.0004276
0.0004072
0.0000181
0.00004366
0.000337
0.00006727
0.0003288
0.0001779
0.0003865
0.0002376
0.0002395
0.00009263
0.0001328
0.0001339
0.0001009
0.0002309
0.0003706
0.0003706
0.0001147
0.0001152

Position (bp)
33220417
33220417
33220417
33220417
33242492
33242492
33242492
33242492
33381840
33381840
33412869
33412869
33412869
33412869
53515483
53533265
97115085
146979589
146988978
169123297
169127361
20381806
20407356
22175235
22175472
22187744
22473288
22474949
22475742
42162825
42163860
42168935
45047791
76896701
76901907
76914712
76915253

Table 3.3. con't
Chr
7

Gene

Ensembl gene ID

Strand Start (bp)

End (bp)

DBF4
CSMD1
RP11-1080G15.1
RP11-624C23.1
AC012215.1
UNC5D
ASPH
RP11-6I2.3
KB-1184D12.1
FSBP
RAD54B
AF216667.1
TMEM71

ENSG00000006634
ENSG00000183117
ENSG00000253557
ENSG00000253535
ENSG00000233863
ENSG00000156687
ENSG00000198363
ENSG00000254288
ENSG00000253585
ENSG00000265817
ENSG00000197275
ENSG00000222570
ENSG00000165071

+
+
+
+
-

87505531
2792875
18942502
24153327
35649365
35092975
62413116
74964575
95109992
95390605
95384188
133693146
133697253

87538856
4852494
19116979
24769586
35653384
35654068
62627155
75012088
95116550
95449180
95487337
133693248
133772958

HAUS6
NOL8
CDC26
PRPF4

ENSG00000147874
ENSG00000198000
ENSG00000176386
ENSG00000136875

+

19053141
95059640
116018115
116037623

19103117
95087918
116037869
116055185

GSN
10 CACNB2

ENSG00000148180
ENSG00000165995

+
+

123970072
18429606

124095121
18830798

VSTM4
TSPAN15
SEC23IP
RPS27P18
11 SCUBE2

ENSG00000165633
ENSG00000099282
ENSG00000107651
ENSG00000233135
ENSG00000175356

+
+
-

50222290
71211229
121652223
127162255
9041071

50323554
71267425
121702014
127162501
9159661

DENND5A

ENSG00000184014
ENSG00000175356
ENSG00000184014

-

9160372
9041071
9160372

9286937
9159661
9286937

NELL1

ENSG00000165973

+

20691117

21597227

8

9
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Band SNP
rs17151066
rs17151097
rs17151110
q21.12 rs11982729
p23.2 rs17414486
p21.3 rs2672282
p21.2 rs17052236
p12 rs16884444
p12 rs16884444
q12.3 rs16927431
q21.11 rs6988353
q22.1 rs2446833
q22.1 rs2470737
q22.1 rs2470737
q24.22 rs7827081
q24.22 rs7827081
rs10956677
p22.1 rs7869414
q22.31 rs16908281
q32 rs17831256
q32 rs17831256
rs12352784
q33.2 rs4837817
p12.33 rs2482100
rs1277768
q11.23 rs4488117
q22.1 rs7078095
q26.11 rs2279939
q26.13 rs3813859
p15.4 rs2647537
rs7931872
rs10840175
p15.4 rs10840176
p15.4 rs10840176
p15.4 rs2133217
rs7394878
p15.1 rs12791900

P-value
0.0001152
0.0001152
0.00006989
0.0003455
0.0004013
0.0002106
0.0002338
0.0001357
0.0001357
0.00009409
0.0003492
0.000418
0.0002017
0.0002017
0.0002315
0.0002315
0.000438
0.0003545
0.0002286
0.0001976
0.0001976
0.0001976
0.0004299
0.00009705
0.0003153
0.0002074
0.00001963
0.0001692
0.000005007
0.0001835
0.0001388
0.0002378
0.0001697
0.0001697
0.0003779
0.0003604
0.0002738

Position (bp)
76917303
76918307
76918782
87516527
4283673
19055204
24462582
35648980
35648980
62424008
74997242
95111326
95407427
95407427
133696552
133696552
133708897
19082832
95072094
116042867
116042867
116045074
123995163
18481080
18499676
50309905
71263424
121693020
127166793
9125301
9142062
9143548
9155570
9155570
9177012
9198276
21022007

Table 3.3. con't
Chr
Gene
11 RNA5SP336
SLC1A2

Ensembl gene ID
ENSG00000201059
ENSG00000165973
ENSG00000110436

Strand
+
-

Start (bp)
End (bp)
21022427
21022543
20691117
21597227
35272753
35441610

Band
p15.1
p15.1
p13

INCENP
RP11-691L4.2

ENSG00000149503
ENSG00000236607

+
+

61891445
61936765

61920635
61937300

q12.3
q12.3

ACY3
AP003385.2
MAML2
CNTN5

ENSG00000132744
ENSG00000227834
ENSG00000184384
ENSG00000149972

+

67410026
67419047
95709762
98891683

67418130
67420875
96076344
100229616

q13.2
q13.2
q21
q22.1

RP11-94P11.4
USP2-AS1
12 PTPRB
LGR5
13 HNF4GP1
MYO16
14 OR4U1P
RP11-116N8.1
SEC23A
FRMD6

ENSG00000254998
ENSG00000245248
ENSG00000127329
ENSG00000139292
ENSG00000228611
ENSG00000041515
ENSG00000258899
ENSG00000258342
ENSG00000100934
ENSG00000139926

+
+
+
+
+
+

105028654
119252488
70910630
71833550
56573334
109248500
20512075
36367188
39501123
51955818

105402424
119397374
71031220
71980090
56574582
109860355
20512986
36532949
39578850
52197445

q22.3
q23.3
q15
q21.1
q21.1
q33.3
q11.2
q13.2
q21.1
q22.1

BMP4
15 FAM189A1
AGBL1
RP11-266O8.1

ENSG00000125378
ENSG00000104059
ENSG00000166748
ENSG00000257060

+
+

54416454
29412457
86685227
93855786

54425479
29862927
87572283
94112712

q22.2
q13.1
q25.3
q26.1

CERS3
16 CASC16
CDH11
RP11-95H3.1
C16orf95

ENSG00000154227
ENSG00000249231
ENSG00000140937
ENSG00000259847
ENSG00000260456

-

100940600
52586002
64977656
65175659
87117168

101085200
52686017
65160015
65210616
87351022

q26.3
q12.2
q21
q21
q24.2

124

SNP
rs12791900
rs7122556
rs3847613
rs11033071
rs7114383
rs11033080
rs7934047
rs4756221
rs1675126
rs1792908
rs11230950
rs12288023
rs12288023
rs12286219
rs614096
rs2010803
rs7947277
rs7949052
rs17108396
rs4486718
rs9316831
rs651270
rs1952805
rs7401172
rs4902308
rs4898705
rs8019441
rs12434228
rs511092
rs11073666
rs8037879
rs735912
rs4965668
rs4784227
rs7203623
rs7206260
rs7498934

P-value
0.0002738
0.0004212
0.000157
0.00032
0.0003204
0.0003811
0.0004051
0.0001532
0.000403
0.0001881
0.000106
0.0003361
0.0003361
0.0001786
0.0003917
0.00009028
0.0002016
0.0001409
0.00008915
0.00006204
0.0002368
0.0002752
0.0001053
0.0003348
0.0003054
0.0003329
0.0002757
0.0001107
0.0004207
0.00008602
0.0001737
0.00008711
0.0003708
0.0003197
0.0002642
0.0003446
0.0003701

Position (bp)
21022007
21045022
35338345
35347685
35356793
35362357
35367925
35378069
61906374
61941265
61941816
67421341
67421341
95770904
99577390
99600358
105301479
119400127
71009354
71899966
56574936
109629324
20516355
36451285
39499158
52109999
52110329
54427602
29733674
87299209
93900397
93900938
101077349
52599188
65138590
65211408
87313604

Table 3.3. con't
Chr
Gene
16 RP11-178L8.5
17 WDR16
AC005772.2
IGF2BP1
RP11-501C14.5
RP11-501C14.6
RP11-120M18.2
WIPI1

Ensembl gene ID
ENSG00000261697
ENSG00000166596
ENSG00000232058
ENSG00000159217
ENSG00000250838
ENSG00000251461
ENSG00000267009
ENSG00000070540
ENSG00000267009
ENSG00000070540
ENSG00000267009
ENSG00000070540
ENSG00000167281
ENSG00000267483
ENSG00000141527
ENSG00000134508

Strand
+
+
+
+
+
+
+
+

RNF125
RP11-53I6.2
LINC00907
RNF165

ENSG00000101695
ENSG00000263917
ENSG00000267586
ENSG00000141622

RP11-146N18.1
19 TJP3
MRPL54
RAX2
AC005307.3
AC005616.1

ENSG00000267134
ENSG00000105289
ENSG00000183617
ENSG00000173976
ENSG00000267243
ENSG00000266893
ENSG00000267243
ENSG00000267537
ENSG00000266893
ENSG00000012124
ENSG00000105695
ENSG00000221874
ENSG00000180257
ENSG00000213801

RBFOX3
CARD14
18 CABLES1

AC005394.1
CD22
MAG
ZNF321P
ZNF816
ZNF816-ZNF321P

Start (bp)
87296365
9479944
14918122
47074774
47072628
47082093
66409764
66417089
66409764
66417089
66409764
66417089
77085427
77085427
78143791
20714528

End (bp)
87326044
9546776
14955593
47133012
47074854
47091087
66521090
66453654
66521090
66453654
66521090
66453654
77613550
77512230
78183130
20840431

Band
q24.2
p13.1
p12
q21.32
q21.32
q21.32
q24.2
q24.2
q24.2
q24.2
q24.2
q24.2
q25.3
q25.3
q25.3
q11.2

+
+
+
+

29598335
29598792
39739247
43906772

29653176
29691742
40271387
44043103

q12.1
q12.1
q12.3
q21.1

+
+
+
+
+
-

61771325
3708107
3762662
3769087
28926295
28982771
28926295
29093286
28982771
35810164
35783028
53431728
53430388
53430388

62090836
3750811
3768573
3772233
29218684
29123635
29218684
29139210
29123635
35838258
35804707
53466076
53466164
53445854

q22.1
p13.3
p13.3
p13.3
q12
q12
q12
q12
q12
q13.12
q13.12
q13.41
q13.41
q13.41
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SNP
rs7498934
rs6503235
rs2323554
rs1495274
rs1495274
rs1495274
rs6501468
rs6501468
rs2909207
rs2909207
rs883541
rs883541
rs8073623
rs8073623
rs3829611
rs4800149
rs8094261
rs7244739
rs17718931
rs17718931
rs7233167
rs4890643
rs9958625
rs11877311
rs475112
rs917546
rs917546
rs1476739
rs1476739
rs9653109
rs9653109
rs9653109
rs11673522
rs11673522
rs8110394
rs8110394
rs8110394

P-value
0.0003701
0.000431
0.00002671
0.000006974
0.000006974
0.000006974
0.00005995
0.00005995
0.00007614
0.00007614
0.00008579
0.00008579
0.0001163
0.0001163
0.0003766
0.00007593
0.0001353
0.00004108
0.000376
0.000376
0.0004234
0.00005549
0.00005135
0.00008493
0.0001404
0.000003929
0.000003929
0.000003327
0.000003327
0.000228
0.000228
0.000228
0.00009619
0.00009619
0.0003313
0.0003313
0.0003313

Position (bp)
87313604
9515777
14927112
47077648
47077648
47077648
66427696
66427696
66439605
66439605
66449122
66449122
77209928
77209928
78161815
20744254
20746728
20747874
29595943
29595943
39905099
43913125
43914787
62032809
3745546
3769834
3769834
29083380
29083380
29090291
29090291
29090291
35807727
35807727
53439481
53439481
53439481

Table 3.3. con't
Chr
Gene
20 MACROD2
RPL7AL3
EYA2
GNAS-AS1
GNAS
RP1-309F20.3
21 SAMSN1
ABCG1
UBASH3A
PCBP3
22 LL22NC03-30E12.13
SOCS2P2
LARGE
RP1-41P2.7

Ensembl gene ID
ENSG00000172264
ENSG00000235208
ENSG00000064655
ENSG00000235590
ENSG00000087460
ENSG00000225806
ENSG00000155307
ENSG00000160179
ENSG00000160185
ENSG00000183570
ENSG00000227710
ENSG00000224465
ENSG00000133424
ENSG00000228587

Strand Start (bp)
End (bp)
+
13976015
16033842
+
+
+
+
+
+
+

16664753
45523263
57393974
57414773
57438583
15857549
43619799
43824008
47063608
22522682
22525369
33558212
36081987

16665049
45817492
57425958
57486247
57463864
15955723
43717354
43867791
47362368
22523027
22525942
34318829
36085420
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Band SNP
p12.1 rs6131652
rs1304179
p12.1 rs6044230
q13.12 rs1541256
q13.32 rs6128441
q13.32 rs35113254
q13.32 rs35113254
q11.2 rs12626593
q22.3 rs225401
q22.3 rs884339
q22.3 rs17004793
q11.22 rs5995601
q11.22 rs5995601
q12.3 rs16992029
q12.3 rs16995953

P-value
0.0003937
0.0004005
0.0001602
0.00001494
0.0003562
0.000007265
0.000007265
0.0004051
0.0003771
0.0003464
0.0002008
0.00006649
0.00006649
0.0002015
0.00007196

Position (bp)
15211513
15296031
16665232
45784212
57402992
57435532
57435532
15857846
43693693
43866505
47119273
22524871
22524871
33668879
36084258

Table 3.4. Differentially expressed genes in KaLwRij bone marrow macrophages
*
*

*
*
*

*

Gene
Tnfrsf26
Tnfrsf23
Samsn1
2210012G02Rik
Mpo
Ctsg
Pdlim4
Tspan32
Ms4a3
Elane
2210012G02Rik
Timp3
Ly6g
Ada
Bgn
Igfbp7
Qpct
Chi3l1
Lrrc27
Lyrm7
Ceacam10
Cd81
Wdfy1
Sparc
Cd276
Fcnb
Scnm1
Mtg1
ND3
Alad
Dmwd
2410091C18Rik

Fold change
-29.9811
-14.6596
-14.4329
-9.58558
6.93897
5.64399
-5.33088
-5.15177
4.77849
4.51361
-4.36785
4.17675
4.09308
3.75752
3.33172
2.95073
-2.89029
2.8762
-2.87336
2.82725
2.76395
-2.62216
2.60413
2.52091
2.23131
2.00202
-1.6946
1.67805
-1.64285
1.60752
1.53818
-1.5002

P-value
2.65E-09
1.89E-07
1.14E-07
4.43E-07
1.54E-06
2.33E-05
3.23E-05
6.34E-07
2.22E-05
1.21E-07
2.98E-05
4.94E-07
3.00E-05
5.59E-05
1.19E-07
3.30E-06
5.46E-05
8.41E-06
1.43E-05
1.19E-06
3.59E-05
8.44E-06
3.57E-06
1.38E-06
1.09E-05
6.59E-06
7.08E-07
4.04E-05
1.77E-05
4.37E-05
1.33E-05
3.72E-05

Fold change is expression in KaLwRij bone marrow macropchages compared to B6
* gene is present on KaLwRij BIP susceptibility candidate gene list

127

Table 3.5. Differentially expressed genes in KaLwRij bone marrow stromal cells
Gene
* Tnfrsf26
* Tnfrsf23
Wdfy1
Tceanc2
* Lyrm7
Mtg1
ND3
5830417I10Rik

Fold change
"11.3288
"21.709
3.27725
"6.67305
2.21795
1.90874
"1.75834
"6.2556

P-value
3.81E"08
6.49E"08
6.87E"07
1.05E"05
8.92E"06
7.88E"06
6.83E"06
1.73E"05

Fold change is expression in KaLwRij compared to B6
* gene is present on KaLwRij BIP susceptibility candidate gene list
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Table 3.6. SAMSN1 variant frequencies in MM patients
Position
Chr21
15830578
15857533
15857592
15857846
15858171
15858207
15858228
15858229
15858302
15872961
15873026
15882622
15884758
15884899
15889304
15889359
15893545
15893567
15893594
15893619
15918508
15918577
15918601
15918714
15954440
15954528

SNP
rs2822669
rs76251857
rs12626593
rs28470776
rs80062901
rs373757186
rs149543089

rs62227165
rs118173592
s376866016
rs73344160
rs34607574
rs368475908
rs150644782
rs760344
rs760345
rs139733326
rs7281104
rs118133999
rs12329657
rs2822785

Allele
(Ref/Alt)
C/T
A/G
G/A
C/G
G/A
G/A
C/T
G/A
T/C
C/T
T/C
T/C
G/A
A/G
C/G
G/A
A/T
A/T
T/C
A/G
T/C
G/C
C/T
A/G
G/A
G/A

Consequence

3' UTR variant
3' UTR variant
3' UTR variant
3' UTR variant
3' UTR variant
3' UTR variant

missense variant

splice region variant
missense variant
missense variant

missense variant

N
366
366
366
366
366
366
366
366
366
366
366
366
366
366
366
366
366
366
366
366
366
366
366
364
366
352

MM patients
variant
alleles
%
44
12.02
1
0.27
3
0.82
34
9.29
1
0.27
3
0.82
1
0.27
1
0.27
1
0.27
1
0.27
8
2.19
0
0
0
0
4
1.09
6
1.64
0
0.00
1
0.27
54
14.75
165
45.08
1
0.27
1
0.27
88
24.04
10
2.73
169
46.43
1
0.27
145
41.19
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N
210
210
210
210
210
210
210
210
210
210
210
210
210
210
210
210
210
210
210
210
210
210
210
210
210
210

Controls
variant
alleles
38
0
2
19
0
4
0
0
0
0
3
1
1
3
3
1
0
28
87
0
0
57
5
107
0
87

odds ratio P-value
%
18.10
0
0.95
9.05
0
1.90
0
0
0
0
1.43
0.48
0.48
1.43
1.43
0.48
0
13.33
41.43
0
0
27.14
2.38
50.95
0
41.43

0.6421
0.0593
private variant
0.8583
0.8683
1.0276
0.9245
private variant
0.4209
0.2634
private variant
private variant
private variant
private variant
1.5540
0.5217
private variant
private variant
0.8090
0.7533
1.1525
0.8432
private variant
private variant
1.1323
0.6360
1.1476
0.4214
private variant
private variant
0.8651
0.4360
1.1359
0.8017
0.8571
0.3396
private variant
0.9902
0.9564

Table 3.6. con't
Position
15954593
15954601
15954660
15954748
15954849
15954862
15955575
15955633
15955648
15955691
15955693
15955779

SNP
rs2822786
rs139465416
rs2822787
rs2822788
rs34228133
rs2822790
rs2822791
rs2822792
rs144975197
rs17240787
rs9980152

Allele
(Ref/Alt)
G/A
G/T
T/C
C/A
T/C
G/A
C/T
G/A
T/C
A/T
G/A
G/A

Consequence
missense variant
missense variant
missense variant

splice region variant
5' UTR variant
5' UTR variant
5' UTR variant

N
366
366
366
366
366
366
364
364
350
366
366
366

MM patients
variant
alleles
%
104
28.42
2
0.55
301
82.24
0
0
17
4.64
5
1.37
15
4.12
15
4.12
273
78.00
1
0.27
0
0
17
4.64

Odds ratio and P-value were calculated by logistic regression analysis.
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N
210
210
210
210
210
210
210
210
210
210
210
210

Controls
variant
alleles
%
50
23.81
1
0.48
163
77.62
1
0.48
17
8.10
4
1.90
17
8.10
17
8.10
156
74.29
1
0.48
1
0.48
17
8.10

odds ratio P-value
1.3256
0.1707
1.1492
0.9101
1.3270
0.1834
private variant
0.5710
0.0921
0.7093
0.6146
0.5098
0.0472
0.5098
0.0472
1.2195
0.3184
0.5714
0.6934
private variant
0.5710
0.0921
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Chapter 4
Summary of work, future directions, and clinical relevancy
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Part I: Summary of work
Contributions to the understanding of Paget’s “congenial soil”

The “seed and soil” hypothesis has been accepted as a model for cancer cell metastasis
for decades, but, despite advances in the field’s knowledge of cancer cell biology and the bone
microenvironment, the definition of a “congenial soil” remains incomplete. This dissertation is
focused on elucidation of this question, addressing both the composition of the bone
microenvironment “soil” and whole-host “congeniality” to disease progression.
We demonstrated a novel role for anti-angiogenic and therapeutic target TSP1 in bone
homeostasis in Chapter 2. We found that TSP1 played important roles in maintaining bone
matrix integrity through effects on materials properties and overall morphology. Further, we
identified TSP1 as a necessary ligand in OC formation, inhibiting iNOS and thus permitting
osteoclastogenesis. Finally, we demonstrated that TSP1-deficient bone failed to inhibit iNOS in
OC, leading to a model of TSP1 as a paracrine signaling molecule, coupling OB activity to OC
formation. These findings have implications for TSP1-pathway directed therapeutics in trial and
in clinical use to have effects on bone that will be discussed in Part II.

In Chapter 3, we focused on identifying genetic risk loci contributing to bone marrowdependent MGUS and MM susceptibility. Using a non-biased approach, we identified large
candidate gene lists that may underlie susceptibility to MGUS and/or MM in humans and BIP,
the analogous disorder in mice. Combining these two datasets, we identified a candidate gene
list of five genes that may contribute to both murine BIP and human MGUS. One of these genes,
Samsn1, drew our particular attention because it is a negative regulator of B-cell activation (Zhu
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et al., 2004). Importantly, we found that BIP-prone KaLwRij mice have complete germline
deletion of Samsn1, the first germline lesion identified in these mice. KaLwRij mouse plasma Bcells had enhanced activity in vitro and vivo, consistent with the published role for Samsn1 as a
negative regulator in B-cells. KaLwRij mice have increased pro-tumorigenic M2-macrophage
activation under basal conditions, and macrophages polarized to M2 have increased ability to
promote tumor growth in vivo. These findings suggest a novel role for Samsn1 in macrophages,
fulfilling a similar inhibitory role as in B-cells. Finally, we demonstrated that restoration of
Samsn1 expression in KaLwRij-derived 5TGM1 myeloma cells reduced proliferation, indicating
that Samsn1 also contributes to cell-autonomous myeloma cell regulation. Thus, we
demonstrated a single risk allele that participates in the negative regulation of both pre-malignant
plasma B-cells and host MGUS- and MM-supportive macrophages.
While our studies focused on the role of Samsn1 in conferring risk to murine BIP, it is
likely not the only susceptibility gene contributing to the KaLwRij BIP phenotype. We will
discuss the utility of further characterization of the KaLwRij mouse strain in Part III.

Collectively, the data presented in Chapter 2 and Chapter 3 contribute to our
understanding of Paget’s “congenial soil,” providing important rationale for studying genes and
proteins with pleiotropic roles in multiple cell types, locations, and pathologic states.

137

Part II: Future directions and clinical significance of Chapter 2

The work described in Chapter 2 more fully characterized the role of TSP1 in bone
homeostasis, but several questions regarding TSP1 function remain. As in other cell types and
processes, it is likely that TSP1 plays pleiotropic, and perhaps contradictory, roles in bone.

What are the effects of bone-resident TSP1 on matrix composition and osteoclast activity?
We found that TSP1 contributes to bone quality, in part through maintenance of bone
material properties. It is unclear, however, whether this phenotype is due to presence of the
TSP1 ligand itself or TSP1 regulation of the stoichiometry and physical organization of other
components of the bone matrix. TSP1 binds many proteins essential for bone quality, including
hydroxyapatite, collagen, and numerous non-collagenous proteins including osteonectin,
fibronectin, osteopontin, and proteoglycans. To determine whether presence of TSP1 influences
the protein stoichiometry of bone, it would be useful to perform mass spectroscopy on
devitalized bone from wild type and TSP1-/- mice. Unfortunately, the technology to perform
mass spectroscopy in rigid calcified bone tissue is currently unavailable. As part of an effort to
map the proteins of the extracellular matrisome, however, methods are being developed to digest
bone lysate while maintaining protein structure with promising preliminary results (Alexandra
Naba, 2013; Hynes and Naba, 2012). As these technologies become available, it will be
important to evaluate mice deficient for TSP1 and other non-collagenous proteins to determine
how they influence each other and, in turn, the bone extra cellular matrix to effect bone strength
and osteoclast function.
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A conditional TSP1 knock out in OBs would be a useful model to further evaluate the
role of OB-deposited TSP1 in bone strength and quality. These mice presumably would not
express TSP1 in the bone matrix or in OBs, but would have active TSP1 signaling elsewhere.
While it has been shown that OBs secrete TSP1 during bone formation (Clezardin et al., 1989;
Robey et al., 1989), it is possible that other cell types also produce TSP1 for deposition in the
bone matrix. If we observed TSP1 in the bone of OB-conditional TSP1-/- mice, we could use the
floxed TSP1 mouse crossed to cell-specific cre mice to isolate the secretory cells contributing
bone matrix TSP1. To achieve a similar mouse model, we would typically create bone marrow
chimeras by lethally irradiating TSP1-/- mice and transplanting wild type bone marrow to
measure normal osteoclast resorption of TSP1-/- bone. TSP1-/- mice, however, are protected
from sub-lethal irradiation (Isenberg et al., 2008) and partially protected from lethal irradiation.
Attempts to engraft wild type donor bone marrow have failed, resulting in a chimeric
hematopoietic compartment containing both wild type and TSP1-/- cells.
In Chapter 2, we identify that loss of TSP1 influences both bone morphology and bone
matrix materials properties, and it is likely that OB expression and secretion of TSP1 plays a role
in these phenotypes. While it has been established that OB secrete TSP1, it is unclear at what
maturation stage OB contribute to TSP1 deposition in bone. It may be interesting to use multiple
OB-lineage cre mice (osterix-cre to target early OBs, osteocalcin-cre to target mature OB, and
DMP1-cre to target osteocytes) to identify the temporal requirement of TSP1 expression and
secretion for matrix deposition during OB maturation. Using this OB-conditional TSP1-/model, we could evaluate bone morphology, bone strength parameters, and bone material
properties as in Chapter 2 to determine if bone strength phenotype in TSP1-/- is solely
contributed to osteoblastic secretion of TSP1. Moreover, beyond the scope of our work
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described here, further work is necessary to understand the role of TSP1 in bone strength and
fracture healing, especially given established roles for TSP1 in wound healing and angiogenesis.
In addition to its role in promoting bone quality, we hypothesize in Chapter 2 that TSP1
deposited in the bone matrix by OB is responsible for inhibiting iNOS transcription in OC
progenitors. If OB-deposited TSP1 is necessary for OC formation, we would observe a similar
OC phenotype in conditional TSP1-/- in OB mice as in the global TSP1-/- mouse: decreased
serum CTX that is rescued upon inhibition of nitric oxide synthase. These experiments would
also further elucidate the role of TSP1 as a paracrine signaling molecule, coupling OB activity to
OC formation via the bone matrix.

What receptors does TSP1 bind to modulate OC activity?
While we demonstrated that TSP1 is a negative regulator of iNOS in pre-OC, it remains
unclear what receptor(s) it binds to exert this effect. In other cell types, both CD47 and CD36
have been implicated in TSP1-mediated inhibition of NO signaling (Isenberg et al., 2006;
Isenberg et al., 2005). Importantly, TSP1 has not previously been described to modulate iNOS,
though effects on eNOS and downstream molecules have been reported. Our lab previously
demonstrated that CD47 negatively regulates iNOS in OC (Uluckan et al., 2009), leading us to
hypothesize that it is likely a requisite receptor for TSP1-mediated NO effects. TSP1-/- mice had
a more severe OC phenotype in vivo than any TSP1-receptor knock out mouse models, including
CD47-/- and CD36-/-, suggesting that TSP1 exerts its effects on OC via multiple different
receptors. To test whether TSP1 binds both CD47 and CD36 to inhibit NO signaling in early OC,
we could evaluate iNOS in OC from double knock-out CD47-/-, CD36-/- mice. If both receptors
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contribute to TSP1-mediated NOS inhibition, treating OC with TSP1 neutralizing antibody
should have no additional effect beyond the null phenotype.

Does TSP1 promote or inhibit metastatic tumor growth in bone?
In addition to understanding its role in homeostasis, it is important to investigate the role
of TSP1 in bone during pathologic states such as bone metastasis. TSP1 was the first identified
endogenous anti-angiogenic, and TSP1-/- mice have increased primary tumor burden and tumorassociated vasculature (Rodriguez-Manzaneque et al., 2001). In some bone metastatic prostate
cancer models however, increased TSP1 promotes tumor progression through effects on cancer
cell migration (Dias et al., 2012; Firlej et al., 2011; John et al., 2010; Tuszynski et al., 1987).
Interestingly, high tumor-derived TSP1 levels are a prognostic marker for cancer progression and
relapse (Firlej et al., 2011). We found that the bone metastatic C42b prostate cancer cell line
expressed significantly higher levels of TSP1 compared to its parental non-metastatic LnCaP cell
line by RNA-seq (Li Jia, unpublished data). Similarly, but to a lesser magnitude, TSP1
expression is also elevated in bone metastatic melanoma cell line subclone B16-F10 compared to
its parental non-metastatic cell line, B16-F0. We would hypothesize that high TSP1-expressing
bone metastatic tumors overcome TSP1’s anti-angiogenic functions and take advantage of other
TSP1 functions such as mediating migration and adhesion. Once in the bone microenvironment,
tumoral secretion of TSP1 will stimulate OC and initiate the vicious cycle of bone metastasis,
leading to increased tumor growth. We would anticipate, therefore, that injection of TSP1-low
primary tumor cell line and TSP1-high bone metastatic subclone into the mammary fat pad of
mice would show similar primary tumor growth, but that the TSP1-high tumor would have
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increased bone metastasis. In an intratibial model, we would anticipate that TSP1-high
expressing tumors would have increased bone lesions and increased tumor burden. Subsequent
overexpression and knock-down experiments in these cell lines would demonstrate sufficiency
and necessity of tumor-derived TSP1 in mediating migration to and growth in bone.
While the experiments outlined address the role of tumor-derived TSP1 in tumor growth
in bone, it is still unclear what role bone microenvironment TSP1 plays in bone metastasis. We
hypothesized that TSP1 would promote tumor growth in bone by promoting OC activity and
stimulating the vicious cycle. Our studies of bone metastasis in TSP1-/- mice, however, have
been largely inconclusive with TSP1-/- mice having modest but non-statistically significant
increases in tumor burden in aggressive intratibial models (B16-F10 melanoma and PyMMTLV1) and an intracardiac model (B16-F10) of bone metastases, but no increases in tumorassociated osteolysis. Though we are unable to make any definitive conclusions, these data are
consistent with the hypothesis that host-derived TSP1 may play different roles in tumor
progression based on location and severity of malignancy. To investigate the role of TSP1 in
bone metastasis, it will be necessary to use a less aggressive model, such as a orthotopic injection
of PyMMT cells into the mammary fat pad of TSP1-/- mice, performing tumor resection, and
monitoring bone metastasis. A slower-growing tumor may allow the time necessary to uncover
subtle effects of TSP1 on metastatic bone tumor burden.
Subtle effects of host TSP1 on bone metastasis may be due in part to the role of TSP1 in
angiogenesis. TSP1 is largely recognized an anti-angiogenic through its interactions with CD47
and αvβ3, but there are also reports that TSP1 interacts with α6 to promote angiogenesis.
Moreover, TSP1’s angiogenic properties have not been evaluated in the sinusoidal blood vessels
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of the bone microenvironment. It would be useful to evaluate the effects of tumor- and hostTSP1 on angiogenesis in the experiments described above.
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Clinical significance
Will pharmacologic modulation of the TSP1 pathway have effects on bone?

It will be interesting to evaluate the bone effects of TSP1-pathway directed therapeutics
under development and in clinical use as anti-cancer therapeutics (TSP1 mimetics and CD47
antibodies) and to modulate blood pressure (NO donors and NOS inhibitors). We anticipate that
agents that mimic TSP1 signaling (TSP1 mimetics, CD47 antagonists, and NOS inhibitors such
as L-NAME used in our study) will stimulate osteoclastic bone resorption. While this increase in
bone remodeling may be of minimal concern in the general population, it will be important to
monitor patients at increased risk of skeletal related events such as cardiovascular disease
patients presenting with osteoporosis and cancer patients at risk for bone metastasis. Our data
provide rationale for TSP1-pathway inhibitory therapeutics (NO donors such as Isordil and
TSP1-blocking CD47 antibodies) to reduce OC activity, especially in comorbidities such as
osteoporosis and bone metastasis. As these TSP1-pathway directed therapeutics become
standard-of-care, it will be important to identify and monitor both harmful and positive bone
effects, including effects on bone mineral density as well as bone quality.
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Part III: Future directions and clinical significance of Chapter 3

The major finding presented in Chapter 3 is that Samsn1 is deleted in the germline of
BIP-resistant KaLwRij mice. KaLwRij have enhanced B-cell and macrophage activation, and
re-expression of Samsn1 in myeloma cells reduces proliferation. Therefore, we hypothesize that
Samsn1 contributes to genetic susceptibility of murine BIP through independent effects on
multiple cell types, and that the SAMSN1 pathway likely participates in human genetic risk to
MGUS and MM.

Is Samsn1 deficiency sufficient to confer increased risk of BIP in mice?
To determine whether Samsn1 deletion is sufficient to confer BIP-susceptibility in mice,
we could use a targeted Samsn1-/- mouse model (Wang et al., 2010). To determine effects on
BIP-susceptibility, we could immunize Samsn1-/- mice and monitor SPEP response as in Figure
3.1b. In addition, to determine whether loss of Samsn1 creates a myeloma-permissive
microenvironment, we could inoculate Samsn1-/- mice with 5TGM1 myeloma cells and monitor
tumor growth. If Samsn1 contributes to host BIP susceptibility and microenvironment support of
myeloma, we would predict that SPEP response and tumor burden in Samsn1-/- mice would be
similar to KaLwRij.

What role do Samsn1-null macrophages play in BIP and myeloma?
The only published role for Samsn1 is in B-cell activation ((Wang et al., 2010; Zhu et al.,
2004)), but many cells of the hematopoietic lineage, including macrophages, are Samsn1
expressors (BioGPS, (Claudio et al., 2001)). In B-cells, SAMSN1 is a proposed adaptor protein
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that interacts with the ITIM domain of PIR-B and phosphorylated SHP-1/2 to inhibit B-cell
activation, likely through modulation of Lyn phosphorylation and subsequent effects on B-cell
receptor (BCR) and its binding partners, including Syk, PI3 kinase, and PLCγ ((Wang et al.,
2010; Zhu et al., 2004)) (Figure 4.1). Notably, many of these proteins participate in regulation
of other hematopoietic cells, with reports of BCR complex proteins to promote and PIR-B
complex proteins to inhibit macrophage activation and function (Brenner et al., 2004; Munitz et
al., 2010; Xie et al., 2014). We found that KaLwRij mice have increased macrophage activation
in vitro and increased pro-tumor effects in vivo, and we hypothesize that these effects are due to
Samsn1 deletion. Repeating these macrophage experiments in Samsn1-/- mice would determine
whether Samsn1 deletion is the causal variant of the KaLwRij macrophage phenotype.
Furthermore, it will also important to identify the macrophage-autonomous role of Samsn1,
including regulatory factors, binding partners, and downstream effects, to identify manipulatable
pathways for modulating MGUS and myeloma microenvironment in a preventative setting.
Increased macrophage activation has been implicated in human MM pathogenesis
(Asimakopoulos et al., 2013; Berardi et al., 2013; Ribatti et al., 2013). We found that KaLwRij
mice have macrophage activation that precedes the onset of detectable BIP. We hypothesize that
the increased KaLwRij macrophage activation increases BIP development, and subsequently
contributes to transformation to overt myeloma. Notably, however, it is unclear both in mice and
in humans whether the microenvironment promotes MGUS and myeloma development or
whether microenvironment changes are a result of increased B-cell activation, representing “lowlevel” MGUS undetectable by current methods. It will be difficult to answer this question using
current mouse models of MGUS, with the KaLwRij mouse only presenting with BIP at 2 years
of age. Vitamin D deficiency and irradiation can accelerate BIP development in KaLwRij mice
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(Michael Tomasson, unpublished data). We predict that chronic activation of macrophages by
LPS treatment or transplant of in vitro activated macrophages may also accelerate BIP
development via increased support of pre-malignant plasma B-cells. In addition, as the field
identifies susceptibility loci contributing to MGUS and MM susceptibility in humans and in
mice, more precise genetic models can be developed to study the pre-malignant
microenvironment and evaluate the contribution of individual microenvironment cell types to
disease progression, including macrophages as well as osteoclasts and bone marrow stromal
cells.

What genetic variation contributes to stepwise progression of myeloma in KaLwRij mice?
We found that KaLwRij mice have homozygous germline deletion of Samsn1, but, while
Samsn1 likely contributes to the increased penetrance of BIP in KaLwRij, it is unlikely to be the
only participating locus. Our SNP analysis identified several thousand variants between BIPresistant B6 mice and BIP-susceptible KaLwRij mice, providing a wealth of information of
genes that may contribute to BIP in mice. Particularly compelling are genes with dramatically
high variation between B6 and KaLwRij, in some cases with more than 100 variant SNPs. In
addition to the germline variants, we also identified differential gene expression between B6 and
KaLwRij in macrophages and bone marrow stromal cells, both known to support MGUS and
MM cells. Interestingly, several differentially expressed genes have genetic variation between
B6 and KaLwRij, suggesting that those alleles confer risk via impacts on the microenvironment.
Importantly, however, we did not identify germline genetic variation in many of the
differentially expressed genes, indicating that their gene expression is dependent on non-cell
autonomous effects or due to downstream effects of KaLwRij genetic variants. It is likely that
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causal gene variants lie in shared or cooperative pathways to modulate B-cells and
microenvironment cells to confer increased BIP risk. Bioinformatics pathway analysis of all
candidate genes would be useful to identify pathways of interest for further investigation.

What role do the other candidate genes (Fstl4, Ccm2, Tenm3, and Csmd1) play in BIP risk?
In addition to whole gene-set analysis, focused examination and verification of the other
four candidate genes identified in the mouse and human integrative analysis would be useful to
further characterize the genetic contributions to BIP-risk in KaLwRij mice and MM-risk in
humans. None of the remaining four candidate genes have been reported to play roles in plasma
B-cells, myeloma cells, or host supportive cells. Based on the success of Samsn1, however, we
anticipate that further investigation of Fstl4, Ccm2, Tenm3, and Csmd1 will identify new roles
for the genes in cells contributing to MM progression.
While most of the research of Ccm2 has focused on its effects in cerebral cavernous
malformations, there is evidence that it is involved in p38 MAP kinase signaling (Zawistowski et
al., 2005), known to promote MM growth and a target for therapeutic intervention (Campbell et
al., 2014). Csmd may also be a good candidate as it exerts anti-tumor effects in solid tumors,
and loss of Csmd1 is associated with poor prognosis in colorectal cancer patients (Tang et al.,
2012; Zhang and Song, 2014). Relatively little is known about the function of Tenm3, with most
of the published research focused on its role in vision. It is possible that Tenm3 underlies a trait
other than BIP-susceptibility present in KaLwRij that has not yet been characterized.
The most intriguing gene for subsequent follow-up studies is Fstl4. While there are no
reports of Fstl4 directly influencing cells contributing to myeloma pathogenesis, there is
evidence for a downstream molecule, activin A, in multiple cell types participating in MM
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progression. Follistatin inhibits the activity of activin A to promote B-cell immunoglobulin
secretion (Ogawa et al., 2008), MM bone disease (Vallet et al., 2010), and pro-tumor M2
macrophage polarization (Sierra-Filardi et al., 2011). Further, the actvin A pathway has direct
clinical implications with increased circulating activin A correlated with increased bone disease
and decreased survival in MM patients (Terpos et al., 2012). With potential roles in multiple cell
types, it will be interesting to characterize the role of Fstl4 in mediating the activin A pathway in
BIP-prone mice and in MGUS patients.

Sequencing of KaLwRij to identify genetic events during myeloma progression
While SNP mapping was successful in our approach described in Chapter 3, the
approach has substantial shortcomings. SNP mapping takes advantage of “marker” SNPs that
are likely in linkage with causal variants, but are not necessarily causal themselves. Moreover,
SNP mapping will not identify small but biologically significant genetic lesions that may
contribute to disease, especially when used to compare two closely related strains. To fully
characterize the KaLwRij mouse strain, whole genome sequencing is necessary to identify all
variants, including protein coding genes, non-coding RNAs, and regulatory regions. Logistically
important, the closely related but BIP-resistant B6 strain is the mouse reference genome and is
complete, well annotated, and publically available.
It is likely that much of the variation between B6 and KaLwRij is unrelated to inherited
BIP risk. To reduce follow-up studies of non-BIP related variation, we could compare the
sequence of the locus of interest from our KaLwRij colony to other isolated BIP-susceptible
KaLwRij colonies. Because of the limited commercial availability, individual laboratories
maintain independent KaLwRij colonies, all of which have been inbred independently for more
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than 20 generations, the requisite for defining a substrain (2013). Comparing our KaLwRij substrain sequence to the sequences of other sub-strains (e.g. Croucher colony and Zannettino
colony at the Garvan Institute, Mundy colony at Vanderbilt University, etc.) will help to filter
variation due to genetic drift. We anticipate that all BIP-susceptible KaLwRij colonies would
share alleles contributing to increased BIP risk.
While the work presented in Chapter 3 explored the transition from a normal state to
BIP, it does not address the transition to overt myeloma. The KaLwRij 5T myeloma model is
the ideal system to identify plasma-cell intrinsic genetic changes between BIP and myeloma.
The 5T myeloma cell lines were isolated from spontaneous myelomas arising in KaLwRij mice,
and can be transplanted into syngeneic KaLwRij mice to propagate the myeloma (Alici et al.,
2004; Asosingh et al., 2000; Vanderkerken et al., 2003). In this work, we utilized 5TGM1
myeloma cells to determine the role of Samsn1 in myeloma cell proliferation. Whole genome
sequencing of the 5TGM1 cell line and comparing the variation to the KaLwRij sequence would
identify genes that are mutated during the BIP-to-myeloma transition in mice. Similar to
comparing our KaLwRij colony sequence to other KaLwRij substrains, it would be useful to
compare the 5TGM1 sequence to other available 5T cell lines (e.g. 5T33vv, 5T33vt, etc.) to filter
any variation due to genetic drift. At the conclusion of these sequencing efforts, therefore, we
would have a genetic model for the plasma-cell intrinsic variation that participates in the stepwise progression of myeloma: normal (B6), “MGUS” (BIP – KaLwRij), and myeloma (5T cell
line).
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Clinical significance:
Genetic screening and treatment strategies for high-risk MGUS patients

Despite advances in treatment, including chemotherapy, proteasome inhibitors, and
bisphosphonates, that target both the malignant plasma cell as well as host supportive cells, MM
remains an invariably fatal disease with a short median survival of only 6 years. MM has a
requisite precursor, MGUS, that represents a unique opportunity for preventative treatment of
malignancy. Despite the rapid progression of MM, however, MGUS remains non-malignant for
decades, and often never transforms to overt myeloma. Because of low rates of progression,
MGUS patients are not clinically treated.
Inherited risk of MM is due to increased risk of MGUS, not increased rate of
transformation from MGUS to myeloma. Notably, plasma-cell autonomous genetic changes
occur during the transition from normal to MGUS, with few variations between MGUS and MM
affected cells (Davies et al., 2003), implicating B-cell extrinsic events in promoting malignancy.
Identifying susceptibility loci to MGUS, specifically in genes that participate in
microenvironment cells, will provide important data for the development of screening strategies
to identify high-risk MGUS patients. Moreover, understanding malignant-cell extrinsic
mechanisms that promote the progression of MGUS to MM will help to identify preventative
strategies to prevent or delay onset of MM.
In our work presented here, we used a strategy to identify inherited genetic variation in
MM patients compared to controls. Our analysis yielded gene candidates that act in multiple cell
types, both B-cells, the current focus of the myeloma field, and in host supportive
microenvironment cells. We focused our efforts on the candidate gene Samsn1 and evaluated its
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biologic function in murine myeloma cells, BIP-susceptible B-cells, and supportive
macrophages. Importantly, we identified two SNPs in Samsn1 that are underrepresented in a
MM patient population. These data provide important rationale for pursuing Samsn1 pathway
genes for both screening of MGUS patients and development of preventative strategies targeted
to both B-cells and macrophages.
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SAMSN1

Figure 4.1.
SAMSN1 is member of the PIR-B / SHP-1/2 B-cell inhibitory complex
Following activation of the B-cell receptor (BCR), Lyn phosphorylates the ITAM for
recruitment of the positive regulatory signaling complex. Lyn also phosphorylates the
ITIM domain of PIR-B for recruitment of SHP-1/2 for negative regulation of B-cells.
SAMSN1 is likely a component of this inhibitory complex, with interactions with the
PIR-B ITIM domains and SHP-1/2.
Modified from (Wang et al., 2010).
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a b s t r a c t
Integrins on both tumor cells and the supporting host stromal cells in bone (osteoclasts, new blood vessels,
inﬂammatory cells, platelets and bone marrow stromal cells) play key roles in enhancing bone metastasis.
Tumor cells localize to speciﬁc tissues through integrin-mediated contacts with extracellular matrix and
stromal cells. Integrin expression and signaling are perturbed in cancer cells, allowing them to “escape” from
cell–cell and cell–matrix tethers, invade, migrate and colonize within new tissues and matrices. Integrin
signaling through αvβ3 and VLA-4 on tumor cells can promote tumor metastasis to and proliferation in the
bone microenvironment. Osteoclast (OC) mediated bone resorption is a critical component of bone metastasis
and can promote tumor growth in bone and αvβ3 integrins are critical to OC function and development.
Tumors in the bone microenvironment can recruit new blood vessel formation, platelets, pro-tumor immune
cells and bone marrow stromal cells that promote tumor growth and invasion in bone. Integrins and their
ligands play critical roles in platelet aggregation (αvβ3 and αIIbβ3), hematopoietic cell mobilization (VLA-4
and osteopontin), neoangiogenesis (αvβ3, αvβ5, α6β4, and β1 integrin) and stromal function (osteopontin
and VLA-4). Integrins are involved in the pathogenesis of bone metastasis at many levels and further study to
deﬁne integrin dysregulation by cancer will yield new therapeutic targets for the prevention and treatment of
bone metastasis.
© 2010 Elsevier Inc. All rights reserved.
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The development of bone metastasis is common in many cancers,
occurring in virtually all patients with multiple myeloma, in 65%–75%
of patients with advanced breast and prostate cancers, and in 30%–
40% of patients with lung cancer [1–3]. The consequences of bone
metastases are often devastating and can cause pain, pathologic
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fractures, spinal cord and other nerve-compression syndromes and
life-threatening hypercalcemia [4]. Both osteolytic lesions and
osteoblastic bone metastases are associated with increased OC activity
and disrupted bone micro-architecture [5,6]. In the bone microenvironment, tumor cells secrete soluble factors that promote bone
remodeling resulting in the release of additional bone matrix-bound
growth factors which further activate OCs and osteoblasts (OB) and
promote tumor growth [3,4,7–16]. Anti-resorptive therapy, e.g. with
bisphosphonates or denosumab, signiﬁcantly decreases skeletal
complications of cancer and is a standard of care for patients with
bone metastases [4,8,17–19]. In addition to their effects on bone,
tumors in the bone microenvironment recruit blood vessel formation,
platelets, immune cells and stromal cells that promote tumor growth
and invasion in bone. Integrin-mediated cell signaling plays a critical
role in many of these processes during bone metastasis, including
platelet aggregation (αIIbβ3), hematopoietic/immune cell mobilization (VLA-4 and osteopontin), neoangiogenesis (αvβ3, αvβ5, α6β4,
and β1 integrin) and stromal function (osteopontin and VLA-4) (see
Fig. 1). For these reasons, the mechanisms by which integrin signaling
mediates the pathogenesis of bone metastasis have been an area of
active research.

open conformation, facilitates high afﬁnity ligand binding and triggers
integrin-mediated cell signaling cascades (outside-in signaling) [24,25].
Many proteins play critical roles in the activation of speciﬁc
integrins, but two cytoplasmic proteins, talin and kindlin, are
necessary for inside-out signaling required for the activation of all
integrin subtypes [23,26–29]. Talin binds to the proximal end of the
beta cytoplasmic tail via a phosphotyrosine-binding (PTB) domain
within its FERM domain [27] and links the integrin to the actin
cytoskeleton [23]. Kindlin 1, 2, or 3, is necessary for talin-induced
integrin activation [26,30,31]. Kindlin, like talin, also interacts with
intracellular proteins resulting in cytoskeleton reorganization and
adhesion [32]. G-protein coupled receptors such as the ADP receptor
P2Y12, also play critical roles in the inside-out signaling required for
integrin activation [25,33,34]. Structure–function analyses on β3
integrins have shown that a membrane-proximal region is important
for inside-out signaling [28,35–40].
In addition to activation by inside-out signaling, ligand binding
and integrin clustering can be signiﬁcantly modulated by growth
factor receptor interactions and other integrin interacting proteins, as
reviewed in [22,23,41]. For example, integrin associated protein,
CD47, augments integrin activation and affects the ability of αvβ3
integrin to cluster upon ligand binding [42]. Ligation of the integrin
then stimulates outside-in signaling that leads to the activation of
numerous signals critical for growth, migration, survival and other
functions, including FAK phosphorylation, ERK signaling, and NF-κB
activation. Thus, integrin signaling in cancer cells and in associated
stromal, endothelial and hematopoietic cells can be inﬂuenced by
intracellular signaling proteins, growth factors, chemokines and other
receptors that participate in regulating integrin function through
effects on integrin activation, ligand binding, ligand afﬁnity and
integrin clustering.
Maintaining adhesion to the ECM, in part through integrin
signaling, is critical to cell survival [43]. Altered cell–cell or cell–
ECM interactions results in disruption of downstream survival
signaling and anchorage-dependent non-transformed cells undergo
anoikis [43]. Under normal conditions, because each cell type
expresses a unique set of integrins that recognize underlying ECM
ligands, this form of apoptosis ensures that detached cells do not
colonize inappropriate locations [43]. Cells that resist anoikis, such as
metastatic cells, take advantage of several different mechanisms so

Integrin structure, activation and signaling
Integrins are heterodimeric transmembrane glycoproteins that
facilitate cell–cell and cell–extracellular matrix (ECM) adhesion and
cell migration [20]. Integrins recruit many intracellular signaling
molecules and can activate survival, proliferation, and motility signaling
pathways [21]. There are 8 beta and 18 alpha integrin subunits that
assemble into 24 unique known combinations in different cell types,
each characterized by distinct ligand binding speciﬁcities (including
collagen, osteopontin, ﬁbronectin, laminin, and others, depending on
the integrin family), signaling abilities, and regulatory mechanisms [22].
Integrins are activated by conformational changes in the integrin
extracellular domains. When the integrin α and β subunit cytoplasmic
and transmembrane domains remain closely juxtaposed, the extracellular domains are held in a closed conformation. Activation by
intracellular signals to the cytoplasmic tails results in separation of the
α and β cytoplasmic and transmembrane domains and exposure of the
extracellular ligand binding domain [23] (inside-out signaling). The

Integrin Expression During Bone Metastasis
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Fig. 1. Integrin Expression During Bone Metastasis: Numerous host stromal cells types interact with tumor cells to facilitate tumor cell homing, colonization and invasion in bone.
Preclinical and clinical evidence demonstrate that speciﬁc integrin expression and signaling on both tumor cells and host cells are central to facilitating bone metastasis.
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that the cell can adhere to a novel ECM, including aberrant integrin
expression [44], constitutive activation of molecules usually activated
via integrin signaling including FAK [45], EGFR [46] and SRC [47], and
lack of activation of pro-apoptotic pathways [48], among others.
The integrin family of adhesion receptors links ECM to the
cytoskeleton through a complex and regulated network of activation,
interaction with numerous growth factor, GPCR, chemokine and
cytokine receptors and induction of complex signaling cascades.

Integrin expression and signaling on tumor cells that metastasize
to bone
Tumor progression, invasion and eventual metastasis require the
activity of many adhesion proteins, including the integrin superfamily. At each stage of cancer progression, subsets of integrin heterodimers are activated, providing the necessary signaling pathways for
adhesion, migration and cell survival. Metastatic tumor cells show
differential integrin heterodimerization and activation compared to
non-metastatic tumor cells that enable the cell to home to and
colonize in a metastatic site, such as the bone marrow cavity [49,50].
In order for primary epithelial cancers to metastasize, the tumor cells
must become resistant to anoikis and detach from the primary tumor
site ECM, enter the vasculature, and eventually colonize a distant site.
Upon reaching a successful metastatic site, however, tumor cells use
both anoikis and anoikis-resistance to their advantage, in some cases
forming micro-metastases that are resistant to cancer treatment via
integrin binding to the underlying bone ECM as reviewed in [51].
Tumor cells must also form interactions between the tumor cell and
bone stroma to establish and maintain skeletal metastasis. Many
integrins have been implicated in tumor cell–host bone stroma
interactions during bone metastasis and tumor growth in bone (Fig. 1,
Table 1), including the β1 and β3 integrin family members.
avβ3 is a receptor for osteopontin, ﬁbronectin, and vitronectin,
ECM proteins that are important bone matrix proteins, and αvβ3 has
been identiﬁed as a critical integrin in breast cancer and prostate
cancer skeletal metastasis [50,52–56]. Interestingly, although αvβ3
has been shown to bind to ﬁbronectin in other locations with high
afﬁnity, tumor αvβ3 integrins do not bind ﬁbronectin in bone marrow
stroma, indicating that αvβ3-expressing tumor cells bind to the bone
stromal ligands vitronectin and osteopontin [57]. In breast cancer,
αvβ3 binding of host osteopontin is necessary for tumor cell
colonization to bone [58]. Bone metastatic cells have a higher
expression of αvβ3 than the primary tumor [53], promoting
adherence to the bone matrix by binding osteopontin expressed by
bone stromal cells [58]. Breast cancer cells that overexpress αvβ3
have increased levels of bone metastasis and associated tumor burden
and osteolysis [52,59–62]. This overexpression of αvβ3 in the tumor
cells leads to increased tumor cell adhesion, migration and invasion to
bone as well as enhanced OC recruitment within the bone microen-

Table 1
Extracellular matrix proteins and the main integrins that participate in bone metastasis
and tumor growth in bone.
Integrin

ECM ligands

αvβ3
α2β1
α4β1 (VLA-4)
αvβ1
αvβ5
αIIbβ3
β2
α1β1
α5β1
α9β1
α6β4

Vitronectin, osteopontin, bone sialoprotein, ﬁbronectin, TSP-1
Collagen I, laminin
VCAM-1 ﬁbronectin, osteopontin
Fibronectin, vitronectin
Vitronectin, osteonectin, bone sialoprotein, ﬁbronectin
Fibrinogen
VCAM-1, ICAM-1, ﬁbrinogen
Collagen
Fibronectin
TSP1
Laminin, TSP-1

vironment [60,61], implicating a role of tumor-speciﬁc αvβ3
expression in breast cancer metastasis to bone as well as tumorassociated osteolysis. Likewise, in prostate cancer cells, active αvβ3 is
necessary for the adherence and migration to bone matrix proteins at
early stages of skeletal metastasis. This tumor cell αvβ3 integrin
expression allows cancer cells to adhere to the bone matrix and
interact directly with the native bone cells, OBs and OCs, as well as
with the bone matrix itself [59].
The β1 family member, α5β1, has been identiﬁed as the primary
integrin receptor for ﬁbronectin on human bone marrow stroma [57].
α5β1 expression on leukemia, prostate and breast cancer cells
facilitates interaction with bone stroma [57,63–65]. Antibody inhibition of α5, β1 or ﬁbronectin blocks prostate cancer tumor cell binding
to bone stroma, indicating necessary roles for both integrin α5β1 on
tumor cells and ﬁbronectin on bone marrow stromal cells [57]. In
breast cancer skeletal metastasis, the interaction between malignant
cell α5β1 and host stromal cell ﬁbronectin contributes to the survival
of growth-arrested tumor cells, a potential mechanism through which
tumor cells can become sequestered and “dormant” within the bone
marrow cavity and may later begin to proliferate to establish a skeletal
metastasis [64]. Upon FGF-2 growth factor stimulation, breast cancer
cells undergo growth arrest and up-regulate α5β1 expression. In most
cases, these cells die, but cells that bind ﬁbronectin via α5β1 and
initiate cell survival signaling cascades survive [64].
Another β1 family member, α2β1, a collagen type I receptor, is
expressed by prostate tumor cells, and its activity promotes invasion
and adherence to the bone stroma. The presence of collagen I, the
most abundant protein in bone, signiﬁcantly increases prostate
epithelial cell adhesion in culture, and antibody inhibition of integrin
subunits α2 and β1 signiﬁcantly inhibits tumor cell binding to stroma
[66]. Hall et al. showed that a skeletal metastatic prostate cancer cell
line, but not cell lines that are metastatic to other organs, binds to
collagen I and that this collagen I binding is α2β1 dependent in vivo
[67]. Interestingly, stromal expression of collagen I does not increase
tumor growth, but instead promotes tumor cell migration [67]. Tumor
cell α2β1 binding of host bone marrow stromal collagen I activates
RhoC GTPase which instigates a signaling cascade responsible for
cytoskeleton reorganization, migration, and, eventually, collagenstimulated invasion and preferential skeletal metastasis [68].
α4β1/vascular cell adhesion molecule-1 (VCAM-1) binding has
been identiﬁed as important for cell–cell contact between α4β1
expressing myeloma cells and VCAM-1 expressing bone marrow
stroma [69]. This interaction contributes to bone tumor growth, OC
stimulation and resultant osteolysis [69,70]. Likewise, epithelial
tumor cells (CHO) that overexpress α4β1 developed signiﬁcantly
more bone metastases than mice inoculated with CHO cells alone
[71]. Bone metastases, but not other metastases, were inhibited by
antibodies against α4 and/or VCAM-1, suggesting a role for α4β1/
VCAM-1 binding in the skeletal metastases of solid tumors [71].
The role of integrins and chemokine cross talk in tumor cell
homing to bone will be discussed later. While many aspects of
tumor–bone stromal interactions remain unknown, it is clear that
speciﬁc interactions between tumor cell integrins and bone stromal
cell ligands are essential for successful homing and metastasis to
bone.
Integrin expression and signaling in osteoclast function and bone
metastasis
Bone invading metastatic tumor cells co-opt integrin signaling
pathways that enhance OC function and recruitment. As part of
bone remodeling, OCs bind to the bone matrix, form an actin ring
mediated sealing zone, secrete enzymes and acid to degrade bone,
and then migrate to a new site. Each of these functions is regulated
in part by integrins located on the membrane surface of the OC,
interacting with neighboring cells and with the ECM [72].
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Several integrins are involved in OC binding to bone, including
αvβ3 (osteopontin, vitronectin, bone sialoprotein), αvβ5 (ﬁbronectin), and α2β1 (collagen) [73,74]. Of these, αvβ3 is the predominant
integrin found on OCs, and antibody inhibition of αvβ3 inhibits OC
attachment to the bone matrix as well as OC mediated bone
resorption [75]. In addition, mice with targeted disruption of β3
integrin (β3−/−) have defective OC function [76] and are protected
from tumor-associated osteolysis [77]. αvβ3 is responsible for
mediating OC-bone recognition [53,75,78,79] and subsequent attachment to the bone matrix [75,80], signaling to create the characteristic
resorptive rufﬂed membrane, regulation of OC spreading, and overall
organization of the cytoskeleton [76,81]. Activation of αvβ3 regulates
OC adhesion and migration on osteopontin, important for OC
polarization and bone resorption [82]. Osteopontin ligand binding of
αvβ3 causes a reduction of OC cytosolic calcium, inducing podosome
formation and subsequent resorption [83]. In addition, αvβ3 is critical
for the activation of c-Src, c-Cbl, and GTPases Rho and Rac, signaling
that is necessary for the cytoskeletal reorganization important in OC
function [81,84,85].
OC targeted therapy is a standard of care for the treatment of
bone metastasis and myeloma bone disease. Tumor cells recruit OCs
resulting in bone destruction and pain [3,86,87]. Because of its
known role in OC function and its high expression in skeletal
metastatic tumors much research has focused on αvβ3 integrin and
its ligands. An important characteristic of αvβ3 mediated cell
adhesion, both in OCs and tumor cells, is the requirement of
osteopontin, an αvβ3 ligand [58]. Osteopontin is a non-collagenous
bone matrix protein that is produced by OBs, OCs, and macrophages
and is found in the ECM adjacent to calciﬁed bone [88–90].
Expression of osteopontin in both the tumor cell and in the bone
microenvironment can promote skeletal metastasis [91,92]. Osteopontin-deﬁcient mice have reduced bone metastasis and tumorinduced osteolysis than wild type controls in a mouse model of
tumor metastasis using syngeneic B16 melanoma cells [93,94],
conﬁrming a role for host cell osteopontin expression during bone
metastasis. Recombinant osteopontin induces cell migration of B16
cells that is inhibited by repressing the ERK/MAPK pathway,
suggesting that the ERK/MAPK pathway regulates bone microenvironment osteopontin levels [91]. Overexpression of osteopontin in
B16 melanoma cells increases cell proliferation and migration,
indicating that the ligand also plays an important role in the tumor
cell itself [91]. It has been demonstrated using a prostate cancer cell
line overexpressing osteopontin that tumor cell osteopontin
regulates MMP-9 secretion and the subsequent CD44/MMP-9
interaction, important for the migration of prostate cancer cells,
contributing to metastatic potential [95]. Osteopontin-producing
tumor cells enhance osteopontin production by OBs [96] and OCs
[97], stimulating osteoclastogenesis, OC adherence, migration, and
bone resorption via host αvβ3 binding [88,98]. Osteopontin
activation of αvβ3 integrin leads to downstream activation of
FAK, c-Src kinase, and Ras-ERK, among other signaling molecules,
resulting in cytoskeletal reorganization, focal adhesion formation,
basolateral membrane differentiation, and osteoclastic resorption
[59,99].
CD47, integrin associated protein, is expressed constitutively
and interacts with integrins, including αvβ3, as part of inside-out
signaling cascades and also operates in an integrin-independent
manner. CD47 plays a role in OC and macrophage biology and
CD47−/− mice have decreased OC number and function [100,101]
which can be rescued in vitro by inhibiting nitric oxide synthase
[101]. CD47−/− mice have decreased bone metastases and tumorassociated osteolysis compared to wild type [101]. During the early
stages of osteoclastogenesis, namely, macrophage fusion, CD47
binds with SIRP1α, a molecule that is transiently induced in
myeloid cells and that likely participates in early fusion events
[102]. In the event of tumor cell metastasis to bone, however, it
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has been reported that cancer cells may utilize this macrophage
self-recognition signaling to fuse with macrophages [103], leading
to mature OCs with tumor cell nuclei and subsequent overexpression of OC stimulation factors, thus leading to increased OC
function [104].
These data underscore the importance of integrins, especially
αvβ3, and its adaptor proteins in OC biology and bone metabolism
and point to the role of OC integrins in regulating growth of cancer
cells in the bone.
Integrins and tumor neovasculature and bone metastasis
Tumor neovascularization is essential for tumor cell invasion and
metastasis. Access to the host blood supply provides the tumor cells
with nutrients and connects the tumor to the circulation, facilitating the
dissemination of metastatic cells. The angiogenic process begins with
the de-stabilization and de-differentiation of local vessels, followed by
activation of endothelial cells (EC), EC migration and proliferation into
the tumor ECM, and ﬁnally organization of ECs into functional vessels.
The ability of tumor cells to activate the normally quiescent vasculature
is proposed to be controlled by an “angiogenic switch” mechanism,
whereby tumor or stromal cells induce changes in the relative balance of
inducers (e.g. vascular endothelial growth factor (VEGF) or TGFβ, PDGF,
TNFα, bFGF) and inhibitors (e.g. thrombospondin-1 [TSP-1]) of
angiogenesis reviewed in [41,105–109]. Activated platelets, tumor
cells, and ﬁbroblasts secrete many of these pro-angiogenic factors. It has
recently been appreciated that macrophage lineage cells play important
roles in promoting tumor-associated angiogenesis [110–113]. Bone
metastasis and bone residing tumors like myeloma also modify and
recruit ECs to enhance neoangiogenesis [114,115].
Many integrin heterodimers have been implicated in tumorassociated angiogenesis [41,105–109,116]. The ﬁrst integrin found to
regulate angiogenesis, αvβ3, is expressed at high levels on tumorassociated vasculature [117,118] and tumor-associated angiogenesis
can be inhibited by β3 integrin neutralizing antibodies [119–122].
αvβ3 has been speciﬁcally implicated in the angiogenesis associated
with prostate cancer bone metastases; antibody inhibition of αvβ3
decreases tumor-associated blood vessels in mice [123]. Interestingly,
Reynolds et al. demonstrated enhanced (not reduced) tumorassociated angiogenesis in subcutaneous tumors in β3−/− mice
[124]. Elevated levels of VEGFR2 were found on tumor-associated
blood vessels in β3−/− mice, and a VEGFR2 inhibitor could block the
enhanced blood vessel formation [125]. It should be noted that an
inhibitor of integrin binding and signaling might have different
consequences than loss of integrin expression. For example, apoptotic
machinery is activated in certain cells expressing integrins that are
not ligand-bound [126–129]. Recent reports that low dose integrin
antagonists can increase tumor growth and angiogenesis while higher
doses suppress tumor growth and angiogenesis [130] underscore the
complexity of targeting β3 integrins for angiogenesis and cancer
therapy.
Another αv integrin, αvβ5, also shows increased expression on
tumor-associated vasculature, and αvβ5 antibodies inhibit VEGFinduced tumor-associated angiogenesis [131]. In contrast, the β3/
β5−/− double knockout mice show enhanced tumor-associated
angiogenesis, as was seen in β3−/− mice [125]. Several hypotheses have been proposed that reconcile the contradictory results
involving the αv integrin family that outline the roles of the
integrins as pro-angiogenic, anti-angiogenic, and/or working
through different pathways as reviewed in [41,108]. It is clear,
however, that αvβ3 and αvβ5 have distinct roles in regulation of
tumor-associated angiogenesis and associated metastasis. The bone
targeted bisphosphonate, zoledronic acid, alters EC integrinmediated adhesion by reduced expression of αvβ3 and αvβ5
integrin on ECs in vitro in one observation [132]. This observation
provides a possible mechanism for OC-independent anti-tumor
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actions for bisphosphonates that have been reported in animal
models [133–135] and clinically [136–139]. Evaluation of the
effects of bisphosphonates on integrin signaling in the tumor–
bone microenvironment is underway.
While much of the research in integrin-mediated angiogenesis has
been focused on the αv integrins, there is evidence that other
heterodimers play a role in angiogenic regulation, particularly the β1
and β4 families. The β1 integrin family (α1β1, α2β1, α5β1, and
α4β1) has a critical role in angiogenesis with β1−/− mice having
severe vascular defects. α1β1 (a collagen receptor) and α2β1 (a
laminin receptor) have been shown to be important for mediating cell
adhesion in VEGF-stimulated ECs [140]. In vivo, function-blocking
antibodies to α1 and α2 signiﬁcantly inhibited VEGF-induced
angiogenesis, indicating a positive regulatory role for α1β1 and
α2β1 expression in tumor-associated angiogenesis [141]. Genetic
data further support a role for the integrin α1β1 as a positive
regulator of angiogenesis as α1-deﬁcient mice show reduced
angiogenesis [142].
Fibronectin receptor α5β1 has also been implicated as a positive
regulator of angiogenesis: α5β1 antagonists inhibit tumor-associated
angiogenesis in mice by inhibition of EC migration and regulating
proliferation and apoptosis [143,144]. Importantly, the α5β1 antagonists did not inhibit angiogenesis induced by VEGF, indicating that the
integrin α5β1 (together with αvβ3) may act in a VEGF-independent
pathway [144]. α4β1, together with its ligand, VCAM-1, expressed in
vessel mural cells, plays an important role in adhesion of ECs and
vascular smooth muscle cells during blood vessel formation [145].
Both anti-α4β1 antibodies and anti-VCAM-1 antibodies inhibit
angiogenesis in vivo. Another integrin, laminin receptor α6β4 is
reported to regulate several aspects of tumor angiogenesis. Genetic
studies revealed that α6β4 promotes endothelial cell migration in
culture; in addition, the integrin is involved in the translational
regulation of VEGF, having a pro-angiogenic effect [146,147].
In many cases, integrins inﬂuence angiogenesis through their
interaction with the integrin ligand thrombospondin 1 (TSP-1). Mice
with a TSP-1 deﬁciency have increased tumor burden and tumorassociated vasculature, both in capillary size and number, while mice
that overexpress TSP-1 have delayed or absent tumor growth and
reduced tumor-associated vasculature [148]. These data indicate that
TSP-1 can contribute to tumor burden via negative regulation of
angiogenesis. In contrast, in a human breast cancer cell line, TSP-1
stimulation up-regulates both integrin subunit α6 mRNA levels and
protein levels which leads to increased adhesion to ECM protein
laminin in vitro, suggesting that TSP-1 facilitates pathogenic angiogenesis [149]. TSP-1 also interacts with α9β1 via its N-terminal
domain and has a positive effect on proliferation and motility in
culture and on angiogenesis in vivo that can be reduced by α9β1
inhibitors. This binding of the microvasculature-associated integrin in
ECs with TSP-1 activates signaling cascades including ERK and
paxillin. Thus, TSP-1 can play both pro- and anti-angiogenic roles,
depending on its speciﬁc integrin interaction.
The roles of integrins in tumor-associated angiogenesis are
complex, not only involving integrin ligand interactions and associated signaling pathways, but also speciﬁc temporal regulation and
indirect effects through proteins such as TSP-1, and are important for
the progression of angiogenesis and eventual metastasis.
Integrin-hematopoietic cell interactions: tumor-induced
mobilization and modulation of bone marrow cells

chemokine receptor CXCR4. OB and bone marrow stromal cells
produce VCAM-1, SDF-1 and osteopontin, all important components
of the “HSC niche” [157–159]. Integrin and chemokine signaling work
in concert to promote HSC and progenitor cell homing and
mobilization in the bone marrow [160]. Disruption of VLA-4/VCAM1 and SDF-1/CXCR4 interactions results in mobilization of HSC into the
circulation [159]. G-CSF mobilization of HSC acts in part through
disruption of VLA-4/VCAM-1 and CXCR4/SDF1 interactions [158,161].
OC resorption can also regulate HSC mobilization and the stem cell
niche [162].
Diverse integrins are expressed on hematopoietic progenitor cells
in speciﬁc patterns and at distinct time points [163]. Integrins not only
mediate the binding of normal progenitor cells to stroma and matrix
molecules, but may also regulate expansion, maturation and differentiation of those cells [164,165]. For example, α4β1 integrin
regulates hematopoietic progenitor cell fate through changes in
integrin expression and activity levels during cell maturation and
differentiation into erythrocytes and neutrophils [165–167]. α4
containing integrins mediate adhesion of hematopoietic progenitors
to stromal cells likely through binding to matrix components such as
ﬁbronectin [168] or cellular receptors such as VCAM-1 [169]. The
integrin subunits α5, α6 and α9 have also been shown to be
expressed by progenitor cells [170–172]. Studies using blocking
antibodies demonstrated that α6 subunit cooperates in collaboration
with the α4 subunit in regulating the homing of progenitor cells [171].
α9β1 integrin is also important for adhesion of progenitor cells to OBs
in the bone marrow [172], illustrating the fact that hematopoiesis
takes place in three dimensional matrices, the so-called bone marrow
niches. These niches are located at the endosteum near OBs and in the
vascular niche close to marrow blood vessels [173].
Tumor cells both in the bone microenvironment and at distant sites
can modulate and mobilize hematopoietic progenitor and immune cells
to promote bone and visceral metastasis and local tumor growth.
Tumor-induced mobilization of VEGFR+ and Sca+kit-bone marrow
derived cells has been implicated in enhancing distant tumor and
metastatic growth [174]. These mobilized VEGFR+ cells also express
α4β1 and can migrate to sites of increased synthesis of matrix
components such as ﬁbronectin and establish a “pre-metastatic niche”
that can favor tumor metastasis and growth [174]. β2 integrins on bone
marrow derived endothelial progenitors can also mediate the adhesion
and VEGF-induced migration of the progenitors to the mature
endothelium of actively remodeling vasculature [175].
Tumor cells from a primary lesion can act at a distance to inﬂuence
bone marrow hematopoiesis through secreted factors such as the
integrin ligand, osteopontin [176]. Primary epithelial tumors can
instigate growth of indolent tumors through modulation of the bone
marrow microenvironment and mobilization and recruitment of bone
marrow cells to distant tumor sites [176,177]. McAllister et al. found
that tumor secretion of osteopontin is necessary but not sufﬁcient in
xenograft models to modulate the bone microenvironment and
promote bone marrow cell recruitment to tumor metastasis [176].
Pazolli et al. found that osteopontin secreted by senescent ﬁbroblasts
promoted tumorigenesis in animal models of skin cancer [178].
Thus tumors cells both in bone and at distant sites can modulate
hematopoiesis in part through osteopontin and bone marrow cell
integrins resulting in the mobilization and recruitment of bone
marrow derived cells that will enhance local and metastatic tumor
growth.
Integrins and tumor cell homing/colonization of bone

The bone marrow is the primary site of hematopoiesis in the adult.
OBs and bone marrow stromal cells regulate hematopoietic stem cell
(HSC) growth, differentiation and bone marrow retention through
numerous signaling pathways including integrin VLA-4/VCAM [150],
chemokine SDF-1/CXCR4, BMPs and Notch [151–156]. Hematopoietic
progenitors and stem cells express the integrin VLA-4 and the

The site of metastasis is tumor cell speciﬁc depending on their
integrin, chemokine receptor and cytokine/receptor expression
proﬁles [50,179–181]. At the metastatic site, normal physiology is
changed towards increased secretion of cytokines and activation of
integrins to support recruitment, survival and growth of tumor cells.
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Metastasizing cancer cells can co-opt the same mechanisms used in
physiological hematopoietic progenitor cell homing to bone through
expression of integrins and chemokines [150,152,153]. CXCR4
expressed on cancer cells can direct those cells to bone [181–186].
The migration of myeloma cells to and across bone marrow stromal
cells is in part regulated by SDF-1α/CXCR4 ligation and up-regulation
of α4β1 (VLA-4) results in adhesion of myeloma cells to the
underlying bone marrow stroma [187]. Likewise, CXCR4 ligation can
increase αvβ3 expression and aggressiveness of metastatic prostate
cancer cells, and disruption of CXCR4 can inhibit prostate cancer bone
metastases [183–185].
It has recently been shown that β3 integrin activity on circulating
CXCR4-positive bone marrow derived cells is important for their
migration and recruitment to sites of angiogenesis. In mice with
mutated tyrosine residues “knocked in” to the β3 integrin locus to
inhibit proper phosphorylation (DiYF mice) [188], CXCR4-positive
bone marrow derived cells were higher in number and defective in
recruitment to subcutaneously implanted tumors or wounds, where
SDF-1 levels were also lower [189]. These data demonstrate that β3
integrin on bone marrow derived cells may be critical for the CXCR4/
SDF-1 gradient, and thus may be important for localization of tumor
cells to the bone microenvironment and also localization of myeloid/
ECs to tumors. Interestingly, CXCR4 deletion on bone marrow cells can
enhance OC activity which could counteract some of the beneﬁcial
effects of CXCR4 inhibition on bone metastases [9].
Integrins expressed by tumor cells, in concert with bone
microenvironment chemokine secretion and further integrin activation, determine the osteotropic characteristics of metastasizing cancer
cells and represent an ideal target for skeletal metastatic cancer
therapy.
Integrins and myeloid/immune cell function during tumor
growth in bone
Myeloid cell integrins are involved in tumor escape from immune
responses and tumor-induced angiogenesis. Bone marrow derived
myeloid cells (macrophages, monocytes, myeloid derived suppressor
cells, and myeloid dendritic cells) migrate to tumors and contribute to
tumor growth, invasion and angiogenesis [190–194]. Macrophages
within tumors, called tumor-associated-macrophages (TAM) [127],
are recruited by chemoattractants such as MCP-1 [195] secreted by
the tumor and then differentiate into tissue macrophages [196]. The
anti-tumor M1 phenotype represents a classical activation that is
induced by pathogens, lipopolysaccharides (LPS) or interferon gamma
resulting in secretion of proinﬂammatory cytokines such as tumor
necrosis factor α (TNFα), interleukin 1β (IL-1 β) and others. M1
macrophages can act in an anti-tumor fashion by secretion of
cytotoxic cytokines and antigen presentation to lymphocytes [197].
The pro-tumor M2 phenotype, represents alternative activation
induced by IL-4 or IL-10 [198]. M2 polarized macrophages promote
tumor cell proliferation and survival, suppress immune responses and
drive tumor neoangiogenesis [197,199–201]. Studies have shown that
the TAM content of tumors and prognosis of patients are inversely
correlated [192,202,203].
β2 integrins are involved in monocyte/myeloid cell migration
through endothelium and in phagocytosis, while β1 integrins mediate
adhesion to matrix proteins and the induction of inﬂammatory genes
[204]. α4β1 and αvβ3 integrins have been implicated in myeloid cell
homing, adhesion and migration to tumors. α4β1 promotes endothelial progenitor cells and monocyte homing and adhesion to sites of
active pathological angiogenesis [205]. Inhibition of α4β1 leads to
suppressed monocyte and macrophage colonization of tumors and
associated vasculature and decreased angiogenesis [194].
The αvβ3 integrin is down-regulated during differentiation of bone
marrow myeloid progenitor cells to monocytes but induced in
macrophages during inﬂammation [206,207]. αvβ3 promotes myeloid
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homing, adhesion and migration of bone marrow derived cells through
the endothelium to sites of tumor angiogenesis [189]. β3 integrins are
involved in phagocytosis of apoptotic cells [208,209] and limit the
secretion of inﬂammatory mediators [207]. Defective macrophage
tumor inﬁltration is observed in TAM from β3−/− bone marrow,
myeloid speciﬁc β3KOM−/− mice and in the signaling defective DiYF
β3 mice (mice with two mutated tyrosine residues) [111,189,210–213],
suggesting that defective cytoskeletal reorganization or lack of
appropriately polarized macrophages [212] within tumors may be due
to β3 integrin deﬁciency.
Myeloid derived suppressor cells (MDSC) [214] represent a
subpopulation of immature myeloid cells that are roughly characterized by GR1+ and by the αMβ2(CD11b) integrin adhesion marker
[214]. The MDSC suppress T-cell antigen receptor mediated immune
responses [190] and can promote TAM M2 polarization [215]. MDSC
from myeloma bearing mice had a greater capacity to become bone
resorbing cells compared to MDSC from control mice [191]. The role of
integrins in MDSC differentiation, recruitment and function is under
investigation. Integrins are involved in monocyte/macrophage differentiation and recruitment to tumors and can inﬂuence local and
metastatic tumor growth.
Integrins and tumor recruited platelets and bone metastasis
Cancer cells co-exist with platelets and mononuclear hematopoietic cells in thrombi located throughout the organs of patients with
metastatic cancer [216–218]. Platelet aggregation and activation
enhances tumor growth and metastasis to bone [77,219]. Platelets
are anuclear metabolically active cells that are formed from bone
marrow megakaryocytes. Platelet aggregation is stimulated by soluble
factors such as ADP and thromboxane (TXA2), membrane proteins,
collagen or von Willebrand factor that are produced by injured
endothelial, inﬂammatory and tumor cells. αIIbβ3 plays a central role
in the initiation of arterial thrombosis and platelet aggregation
[220,221]. αIIbβ3 integrins are expressed on the surface of megakaryocytes and platelets and are undetectable on any other noncancerous cell type. Mice globally deﬁcient for the β3 integrin have
prolonged bleeding times, defects in platelet aggregation and clot
retraction and cutaneous and gastrointestinal bleeding, all characteristics of Glanzmann's thrombasthenia, [222] a disease characterized by
functional reduction or absence of αIIbβ3 in humans. Targeting β3
integrins by monoclonal antibodies to the receptor (abciximab/
Reopro) or by inhibiting the binding of the ligand ﬁbrinogen to the
receptor (tiroﬁban/Integrilin) are used in patients with acute coronary
and cerebral vascular syndromes but have signiﬁcant bleeding risks
that prevent their usefulness for chronic uses such as cancer.
Tumor cell lines have been shown to induce platelet aggregation
and adhesion in vitro through mechanisms involving αIIbβ3 integrin,
ADP, thrombin, von Willebrand factor and selectins [77,223–229]. The
metastatic potential of tumor cell lines is markedly diminished in
mice with defective platelet aggregation (β3 integrin−/−, Gaq−/−,
Par4−/−, NFE2−/− and ﬁbrinogen−/−) [77,219,223,226,228–244].
β3−/− mice are protected from bone metastasis in part through a
mechanism involving defective platelet aggregation [77]. Additionally, tumor cells engineered to respond to platelet-derived lysophosphatidic acid (LPA) have enhanced bone metastatic potential in mice
[219]. Platelets also represent a signiﬁcant source of pro-angiogenic
(VEGF) and anti-angiogenic factors (TSP-1) and are recruited to tumor
sites where their aggregation could affect local tumor growth [245].
Platelet-speciﬁc integrin targeting is a promising therapeutic approach for inhibiting bone metastasis, especially to prevent or slow
metastasis.
In contrast to platelets, bone marrow megakaryocytes can inhibit
prostate cancer tumor growth in bone [246]. Megakaryocytes can
indirectly inhibit bone resorption by inhibiting OC formation [247].
The negative effect of megakaryocytes on bone resorption is likely
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mediated in part through the OC inhibitory factor osteoprotegrin that
is contained in secretory granules of platelets and megakaryocytes
[248,249]. Adhesion of mature polyploid megakaryocytes to ﬁbronectin is also mediated by β1 subunit containing integrins [250,251].
Megakaryocytes may also inﬂuence bone remodeling and resorption
through effects on OB proliferation that are mediated by the α3β1,
α5β1 and glycoprotein IIb integrins [252]. Given the location of
mature megakaryocytes at vascular sinusoids, they are also among the
ﬁrst cells to physically encounter cancer cells as they enter the bone
marrow, so a direct mechanism of action involving integrin-mediated
signal transduction could be involved. Interestingly, bisphosphonates
(BP) increase megakaryocyte proliferation and increase the platelet
concentration of the anti-angiogenic integrin ligand TSP-1 [253–255]
which suggests non-OC mechanisms of BPs' action in decreasing
tumor growth in bone. Thus, platelets and their megakaryocytic
precursors interact with cancer cells before, during and after
metastasis to bone through interactions mainly determined by
integrins and their ligands.

Integrins and bone metastasis: Therapeutic aspects
Because of the wide range of functions in physiological and
pathological processes, the integrin family of adhesion receptors has
been adopted as a promising target for metastatic bone diseases.
Several tumor cell types express an abnormal integrin proﬁle
compared to non-tumor cells [41,51,256], providing an opportunity
for speciﬁc targeting. Targeting integrins on both tumor and/or host
cells has proven to be effective not only in blocking local cancer
progression, but also in reducing tumor cell detachment from their
primary site in preclinical models [257–259].
In recent years, integrins on the tumor cells and the endothelium
have been targeted by monoclonal antibodies and RGD peptides in
order to reduce tumor angiogenesis [109,260]. Integrin antagonists,
including humanized monoclonal antibodies, small molecule antagonists and cyclic peptides, have been developed based on the
recognition sequences of integrin physiological ligands [261]. Several
compounds are already in clinical use or undergoing their clinical
evaluation for various diseases.
For the future treatment of skeletal metastasis, the αvβ3 integrin
has become an attractive target because of its expression in tumor and
angiogenic cells, its role in OC differentiation and function and its role
in tumor cell homing to bone [53,60,61,183,262–267]. The multiple
expected beneﬁcial effects on endothelial, cancer and osteoclastic
cells instigated a signiﬁcant effort to develop drug candidates that
target the αvβ3 integrin for therapy of skeletal complications of
cancer. These strategies resulted predominantly in antagonists of
αvβ3, αvβ5 and αIIβ3 integrins that showed efﬁcacy in animal
models. Peptidomimentic antagonists of the αvβ3 and αvβ5 integrins
were successfully used to inhibit OC in vitro and to reduce bone loss in
a rat osteoporosis model [268]. An active nonpeptide αvβ3 integrin
antagonist and anti-αvβ3 antibodies were shown to hinder cancer
induced bone loss [79,268–270]. It is possible that the current
treatment for bone metastasis, BPs, may also exert an effect on
αvβ3 on both ECs [132] as well as OCs in a similar manner.
Many drugs candidates targeting integrin αvβ3 have advanced to
the clinic for the treatment of osteoporosis and cancer, though none
have speciﬁcally targeted patients with bone metastases. A lipophilic
isoester of RGD (L000845704), developed by Merck, is effective in
increasing bone mineral density (BMD) in postmenopausal women
[271]. Another inhibitor, RGD-mimetic cyclic peptide Cilengitide
(EMD-1219974) directed at both αvβ3 and αvβ5 [272] and currently
investigated by MerckSerono, is in advanced stages of clinical testing
for the treatment of glioblastoma multiforme and is under investigation for the treatment of squamous cell carcinoma, prostate cancer,
and lung cancer (Phase II).

Clinical trials of function-blocking antibodies are also ongoing,
including Vitaxin (LM609), a humanized monoclonal IgG1 antibody
against the extracellular domain of the αvβ3 integrin heterodimer.
Vitaxin had substantial anti-angiogenic effects in preclinical models
[119,262] and has shown direct anti-tumor effects as well as impaired
bone resorption by inhibiting OC attachment to the bone surface
[273]. Another monoclonal antibody (CNTO95), directed against the
αv subunit, is under development by Centocor and is in phases I–II
testing for solid tumors. Two other additions to this therapeutic family
are planned to be more speciﬁcally evaluated for their effects on bone
metastasis [62], organic small molecule GLPG0187 [62] and peptide
antagonist S247 [257].
Given the participation of the OCs, blood vessels and platelets in
bone metastases, it may be beneﬁcial to block both αvβ3 and αIIβ3
integrins on host cells. This concept of combination inhibition relies
on the common RGD ligand binding domains of αvβ3, αvβ5 and
αIIbβ3. In fact, many of the synthetically designed αvβ3 integrin
inhibitors display some selectivity towards αvβ5 integrin, and, in
the case of Cilengitide, this dual antagonism is part of the
mechanism to treat cancer by inhibiting neoangiogenesis as well
as invasion [274,275]. The strategy to combine multiple targets also
bears some risks with regards to the desired high therapeutic
speciﬁcity and low off-target toxicity. This issue is further
complicated by the differential function of the integrins as
determined by their location, expression level, activation status
and ligand binding. Studies in animal models and xenograft tumor
models have demonstrated that low concentrations of αvβ3
integrin antagonists can act as integrin agonists [130,276,277].
Further research is necessary to identify optimal drug dosing and
targeting that overcome the problem of generalized integrin
inhibition to reduce or prevent skeletal metastasis.
Another area of active research in bone metastasis therapeutics
is the speciﬁc targeting of integrins on HSCs or progenitors that
prepare the metastatic niche and enhance bone marrow colonization by cancer cells which then instigate the vicious cycle of bone
metastasis [278,279]. Interfering with integrin-mediated homing of
cancer cells to the cells to the bone represents an early option for
intervention. siRNA against the αv integrin subunit was used to
prevent the progression of prostate cancer to bone by interfering
with the ECM–integrin interaction [280]. In another approach, a
disintegrin and a neutralizing antibody to VCAM-1 or its receptor
α4β1 integrin reduced metastasis of melanoma cells and diminished osteolysis by decreasing OC activity in a myeloma in vitro
model [69,281]. These strategies, however, are not yet in clinical
trials. An exciting new approach to cancer therapy takes advantage
of the fact that cancer cells use CXCR4 and VLA-4 to home to and
engraft in the marrow. HSC mobilizing agents such as AMD3100 and
anti-VLA-4 targeted agents can be used to mobilize leukemia and
myeloma cells into the blood from the bone marrow leading to
increased sensitivity to chemotherapy [282–284] in mice. This
approach is now being tested in clinical trials.
Future perspectives
Despite the high level of complexity of the integrin family, the
β3 integrin remains a major target in the search for effective
therapies for skeletal metastasis. In recent years, a steady increase
in knowledge has led to clinical testing of several interesting
compounds. There remains, however, a lack of clarity concerning
the exact roles of the integrins in different cell types. In the initiated
clinical studies using αvβ3 integrin antagonists, the overall effect in
reducing tumor growth and pathological angiogenesis in fast
progressing deadly tumors may outweigh potential undesired
effects in tissues or cells other than tumor or endothelial origin.
Drugs designed to tackle skeletal complications of cancer must be
targeted to the bone microenvironment. This fact is underscored by
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the clinical successes of the bone matrix targeted bisphosphonates
and the OC targeted denosumab in treating and preventing skeletal
complications of bone metastases and myeloma. A detailed
understanding of the role of integrin regulation in both the
metastatic tumor cells and the tumor-associated stroma will allow
for a more targeted and focused approach to treat bone metastases.
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